Targeting the menin-MLL-LEDGF Interaction with Small Molecule Inhibitors. by Pollock, Jonathan
 
 
TARGETING THE MENIN-MLL-LEDGF 







A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
(Molecular and Cellular Pathology) 






Assistant Professor Tomasz Cierpicki, Co-Chair 
Assistant Professor Jolanta Grembecka, Co-Chair 
Professor Anna K. Mapp  
Assistant Professor Andrew G. Muntean  










© Jonathan Pollock 
 
 


















I would first like to thank my mentors Jolanta Grembecka and Tomasz Cierpicki for their 
guidance throughout my graduate school experience.  The former and current members of the 
TCJG lab have provided a supportive community both experimentally and emotionally. I would 
like to especially thank the former lab members George Lund, Felicia Gray, David Rogawski and 
Dmitry Borkin for their friendship and shared experiences throughout this process.  My thesis 
committee has helped me by providing instrumental feedback and support.   
I would also like to thank my friends and family that motivated me and supported my 
efforts to embark on this path.  My friends in Ann Arbor and in Chicago have provided a way to 
relieve stress, stay connected and I have had many enjoyable moments for which I am grateful.   
My parents Patricia and Ralph Pollock have always supported my decisions and provided a 
warm loving home environment which allowed me to get reach my goals, I am very lucky to 
have them.  I would like to thank my brothers, Michael, Ben, and Kyle for their encouragement. I 
would also like to thank my chosen family, the Meyers, whom have always supported and loved 
me as one of their own.  I am very lucky to have you all in my life. 
Finally I would like to thank the most important person in my life, Melissa. You make me 
a better person every day.  You have always built me up and seen my potential when I didn’t 
know it was there.  Your love and support through my graduate career is the only way I could 





Table of Contents 
Dedication ...................................................................................................................................... ii 
Acknowledgements ...................................................................................................................... iii 
List of Figures .............................................................................................................................. vii 
List of Tables ................................................................................................................................ ix 
List of Equations ........................................................................................................................... x 
List of Schematics ........................................................................................................................ xi 
List of Appendices ....................................................................................................................... xii 
List of Abbreviations ................................................................................................................. xiii 
Abstract ........................................................................................................................................ xv 
Chapter 1: Introduction ............................................................................................................... 1 
A. Background............................................................................................................................ 1 
A.1 Wild-type MLL .............................................................................................................. 1 
A.2 MLL translocations in acute leukemia ......................................................................... 2 
A.3 MLL translocations ...................................................................................................... 2 
A.4 WT MLL in leukemogenesis.......................................................................................... 3 
A.5 HOX genes in MLL rearranged leukemia .................................................................... 3 
B. The menin-MLL-LEDGF ternary complex ........................................................................ 5 
B.1 Importance of the interaction between menin-MLL-LEDGF for leukemogenesis ....... 5 
B.2 Structural  studies on menin ......................................................................................... 7 
B.3 Structure characterization of the menin-MLL interaction ........................................... 7 
C. Targeting the menin-MLL interaction with small molecules ........................................... 9 
C.1 Identifying small molecule inhibitors of the menin-MLL interaction .......................... 9 
C.2 Targeting the bivalent interaction .............................................................................. 13 
C.3 Potential applications of menin inhibitors ................................................................. 14 
Chapter 2: Rational Design of Orthogonal Multipolar Interactions with Fluorine in 
Protein−Ligand Complexes ........................................................................................................ 16 
A. Abstract ................................................................................................................................ 16 
B.  Background ......................................................................................................................... 17 
C.  Results and Discussion ....................................................................................................... 18 
v 
C.1 Trifluoromethyl Groups in Menin−MLL Inhibitors Form Close Contacts with Protein 
Backbone. .......................................................................................................................... 18 
C.2 Development of FMAP Algorithm To Predict Multipolar C−F···C=O Interactions. 19 
C.3 Interactions of Trifluoromethyl−Thiadiazole Moiety with Menin. ............................ 21 
C.4. Interactions of Trifluoroethyl Group in Thienopyrimidine Core with Menin. .......... 24 
D. Conclusions .......................................................................................................................... 25 
Chapter 3: Development of inhibitors targeting the menin-MLL interaction ...................... 28 
A. Abstract ................................................................................................................................ 28 
B. Background .......................................................................................................................... 29 
C. Results and Discussion ........................................................................................................ 30 
C.1 Modifications of MI-2-2 to explore the menin binding pocket ................................... 30 
C.2 Investigation of indole nitrogen substituents on MI-136 scaffold .............................. 34 
C.3. Exploring modifications at positions 3, 4, and 6 of the of indole ring in MI-136 
scaffold .............................................................................................................................. 40 
C.4 Generating analogs through combinations of optimal substituents on the indole ring 
in MI-136 scaffold ............................................................................................................. 44 
C.5 Pharmacokinetic analysis of menin-MLL inhibitors in a murine model. ................... 50 
C.6 MI-503 treatment reduces MLL leukemia burden and improves survival in murine 
model. ................................................................................................................................ 51 
D. Conclusion............................................................................................................................ 52 
Chapter 4: Design and characterization of the hydroxy- and aminomethylpiperidine class 
of menin-MLL inhibitors ........................................................................................................... 54 
A. Abstract ................................................................................................................................ 54 
B.  Background ......................................................................................................................... 55 
B.1 Identification of a chemically distinct class of menin-MLL inhibitors ....................... 55 
C.  Results and Discussion ....................................................................................................... 56 
C.1 HTS campaign and identification of the minimal pharmacophore. ........................... 56 
C.2 Structure based-design of MIV analogs ..................................................................... 59 
C.3 Hydroxymethylpiperidine Inhibitors Mimic the Most Critical Interactions of MLL 
with Menin. ....................................................................................................................... 60 
C.4 Design of orthogonal multipolar interaction of MIV analog with the menin backbone
........................................................................................................................................... 63 
C.5 Increasing the polarity of the MIV class of menin-MLL inhibitors............................ 64 
C.6 Identification of optimal substituents at the tail region ............................................. 65 
C.7 Exploring the hydrogen bond network in the head region ......................................... 66 
D. Conclusions .......................................................................................................................... 67 
Chapter 5: Development of covalent inhibitors of the menin-MLL interaction ................... 71 
A. Abstract ................................................................................................................................ 71 
B.  Background ......................................................................................................................... 72 
B.1 Advantages and disadvantages of covalent inhibitors ............................................... 72 
B.2 Design of covalent inhibitors of PPIs ......................................................................... 72 
vi 
B.3 Biochemical characterization of covalent inhibitors ................................................. 73 
C.  Results ................................................................................................................................. 75 
C.1 Investigation of accessible cysteine residues near the small molecule binding pocket 
of menin ............................................................................................................................. 75 
C.2 Structure based-design of covalent thienopyrimidine class of menin-MLL inhibitors
........................................................................................................................................... 77 
C.3 Characterizing the potency and rate of menin engagement of the covalent inhibitors.
........................................................................................................................................... 82 
C.4. Structure-based design and characterization of acrylamide covalent inhibitors ..... 85 
C.5 Investigating the reactivity of the covalent menin-MLL inhibitors with glutathione. 88 
C.6 Activity of covalent inhibitors of the menin-MLL interaction in leukemic cells. ....... 89 
C.7 Detection of menin engagement in MLL leukemic cells and bone marrow in vivo. .. 90 
D.  Conclusion........................................................................................................................... 94 
Chapter 6: Conclusions and Future Directions ........................................................................ 96 
A. Conclusions .......................................................................................................................... 96 
A.1 Fluorine-backbone interactions contribute to high affinity interaction with menin .. 97 
A.2 Optimization of small molecule inhibitors of the menin-MLL interaction to 
demonstrate in vivo efficacy.............................................................................................. 98 
B. Future Directions............................................................................................................... 101 
B.1 Future development of the menin-MLL inhibitors.................................................... 101 
B.2 Investigation of menin-MLL inhibitors in other malignancies ................................. 101 
B.3 Structural investigation of the IBD interaction with MLL identifies new interaction 
motif and potential therapeutic target ............................................................................ 101 
Materials and Methods ............................................................................................................. 103 
Appendices……………………………………………………………………………………..111 






List of Figures 
Figure 1.1 Crystal structure of the menin-MLL-LEDGF complex. ................................................ 6 
Figure 1.2 Characterization of the menin-MLL interaction. ......................................................... 10 
Figure 1.3 Thienopyrimidine class of menin-MLL inhibitors. ..................................................... 11 
Figure 1.4  Reported inhibitors of the menin-MLL interaction. ................................................... 13 
Figure 2.1 Inhibitors of the menin−MLL interaction containing CF3 groups............................... 19 
Figure 2.2 Prediction of favorable C−F···C=O interactions using FMAP algorithm. ................. 21 
Figure 2.3 Effect of fluorine substitutions in thiadiazole moiety on activity of menin−MLL 
inhibitors. ...................................................................................................................................... 23 
Figure 2.4 Effect of fluorine substitutions in thienopyrimidine moiety on activity of menin−MLL 
inhibitors. ...................................................................................................................................... 25 
Figure 3.1 Crystal structure of MI-2-2 bound to menin. ............................................................... 30 
Figure 3.2 Crystal structure of MI-136 bound to menin. .............................................................. 34 
Figure 3.3 Structure-based design of indole nitrogen substituents. .............................................. 36 
Figure 3.4 Structure-based design of indole nitrogen substituents. .............................................. 37 
Figure 3.5 Structure-based design of substituents at position 4 of the indole. ............................. 40 
Figure 3.6 Structure-based design of indole position 6 modifications in MI-136. ....................... 42 
Figure 3.7 Exploring combinations of substituent at positions 1 and 4 of indole. ....................... 46 
Figure 3.8 Analysis of substituent combinations at positions 1 and 6 of indole. ......................... 47 
Figure 3.9 Exploring combinations of substituent at positions 1, 4 and 6 of indole. ................... 48 
Figure 3.10 Treatment with MI-503 reduces tumor burden and demonstrates survival benefit... 51 
Figure 4.1 Identification of the most potent HTS hit. ................................................................... 57 
Figure 4.2 Determining binding affinity of each MIV-3 enantiomer. .......................................... 58 
Figure 4.3 MIV-3 enantiomers bind to menin in the MLL binding site. ...................................... 60 
Figure 4.4 MIV-3R binding mode to menin. ................................................................................ 62 
Figure 4.5 Crystal structure of MIV-4 bound to menin. ............................................................... 64 
Figure 4.6 Crystal structure of MIV-5 bound to menin. ............................................................... 65 
viii 
Figure 4.7 Crystal structure of MIV-5 and MIV-7 bound to menin. ............................................ 66 
Figure 4.8 MIV-3R and MIV-6R binding modes to menin are investigated. ............................... 67 
Figure 5.1 Crystal structure of MI-503 bound to menin. .............................................................. 76 
Figure 5.2 Design of BD615 with an acrylamide reactive moiety. .............................................. 78 
Figure 5.3 Design of irreversible inhibitor BD712 with a propynamide reactive moiety. ........... 79 
Figure 5.4 Design of irreversible inhibitor BD688 with a vinylsulfonamide reactive moiety. .... 81 
Figure 5.5 Characterizing irreversible inhibitor rates of menin engagement. .............................. 84 
Figure 5.6  Structure-based design of acrylamide covalent inhibitors. ......................................... 86 
Figure 5.7 Structure-based design of aromatic substituted acrylamides with menin. .................. 87 
Figure 5.8 Structure-based optimization of polar interactions of aromatic substituted acrylamides 
with menin. ................................................................................................................................... 87 
Figure 5.9 Menin engagement in cells. ......................................................................................... 92 
Figure 5.10 Determination of the rate of menin turnover with washout experiments. ................. 93 
Figure 5.11 CETSA analysis to assess menin engagement in the bone marrow in vivo. ............. 94 
Figure 6.1 Development of menin-MLL inhibitors. ................................................................... 100 
Figure A.1 Structure determination and biophysical characterization of the MLL-IBD interaction.
..................................................................................................................................................... 113 
Figure A.2 The IBD interface with MLL and IN overlaps. ........................................................ 116 
Figure B.1 Identification and characterization of fragment screening hits. ................................ 121 








List of Tables 
Table 3.1 SAR and activities of analogues of the thienopyrimidine class of menin-MLL 
inhibitors. ...................................................................................................................................... 32 
Table 3.2 SAR and properties of analogues with substitutions at position 2 of indole. ............... 33 
Table 3.3 SAR and properties of analogues with substitutions at position 1 of indole. ............... 38 
Table 3.4 SAR and properties of analogues with substitutions at position 1 of indole. ............... 39 
Table 3.5 SAR and properties of analogues with substitutions at position 3, 4, or 6 of indole. ... 43 
Table 3.6 SAR and properties of analogues with substitutions at positions 3, 4, or 6 of indole. . 45 
Table 3.7 SAR and properties of analogues with substitutions at positions 3, 4, or 6 of indole. . 49 
Table 3.8 Pharmacokinetic profile of menin-MLL inhibitors in blood plasma of murine models.
....................................................................................................................................................... 50 
Table 4.1 SAR and activity of MIV analogues. ............................................................................ 57 
Table 4.2 SAR and activity of MIV analogues ............................................................................. 69 
Table 5.1 SAR and activities of covalent analogues of the thienopyrimidine class of menin-MLL 
inhibitors. ...................................................................................................................................... 77 
Table 5.2 SAR and properties of analogues. .............................................................................. 83 
Table 5.3 SAR and properties of analogues. .............................................................................. 86 
Table 5.4 Reactivity of inhibitors with glutathione. ..................................................................... 88 
Table 5.5 SAR and properties of analogues. .............................................................................. 90 




List of Equations 
Equation 5.1 Equilibrium equation ............................................................................................... 84 
Equation 5.2 Pseudo-first order rate equation and half-life derivatization. .................................. 84 
Equation B.1 Calculation of chemical shift perturbations .......................................................... 106 





List of Schematics 
Schematic 1.1 Menin-MLL-LEDGF ternary complex assembly. .................................................. 4 




List of Appendices 
Appendix A: The same site on IBD of LEDGF binds to both MLL and HIV-IN. .............. 111 
A. Abstract .............................................................................................................................. 111 
B.  Background ....................................................................................................................... 112 
C. Results and Discussion ...................................................................................................... 113 
C.1 Structural and biochemical analysis of the menin-MLL interaction with IBD. ....... 114 
C.2 HIV-IN binding to IBD overlaps with the MLL binding interface. .......................... 114 
D.  Conclusions ....................................................................................................................... 117 
Appendix B: Fragment screening of IBD-LEDGF by NMR ................................................. 118 
A. Abstract .............................................................................................................................. 118 
B.  Background ....................................................................................................................... 119 
C. Results and Discussion ...................................................................................................... 120 
C.1 Identification and characterization of small molecule fragments that bind to IBD. 120 
C.2 Development of the structure activity relationship (SAR) for 3CC7 ........................ 122 
D.  Conclusion......................................................................................................................... 125 





List of Abbreviations 
AlphaLISA Amplified Luminescence Proximity Homogenous Assay 
AML Acute myeloid leukemia 
ALL Acute lymphoblastic leukemia 
BMC Bone marrow cells 
BME β-mercaptoethanol 
CETSA Cellular thermoshift assay 
D2O Deuterium oxide 
DMSO Dimethyl sulfoxide 
DTT Dithiothreitol 
FBDD Fragment based drug design 
FITC Fluorescein 
FP Fluorescence polarization 
FRET Förster resonance energy transfer  
GI50 Half-maximal growth inhibition 
GSH Glutathione 
H3K4 Histone 3 lysine 4 
H3K4me3 Histone 3 lysine 4 tri-methylation 
HM-2 Hoxa9 and Meis1 transformed murine BMCs 
HTRF Homogeneous Time Resolved Fluorescence 
HTS High-throughput screen 
IBD Integrase binding domain 
IBM1 IBD binding motif 1 
IBM2 IBD binding motif 2 
IC50 Half-maximal inhibitory concentration 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
ITC Isothermal titration calorimetry 
LC-MS Liquid chromatography couple with mass spectrometry 
LEDGF Lens epithelial-derived growth factor 
MBM1 Menin binding motif 1 
MBM2 Menin binding motif 2 
MLL Mixed lineage leukemia 1 
Ni-NTA Nickle nitrilotriacetic acid 
NMR Nuclear Magnetic Resonance 
xiv 
PDB Protein Data Bank 
PPI Protein-protein interaction 
SAR Structure Activity Relationship 
TCEP tris(2-carboxyethyl)phosphine 
TPR Tetratricopeptide repeat 






Mixed Lineage Leukemia 1 (MLL) is a large multi-domain protein (430 kDa) encoded by 
the MLL gene that catalyzes the methylation of histone H3 lysine 4 (H3K4).  Chromosomal 
translocations of the Mixed Lineage Leukemia (MLL) gene result in acute myeloid and 
lymphoblastic leukemias. MLL mediated leukemia is present in about 10% of adult acute 
leukemia and up to 70% of infant leukemias.  Patients with MLL leukemia do not respond well 
to conventional treatment methods; therefore, have very poor prognosis with only about a 35% 
overall 5-year survival rate and high risk of relapse. This demonstrates the urgent need for novel 
targeted therapeutics to treat these leukemias.  
Chromosomal translocation of the MLL gene with one of over 60 partner genes generates 
an oncogenic chimeric fusion protein. MLL fusion proteins lead to enhanced cell proliferation, 
up-regulation of Hoxa9 and Meis1 genes and block hematopoietic differentiation, ultimately 
leading to acute leukemia. The oncogenic function of MLL fusion proteins is reliant on the 
interaction with menin and with Lens Epithelium Derived Growth Factor (LEDGF).  Menin 
functions as a scaffolding protein and interacts with wild type (WT) MLL or MLL fusion 
proteins which are localized to target genes through association with LEDGF. Formation of the 
menin-MLL-LEDGF ternary complex is critical for MLL associated gene regulation and 
leukemogenic transformation.  Therefore, inhibition of the menin-MLL interaction should 
abrogate the development and progression of MLL leukemia. 
Our laboratory was the first to report small molecule inhibitors of the menin-MLL 
interaction.  We have identified two classes of reversible menin-MLL inhibitors and rationally 
designed a new class of covalent menin-MLL inhibitors. Using high resolution crystal structures 
xvi 
of menin in complex with inhibitors we applied structure-based design to further optimize 
inhibitors of the menin-MLL interaction. We performed extensive characterization and 
optimization of potency, solubility and pharmacokinetic properties of these compounds. These 
efforts led to the development of compounds suitable for in vivo analysis and demonstrated 
significant survival benefit in murine models of MLL leukemias. Overall, we have demonstrated 
that menin-MLL inhibitors may offer a novel therapeutic strategy for MLL leukemia patients and 
have developed a promising lead scaffold for clinical optimization. 
1 
 
Chapter 1: Introduction 
A. Background 
A.1 Wild-type MLL 
Mixed Lineage Leukemia 1 (MLL1, referred to as MLL and KMT2A) is a large multi-
domain protein (430 kDa) encoded by the MLL gene that catalyzes the methylation of histone H3 
lysine 4 (H3K4).
2-4
  MLL is a human homolog of the trithorax (Trx) group proteins, which is 
required for body patterning in drosophila,
5
 and is required for normal mouse development,
6,7
  
Importantly MLL expression is necessary for maintained expression of Homeotic (Hox) genes 
and plays a role in normal hematopoiesis.
4
 MLL is post-translationally cleaved by the protease 






  These fragments re-associate non-
covalently and migrate to the nucleus where they perform transcriptional regulatory functions.
8
  
Once in the nucleus, the wild type (WT) MLL is then recruited to target genes via the N-terminal 
domain of MLL by interactions with menin, lens epithelium derived growth factor LEDGF, and 
c-Myb, and through the CXXC domain, which leads to transcriptional activation.
9, 10, 11, 12
  The 
H3K4me3 is catalyzed by the MLL C-terminal SET domain and association with essential 
cofactors Wdr5, Ash2L, and Rbbp5 is needed for catalytic activity resulting in gene activation. 
13, 14, 15
  H3K4me3 is an epigenetic conserved mark for transcriptionally active chromatin.
16,17
  
H3K4me3 mark is enriched near the transcription start sites of transcriptionally active genes. 
17,18
 
Hox genes are considered important downstream targets of MLL and are tightly controlled 
through epigenetic modifications.
2,19, 20
  Hoxa9 and Meis1 are essential for hematopoietic stem 




 has only a minor hematopoietic 
defect.
23
 Hoxa9 and Meis1 normally become down-regulated through the progression of 
2 
hematopoietic progenitor cells to a fully differentiated state.
11,22
  Failure to repress Hox 




A.2 MLL translocations in acute leukemia 
Chromosomal translocations that result in a chimeric fusion gene represent a common 
mechanism in several types of malignances especially in acute leukemias.
25
  Mixed Lineage 
Leukemia (MLL) is localized at chromosome band 11q23, and is a common target for 
chromosomal rearrangements.  MLL-rearrangements found in patients with acute myeloid 
leukemia (AML) and acute lymphoblastic leukemia (ALL) represent 10% of de novo cases 
26,27
 
and 30% of therapy related acute leukemias.
28
  MLL mediated leukemia is present in about 10% 
of adult acute leukemia
29
 and about 70% of acute lymphoid leukemia (ALL) and 35-50% of 
acute myeloid leukemia (AML) in infants.
30
  MLL leukemias have relatively few cooperating 
mutations potentially making them more amenable to therapeutics targeting the fusion protein.
31
 
Patients with MLL leukemia do not respond well to conventional treatment methods; therefore, 
have very poor prognosis with only about a 35% overall 5-year survival rate 
32
 and high risk of 
relapse.
24
  This demonstrates the urgent need for novel therapeutic strategies to treat these 
leukemias.  
A.3 MLL translocations 
Chromosomal translocation of the MLL gene results in an in-frame fusion with one of 
over 60 partner genes and the expression of a chimeric fusion protein.
33, 27,34
  The most frequent 
MLL fusion partners are AF4, AF9, ENL, AF6, ELL and AF10.
22,35
  The resultant fusion protein 
has the N-terminal domain of MLL conserved and the C-terminal domain of the partner protein. 
This fusion protein has aberrant regulatory activity and multiple downstream oncogenic effects.  
The chimeric fusion protein is not post-translationally modified, as is the case for WT MLL, 
because the Taspase1 protease-binding site is not conserved.
36
  The gene that MLL is fused with 
can have varying effects on the oncogenic activity of the mutant MLL fusion protein. There are 
two main classes of fusion partners, nuclear and cytosolic. Both classes can have oncogenic 
downstream effects, but the nuclear pathway fusion proteins are most common and are the most 
thoroughly characterized. In the nuclear pathway, the chimeric MLL fusion protein disrupts the 
3 
activity of the normal epigenetic regulatory complex. This perturbation of WT MLL function 
results in the upregulation and overexpression of Hox genes that are essential for normal 
hematopoiesis.
37, 38 
 However, there are less common fusion partners that are cytosolic proteins 
including AF6, GAS7, EEN, septin proteins.
39
  MLL-GAS7 is able to achieve leukemic 
transformation in the absence of Hoxa7, or Hoxa9,
40
 however, this cytosolic fusion partner 
transformation mechanism is not well understood. Despite MLL fusions using different 
mechanisms for transformation, they all may be susceptible to menin-MLL inhibitors.
41
 The 
critical dependence of MLL fusion proteins on the interaction with menin-LEDGF demonstrates 
the importance of the N-terminal region of MLL. The lack of the C-terminal portion of WT MLL 
in the MLL fusion proteins would appear to suggest that for the progression of leukemogenesis 
this region of MLL is not required. 
A.4 WT MLL in leukemogenesis 
Cells with MLL rearrangements have one allele that remains intact and produces WT 
MLL. 
42,43
  Therefore, MLL fusion proteins lack the C-terminus of MLL that is necessary for 
gene activation but this region is still expressed in the remaining WT allele allowing for WT 
MLL function to be carried out.  It has been demonstrated that the remaining WT allele of MLL 
remains intact in MLL-AF9 leukemias and plays a critical role.
11, 42
   Knockdown of WT MLL in 
MLL-AF9 transformed cells leads to a decrease in Hox gene transcription and WT MLL 
mediated H3K4me3.
42
  Together this indicates the WT MLL is required for the maintenance of 
the transformed state of MLL rearranged leukemias.
42
  With the absence of a direct interaction 
between MLL-AF9 and WT MLL,
11
 the WT MLL may play a role in laying the foundational 
epigenetic landscape that is required for MLL fusion proteins to mediate oncogenesis.    
A.5 HOX genes in MLL rearranged leukemia 
Disruption of WT MLL through a chromosomal translocation event can result in the 
upregulation of Hox genes, particularly Hoxa7 and Hoxa9.
38,44,45
  This leads to the blockage of 
hematopoietic differentiation and stimulates rapid cell proliferation resulting in acute leukemia.
46
  
The deregulation of Hoxa7, Hoxa9 and Meis1 represents a critical step in the progression of 
leukemogenesis by MLL fusion proteins.
38,47-49
  The molecular mechanisms that HOXA9 uses to 
regulate subsequent gene expression and block cell differentiation are still largely unknown.  
4 
However, it is known that HOXA9 protein can dimerize with MEIS1, which increases the 
specificity of HOXA9’s recognition of target genes.
22
 During cell differentiation and the late 
stages of maturation, Hoxa9 expression decreases, and overexpression results in the sustained 
ability for cells to self-renew.
48
  However, in MLL translocated leukemias constitutive 
expression of Hoxa9 and Meis1 blocks hematopoietic cell differentiation.
50
  The importance of 
Hox genes role in leukemogenic transformation, particularly, the dimerization partners HOXA9 
and MEIS1 are the most well characterized targets.
51-53
  In addition, the upregulation of Hoxa9 
and Meis1 genes leads to superior proliferation and differentiation block in hematopoietic cells 
resulting in acute leukemia.
37,38,50
  Transduction of Hoxa9 and Meis1 genes into bone marrow 
progenitor cells accelerates the progression of acute leukemia in mouse models and can mimic 
MLL-AF9 leukemic disease.
38,54
  Importantly, Hoxa9 and Meis1 overexpression can rescue the 
bone marrow colony formation deficiencies caused by loss of menin, a critical interaction partner 
of MLL, or WT MLL.
12,42
  Overall, this demonstrates the importance of Hox genes in mediating 
MLL rearranged leukemias. 
 
Schematic 1.1 Menin-MLL-LEDGF ternary complex assembly.  
The schematic highlighting the assembly of WT MLL and MLL fusion proteins with menin and LEDGF.  The N-
terminal region of MLL is maintained in the MLL-fusion proteins where the interaction sites for menin and LEDGF 
are located. 
5 
B. The menin-MLL-LEDGF ternary complex 
B.1 Importance of the interaction between menin-MLL-LEDGF for leukemogenesis 
The MLL fusion proteins oncogenic function is reliant on the interaction with menin
12,55
 
and with Lens Epithelium Derived Growth Factor (LEDGF).
9
  Menin is encoded by the Multiple 
Endocrine Neoplasia I (MEN1) and is considered a tumor suppressor protein in cells of the 
endocrine lineage.
56
  However, menin also is an essential oncogenic cofactor of MLL fusion 




  Studies in 
our laboratory have revealed that menin binds to the N-terminal region of MLL with a very high 
binding affinity (Kd = 6.8 nM).
55,58,59
  Importantly, this N-terminal region of MLL is present in 
all of the MLL fusion proteins and this interaction is needed for recruiting MLL and MLL fusion 
proteins to the target genes.
12,55,58,60
 
The menin-MLL interaction is necessary for the upregulation of Hoxa9 and Meis1 as it 
has been demonstrated that disruption of this interaction abolishes the aberrant expression of Hox 
genes and reverses the oncogenic characteristics of MLL-transformed leukemic blasts.
55
  
Therefore, targeting the menin-MLL interaction has been postulated as a possible therapeutic 





Menin plays an important role as a scaffold protein in the menin-MLL-LEDGF ternary 
complex. Loss of menin or Lens Epithelial Derived Growth Factor (LEDGF) disrupts 
localization of MLL or MLL fusion proteins to target genes. Neither menin nor MLL
N
 alone are 
capable of potent interactions with LEDGF.
62
  The crystal structure of the ternary complex 
demonstrates the integrase binding domain (IBD) of LEDGF being involved in direct 
interactions with both menin and MLL (Figure 1.1).
9,62
  LEDGF makes direct contacts with 
menin-MLL1 and disruption of this interaction abrogates acute leukemia in mouse models.
9
  
Thus, LEDGF is a critical cofactor for MLL associated gene regulation and leukemogenic 
transformation.
63
 This data suggests the LEDGF interaction with menin-MLL may be a 




Figure 1.1 Crystal structure of the menin-MLL-LEDGF complex.   
Menin (green) is primarily alpha-helical globular protein with a large central cavity that binds MLL (yellow).  MLL 
makes additional contacts with IBD-LEDGF (cyan) to hold this ternary complex together.  Figure is prepared based 
on the crystal structure of menin-MLL-LEDGF (PDB: 3U88). 
7 
B.2 Structural  studies on menin 
NMR and bioinformatics studies demonstrate that menin is a globular protein with 
several regions of disordered fragments.
64
  The crystal structure of menin from Nematostella 
vectensis was solved first by  Cierpicki’s laboratory and deletion of an internal loop fragment 
and the C-termini was required for this construct to crystalize.
65
  Similarly, deletion of an 
internal loop was necessary to solve the human menin crystal structure.
62
  However, the 
resolution of the human menin crystal structure was rather poor (above 2.5 Å)
62
 and it only 
improved substantially when our laboratory performed more extensive deletion of loop regions 
to obtain crystals capable of diffracting to1.3 Å resolution (1.3 Å).
59,62
   
Structural analysis of menin revealed a primarily α-helical protein with a tetratricopeptide 




  There is high sequence homology in the structured core 
region between human menin and Nematostella menin exceeding 50%.
65,67
  The differences in 
the sequence of these homologs are evident in the three loop regions and the C-terminus.  Menin 
contains a large central cavity (5,000 Å) formed by the TPR motif.  This cavity is relatively rigid 
and composed of hydrophobic side chains and lined with several acidic residues.
66
  This cavity 
on menin represents the interface site for the MLL or JunD-menin protein-protein 
interaction.
62,66,68
  Comparing the binding interactions of MLL or JunD to apo-menin 
demonstrate the structural rigidity of this central cavity with no conformational changes. This 
large, well-defined binding pocket of menin suggests this cavity is suitable to target with small 
molecule inhibitors. 
B.3 Structure characterization of the menin-MLL interaction 
The N-terminal region of MLL is involved in the interaction with menin, specifically the 
fragment of MLL with the RWRFP sequence.
55
  Further characterization of this interface 
revealed the interaction sequence of MLL required for the high affinity binding extends to the 
first 46 amino acid of the N-terminus.
58
  The Isothermal Titration Calorimetry (ITC) 
characterization of the menin-MLL interaction performed by Grembecka et al.
59
 determined that 
MLL (residues 1-46) binds to menin with low nanomolar potency (Kd = 6.8 nM).
59
  Further 
analysis of the sequence identified two binding motifs within this N-terminal fragment.
59
  The 
menin binding motif 1 (MBM1) is defined as residues 4-15 of MLL that binds to menin with a 
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Kd = 53 nM and the second motif (MBM2) encompasses MLL residues 23-40 and binds to 
menin with much lower affinity Kd = 1.4 μM as assessed by ITC.
59
  Interestingly, these two 
motifs bind with a negative cooperativity, that is, there is a competition between these two motifs 
for the binding interaction with menin.
59
  
MBM1 binds to the large hydrophobic cavity of menin in an extended conformation 
forming both electrostatic and hydrophobic interactions.
62,66
  Alanine scanning mutagenesis 
determined that residues F9, P10, and P13 were the most important residues for the high affinity 
binding of MBM1 (Figure 1.2 B and C).
59
  F9 is the most important hydrophobic interaction in 
the MBM1 region with alanine replacement resulting in over 2200-fold decrease in the binding 
affinity, followed by P10 and P13 to alanine substitution leading to a 30- and 50-fold decrease in 
the binding affinity, respectively. 
The MBM2 motif on MLL is composed of several arginine residues and forms an 
electrostatic interaction with the acidic residues that line the central cavity of menin.
66
  Studies in 
Cierpicki’s lab have identified that D252K and L289K point mutations resulted in a significant 
reduction of MBM2 binding to menin (Figure 1.2 D).
66
  Based on this analysis MBM2 has been 
described as an “electrostatic anchor” to enhance the binding of the high affinity motif, MBM1, 
with menin.
67
  Co-immunoprecipitation experiments have demonstrated a possible more distant 
menin interaction motif within MLL consisting of residues 640-1251 of MLL.
55
  However, the 
N-terminus of MLL (containing both the MBM1 and MBM2) over expressed is adequate to 
block proliferation of bone marrow cells transformed with MLL-AF9.
58
  
This complicated multivalent interaction of MLL to menin provides a potentially 
problematic system to inhibit with small molecules.  Blocking the whole MLL interaction 
interface would be difficult to achieve with small molecules.  The large hydrophobic cavity on 
menin provides a promising location for small molecules but the question arises whether 
disruption of the MBM1-menin interaction is sufficient to block the association of MLL with 
menin?  Importantly, the deletion of just 5 residues of MBM1 was able to abrogate the 
progression of acute leukemia in mouse models of MLL leukemia in the context of MLL-ENL 
fusion protein,
55
 demonstrating that interfering with the MBM1 interaction with menin is suitable 
for the effective disruption of the entire menin-MLL complex. Additionally, the alanine scanning 
mutagenesis identified the F9A mutant to severely impair the binding of the MLL fragment to 
9 
menin with a Kd = 1.5 µM.
59
  This marked decrease in the binding affinity is reflected by over 
150-fold weaker affinity when compared to the WT sequence.
59
  Competition experiments with 
the MBM1 peptide show that disruption of the interaction of menin and MLL comprising both 
MBM1 and MBM2 regions is sufficient to completely dissociate the MLL-menin complex.  
Overall, disruption of the MBM1 high affinity site binding to menin is sufficient to disrupt the 
bivalent interaction motifs of MLL and completely eliminate the complex formation. 
Importantly, the large binding interface of the MBM1 region in the central region of menin may 
pose as a promising cavity to develop small molecule inhibitors.  
C. Targeting the menin-MLL interaction with small molecules 
C.1 Identifying small molecule inhibitors of the menin-MLL interaction 
Our laboratory was the first to report small molecule inhibitors of the menin-MLL 
interaction. Before my involvement in this project, Grembecka and Cierpicki’s laboratories have 
discovered and reported the thienopyrimidine class of menin-MLL inhibitors
68
 This class of 
compounds was found through a High Throughput Screen (HTS) with a competitive 
fluorescence polarization (FP) assay using a fluorescein (FITC)-labeled peptide corresponding to 
the MBM1 sequence.
68
  The HTS hit (MI-1) belonging to the thienopyrimidine scaffold was 
found as the most potent small molecule from the screen, IC50 = 1.9 µM (Figure 1.3).
68
  
Extensive medicinal chemistry efforts in Grembecka’s laboratory combined with structure-based 






Figure 1.2 Characterization of the menin-MLL interaction.   
A. Figure adapted from (Cierpicki 2014)
67
 The binding constants (Kd) were determined by employing FP for the MBM1 
peptide and MBM2 peptide while IC was used for the peptide incorporating both MBM1 and MBM2 motifs. All FP 
measurements were done for synthetic peptides labeled with the N-terminal fluorescein. The ITC experiments were carried out 
for unlabeled peptides.  B.  Figure adapted from (Cierpicki 2014)
67
 The MBM1 binding interface with menin with the most 
important residues for the binding interaction as determined by alanine scanning mutagenesis followed by FP analysis is 
highlighted in red. C.  Figure from (Cierpicki 2014)
67
 Quantification of the fold decrease in potency of the mutant peptides 
determined by FP. D.   Figure adapted from (Cierpicki 2014)
67
 The surface representation of menin structure (gray) is 








Figure 1.3 Thienopyrimidine class of menin-MLL inhibitors.  
A. The development of the thienopyrimidine class of menin-MLL inhibitors from 
HTS hit compound, MI-1 to MI-2-2.  B. The co-crystal structure of MI-2-2 
bound to menin. 
 
The crystal structure of MI-2-2 in complex with menin solved in Dr. Cierpicki’s 
laboratory revealed that MI-2-2 binds to the MLL binding site on menin.  Additionally, there are 
no major conformational changes of menin when comparing the apo structure with the MI-2 
bound menin structure; this demonstrates the rigidity of this binding pocket.  MI-2-2 forms 
several hydrogen bonds with the thienopyrimidine region to Tyr276 and Asn282 and 
hydrophobic contacts with Tyr319 and Tyr323. The trifluoroethyl substituent was in close 
distance to the protein backbone, resulting in an increased potency of this compound.
66
  The 
fluorine atoms were making orthogonal multipolar contacts with His181 backbone atoms.
1
 These 




significantly to the binding potency.
69
  Overall, the thienopyrimidine class represents a promising 
scaffold for further development of menin-MLL inhibitors as a potential   therapeutic strategy to 
treat patients with MLL translocations. Indeed, our additional lead optimization efforts discussed 
in detail in the following chapters have led to the identification of much more potent 
thienopyrimidine menin-MLL inhibitors, including MI-503 (IC50 = 14nM, Figure 1.4) and 
several others with low nanomolar IC50 values (see Chapter 4).
70,71
  
In addition to thienopyrimidine class, our laboratory has pursued the development of a 
different class of menin-MLL inhibitors, resulting from the  HTS performed at the NIH MLPCN 
(Molecular Libraries Probe Production Centers Network).
72
  The inhibitor identified from this 
screening, MIV-1 (IC50 = 12 µM), which consist of a hydroxymethyl piperidine scaffold, was 
further optimized within this project, resulting in MIV-6 (IC50 = 56 nM)
73
 (Figure 5.1), and will 
be discussed in details in Chapter 5. 
During the course of this project other groups have also reported menin-MLL inhibitors. 
For example, studies in Wang’s laboratory (University of Michigan) resulted in peptidomimetics 
that mimic the MBM1 region of MLL. The MBM1 fragment of MLL binds to menin in a U-
shaped conformation with the sidechain of R8 oriented near the backbone carbonyl group of P13 
providing a rationale for generating a macrocyclic analog.
74
  The macrocyclic analogs 
significantly improved the potency, and further modification of the side chains produced MCP-1 
with a Ki = 4.7 nM (Figure 1.4).  The MCP-1 analog is over ~600-fold more potent than the 
linear analog.
74
  The cellular activity of these peptidomimetics, however, has not been reported 
suggesting that further optimization is likely necessary to yield cell-permeable drug-like 
molecules. 
13 
 More recently few other reports were published on inhibitors targeting the menin-MLL 
interface.  A natural product-like compound (1a) was identified through an in silico screening 
approach followed up with structure-based design and evaluated in biochemical assay for menin-
MLL inhibition (Figure 1.4).
75
  However, no validation of the direct binding of this compound to 
menin has been provided.
75
  Another in silico screening approach screened FDA approved 
therapeutics that inhibits the menin-MLL interaction and identified neomycin and tobramycin 
(Figure 1.4).
76
  Follow-up of these hits was then performed through biochemical characterization 
determining these antibiotics disrupt the menin-MLL binding event in the range of ~20-60 µM 
representing relatively weak menin-MLL inhibitors.
76
  Further validation of these antibiotics for 
their direct binding to menin is required before pursuing additional optimization efforts. 
C.2 Targeting the bivalent interaction 
The bivalent nature of MLL binding to menin embodies a difficult mechanism for 
inhibition through small molecules.  The hydrophobic pocket on menin is relatively rigid and 
 
Figure 1.4  Reported inhibitors of the menin-MLL interaction.   
IC50 and Ki values are from a Fluorescence Polarization Assay. 
14 
highly supportive of binding small molecules based on the binding of the MBM1 peptide 
compared to menin without a binding partner. Evidence has demonstrated that loss of the high 
affinity MBM1 binding interaction with menin is sufficient for disruption of the entire menin-
MLL complex.
77
  This allows us to target the MBM1 interaction with small molecule inhibitors 
leading to abrogation of the leukemogenic mechanism of MLL oncogenic fusion proteins.
59,68
  
Grembecka et. al. have employed biophysical and biochemical methods to investigate the 
disruption of the bivalent binding of MLL with menin by small molecule inhibitors.
59
  MI-2-2 
was explored in competition experiments with MBM1, MBM2 and MLL4-43 which encompasses 
both binding fragments.
68
  MI-2-2 binds to menin with Kd = 22 nM, and inhibits the MBM1-
menin binding with an IC50 = 46 nM.
66
  However, no effect of MI-2-2 on MBM2-menin 
interaction was detected.
66
  This demonstrates the MBM2 binding interface is not inhibited by 
MI-2-2.  Competition experiments with MI-2-2 in the FP assay incorporating MLL4-43 showed a 
10-fold reduction in the MI-2-2 potency as compared to the FP assay with the MBM1 peptide.
66
  
This has shown that even though the MBM2 binding to menin is weak (Kd = 1 µM), it does 
contribute to decreased inhibitory activity of MI-2-2.  The MLL4-43 bivalent binding to menin 
displays slower kinetics of binding in comparison with MBM1 alone and needs a longer 
incubation period to achieve a stable equilibrium.
68
  This demonstrates that small molecule 
inhibitors targeting the MBM1 interface with menin are capable of disrupting the entire menin-
MLL binding event but the presence of MBM2 decreases the potency of these compounds in 
blocking the menin-MLL interaction. This bivalent interaction produces a more complex system 
to inhibit the menin-MLL interaction.  Inhibitors targeting the MBM1 site will have a reduced 
potency when targeting the bivalent MLL interaction with menin. As a result, inhibitors targeting 
solely the MBM1 site will likely require very potent in vitro binding affinity to demonstrate 
strong efficacy in vivo.  
C.3 Potential applications of menin inhibitors 
Menin was postulated to be a promising target in acute leukemias as a result of the role of 
menin in the MLL fusion protein mediated leukemogenic transformation.
55
  MLL fusion proteins 
require the interaction with menin for leukemic transformation and eliminating the menin from 
the MLL fusion protein inhibits the progression of leukemia. Therefore, small molecule 
inhibitors of the menin-MLL interaction might represent new potential therapeutic strategy for 
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MLL leukemia. Furthermore, more recent studies have shown that targeting the menin interface 









 cancers and potentially provide a way to chemo-
sensitize cancer cells to chemotherapeutic agents through the down regulation of MDR1.
82
  
Additionally, WT MLL has been found to be amplified in sub-types of AML and myelodysplasia 
and Hoxa9 have been found to be overexpressed in up to 50% of AMLs which may further 
expand the potential therapeutic applications of menin-MLL inhibitors.
34,83-85
 Importantly, recent 
studies have provided evidence to suggest that menin may be a dispensable co-factor of MLL1 
for normal hematopoiesis.
86
  Therefore, it would be expected that no on-target toxicity would be 
evident, at least in the context of the normal hematopoietic system, through targeting the menin-
MLL complex.
86
  In the endocrine system, menin is a tumor suppressor protein requiring an 
additional investigation of the menin-MLL complex in the endocrine system.
56,57
 
Menin is a viable target for small molecule inhibitor development. The central cavity of 
menin where MBM1 binds is a large, well-defined, relatively rigid pocket providing a promising 
site for binding small molecule inhibitor.  In the subsequent chapters, we will discuss further 
development of two classes of menin-MLL inhibitors and derive a new class of inhibitors into 
potent small molecules targeting the menin-MLL interaction.  Structure-based design utilizing 
the high resolution crystals structures of menin in complex with inhibitors greatly facilitated our 




Chapter 2: Rational Design of Orthogonal Multipolar Interactions 
with Fluorine in Protein−Ligand Complexes 
*The text and figures in this chapter are adapted from the following manuscript: Pollock, J.; 
Borkin, D.; Lund, G.; Purohit, T.; Dyguda-Kazimierowicz, E.; Grembecka, J.; Cierpicki, T. 
Rational Design of Orthogonal Multipolar Interactions with Fluorine in Protein-Ligand 
Complexes. J Med Chem 2015, 58, 7465-74. 
A. Abstract 
Multipolar interactions involving fluorine and the protein backbone have been frequently 
observed in protein−ligand complexes. Such fluorine−backbone interactions may substantially 
contribute to the high affinity of small molecule inhibitors. Here we found that introduction of 
trifluoromethyl groups into two different sites in the thienopyrimidine class of menin−MLL 
inhibitors considerably improved their inhibitory activity. In both cases, trifluoromethyl groups 
are engaged in short interactions with the backbone of menin. In order to understand the effect of 
fluorine, we synthesized a series of analogues by systematically changing the number of fluorine 
atoms, and we determined high-resolution crystal structures of the complexes with menin. We 
found that introduction of fluorine at favorable geometry for interactions with backbone 
carbonyls may improve the activity of menin−MLL inhibitors as much as 5- to 10-fold. In order 
to facilitate the design of multipolar fluorine−backbone interactions in protein−ligand 
complexes, we developed a computational algorithm named FMAP, which calculates 
fluorophilic sites in proximity to the protein backbone. We postulate that multipolar 
fluorine−backbone interactions may represent an attractive approach to improve inhibitors of 
protein−protein interactions. 
17 
B.  Background 
Fluorine has been recognized as a valuable element in medicinal chemistry, and about 
20−25% known drugs contain fluorine atoms.
87-89
 Fluorine is the most electronegative element 
and has a strong effect on physicochemical and conformational properties of organic 
compounds.
89
 As a consequence, introduction of fluorine atoms into ligands is a promising 
strategy in lead optimization to strengthen protein−ligand interactions. Furthermore, introduction 
of fluorine into ligand molecules affects physicochemical properties and modulates absorption, 
distribution, metabolism, and excretion in drug-like molecules.
88,89
 Fluorine can enhance ligand 
affinity through interaction with both polar and hydrophobic groups in proteins.
90
 Fluorine 
scanning has been proposed as an effective strategy for ligand optimization.
69,91
 Systematic 
incorporation of fluorine at different positions in a series of thrombin inhibitors revealed that 
introduction of fluorine into the benzyl ring enhanced the binding affinity by 6-fold.
91
 As a step 
toward the identification of fluorophilic hot-spots in proteins, it has been proposed to use 
19
F 
NMR ligand-based screening of fluorinated fragments
92
 and a combination of screening and 
computational analysis.
93
 However, a rational approach for designing fluorinated ligands is 
missing.  
We previously identified the thienopyrimidine class of compounds which directly bind to 
menin and inhibit the protein−protein interaction (PPI) between menin and MLL with nanomolar 
affinity.
68
 Substitution of a propyl group on the thienopyrimidine scaffold with trifluoroethyl, 
which resulted in the MI-2-2 compound, leads to a significant 10-fold increase in the binding 
affinity.
66
 The crystal structure of MI-2-2 bound to menin revealed that the CF3 group is 
involved in close contacts with the protein backbone. This demonstrates that fluorine−backbone 
interactions offer excellent opportunities to enhance the activity of inhibitors targeting 
protein−protein interactions. However, introduction of fluorine atoms into ligand molecules 
might be synthetically challenging or may require multistep synthesis. Therefore, a method for 
rational design of favorable fluorine interactions in protein−ligand complexes would 
significantly facilitate inhibitor development in drug discovery projects. In order to understand 
the effect of fluorine substitutions, we synthesized series of MI-2-2 analogues systematically 
changing the number of fluorine atoms in two different groups and determined high-resolution 
crystal structures of the inhibitors bound to menin. We found that when fluorine atoms in menin 
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inhibitors are involved in the orthogonal multipolar C−F···C=O interactions, it significantly 
enhances ligand binding affinity. On the basis of these findings, we developed a computational 
algorithm named FMAP to support structure-based design of favorable C−F···C=O interactions 
in protein−ligand complexes, and we demonstrated its applicability to known fluorine-containing 
small molecule inhibitors. This study should facilitate rational development of fluorinated 
ligands for drug discovery applications.  
My contribution to this project was to crystalize the menin-inhibitor complexes, solve the 
crystal structures of these complexes and perform structural analysis of the thienopyrimidine 
class of inhibitors to characterize the fluorine-backbone interactions with menin.  I then 
performed the FP assay to determine the potency of inhibitors targeting the menin-MLL 
interaction for each of the analogs generated. To further validate the FMAP algorithm, I 
performed FMAP analysis of several PDB structures to identify examples where a H to F 
substitution improved the potency of small molecules. 
C.  Results and Discussion 
C.1 Trifluoromethyl Groups in Menin−MLL Inhibitors Form Close Contacts with Protein 
Backbone.  
We previously performed extensive medicinal chemistry optimization of the 
thienopyrimidine class of menin−MLL inhibitors and found that substitution of propyl in the MI-
2 compound by trifluoroethyl group resulted in a substantial, 10-fold increase in the activity of 
MI-2-2 (Figure 2.1 A).
1,66
 Due to difficulties for further substitutions and potential metabolic 
liability of the thiazoline moiety, we modified this class of compounds by replacing thiazoline 
with an aromatic thiadiazole ring. Although the unsubstituted thiadiazole analogue is very 
weak,
68
 we found that introduction of the trifluoromethyl group substantially improved the 
activity, resulting in MI-2-3 with IC50 = 92 nM (Figure 2.1 A). Both compounds, MI-2-2 and 
MI-2-3, are potent inhibitors of the menin−MLL interaction with the IC50 values below 100 nM 
(Figure 2.1 A). Our previous studies revealed that one fluorine atom from the trifluoroethyl 
group in MI-2-2 forms close contacts with the backbone atoms on menin and is located within 
3.0 Å distance to the backbone carbonyl of His181,
66
 suggesting that this interaction might play 
an important role in increasing the inhibitory activity of MI-2-2 over MI-2. To understand the 
molecular basis of high binding affinity of MI-2-3, we determined the crystal structure of its 
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complex with menin. The newly developed MI-2-3 with an additional trifluoromethyl group 
binds to menin in a similar binding mode as MI-2-2 (Figure 2.1 B).  Interestingly, the new CF3 
group within the trifluoromethyl−thiadiazole moiety also forms close contacts with the menin 
backbone (Figure 2.1 B), and one of the fluorine atoms is located 3.4 Å from the carbonyl group 
of Met322. Therefore, the fluorine atoms in both CF3 groups of MI-2-3 are involved in 
orthogonal multipolar C−F···C=O interactions with the backbone atoms in two different regions 
on menin. To assess the contribution of the CF3 group in MI-2-3, we synthesized MI-326 by 
replacing trifluoromethyl with the methyl group and found that it led to ∼8-fold decrease in the 
inhibitory activity (IC50 = 779 nM for MI-326).
1
 These two examples, MI-2-2 and MI-2-3, 




Figure 2.1 Inhibitors of the menin−MLL interaction containing CF3 groups. 
Figure adapted from (Pollock 2015)
1
 A. Compound structures and IC50 values were measured by fluorescence 
polarization assay. B. Crystal structure of MI-2-3 bound to menin. Short C−F···C=O distances are shown using 
dashed lines. 
C.2 Development of FMAP Algorithm To Predict Multipolar C−F···C=O Interactions.  
Multipolar interactions involving fluorine atoms have been recognized for their 
pronounced effect on protein−ligand interactions, and well-placed fluorine may substantially 
enhance the activity of small molecule inhibitors. 
69,88,91,94
 Introduction of trifluoromethyl groups 
in menin inhibitors resulted in a significant improvement of inhibitory activity due to formation 
of short-distance multipolar interactions with the protein backbone. We therefore sought whether 
such interactions could be rationally designed. First, we analyzed the geometry of 
A. B. 
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fluorine−backbone interactions in known high resolution crystal structures of protein−ligand 
complexes.
1
 Out of 2559 structures containing fluorinated ligands, we found 442 complexes with 
a fluorine atom within 3.5 Å of either the backbone carbonyl carbon or amide nitrogen. This 
search demonstrated that fluorine is frequently located within a short distance of the backbone 
carbonyl group with the C−F bond preferably oriented in the orthogonal arrangement relative to 
the plane of the peptide bond (Figure 2.2 A). This exemplifies a presence of multipolar 
C−F···C=O interactions as described in detail in the previous studies.
88,94
  
On the basis of the analysis of protein−ligand complexes from the Protein Data Bank 
(PDB), we developed an algorithm (FMAP) for mapping sites for fluorine atoms on protein 
structures to form favorable C−F···C=O interactions with the protein backbone. The geometric 
criteria used in FMAP have been selected to encompass ∼80% of fluorine sites found in the 
experimental structures in PDB. Fluorine sites are mapped onto a protein structure through a 
Pymol
95
 extension and are represented as a surface spanning 2.8−3.2 Å range from the peptide 
bond (Figure 2.2 A). FMAP also eliminates unlikely fluorine positions through filters based on 
unfavorable geometry for multipolar interactions as well as steric clashes with protein atoms.
1
  
We employed FMAP to analyze the inhibitor binding site on menin and found that there 
are two potential sites for accessing close contacts between fluorine and protein backbone. 
Importantly, both sites are occupied by the CF3 groups in the complex of menin with MI-2-3 
(Figure 2.2 B), supporting the utility of FMAP for the prediction of fluorophilic sites in protein 
structures. The first site is relatively small and is occupied by the CF3 group connected to the 
thiadiazole moiety, whereas the second site is much larger and is occupied by the trifluoroethyl 
group attached to the thienopyrimidine scaffold. Close inspection of the menin-MI-2-3 crystal 
structure revealed that only a single fluorine in each CF3 group has favorable geometry for 
C−F···C=O interactions with backbone. On the basis of this analysis, we concluded that most 




Figure 2.2 Prediction of favorable C−F···C=O interactions using FMAP algorithm. 
Figure adapted from (Pollock 2015)
1
 A. Combined analysis of protein−ligand structures from PDB, with FMAP 
predictions of the potential fluorine positions and their representative C−F bonds relative to backbone peptide bond. 
Positions of fluorine atoms derived from the protein−ligand complexes found in PDB are shown as cyan points. 
FMAP prediction is shown as purple surface with orange vectors shown for representative C−F bonds. (George 
Lund) B. FMAP prediction for the menin-MI-2-3 complex. Purple surface represents favorable positions for 
fluorine atoms to interact with the protein backbone. 
C.3 Interactions of Trifluoromethyl−Thiadiazole Moiety with Menin.  
FMAP analysis suggested that only one fluorine atom in the CF3 group within the 
trifluoromethyl-thiadiazole moiety of MI-2-3 is capable of favorable interactions with the 
backbone carbonyl of Met332. In order to evaluate the contributions of fluorine atoms to the 
binding affinity of MI-2-3, we synthesized a series of analogues replacing CF3 with CH3, CH2F, 
and CHF2 groups (Figure 2.3). First, we assessed the effect of substituting CF3 by CH3 and 
found that the absence of the three fluorine atoms in MI-326 results in >8 fold decrease in the 
inhibitory activity (Figure 2.3 A). The crystal structure revealed that MI-326 binds to menin in a 
very similar manner as MI-2-3 (Figure 2.3 B), and the difference in the binding affinity 




additional analogues with two (MI-319) and single (MI-333) fluorines. The inhibitory activity of 
MI-319 is very similar to MI-2-3 indicating no differences between CF3 and CHF2 groups 
(Figure 2.3 A). Surprisingly, MI-333, which harbors the CH2F group, has about 20-fold weaker 
activity than MI-2-3 and is even 2-fold less potent than MI-326 with no fluorines (Figure 2.3 
A). To explain this effect, we determined the crystal structures of MI-333 and MI-319 bound to 
menin. The CHF2 group in MI-319 binds in a very similar manner as CF3 with one of the 
fluorine atoms in a short, 3.2 Å, distance to the backbone carbonyl of Met322 (Figure 2.3 B). On 
the contrary, the single fluorine in MI-333 adopts a position that is tilted approximately 38.5° 
from the plane of the thiadiazole ring and points away from the protein backbone (3.7 Å distance 
to C=O of Met322) (Figure 2.3 B). As a consequence, the fluorine is too far to be involved in a 
favorable multipolar C−F···C=O interactions, and no gain in the activity is observed for MI-333 




The orientation of the CH2F group relative to the thiadiazole ring was unexpected, 
emphasizing a strong conformational effect of the fluorine atom. As previously observed, 
substitution of H by F can profoundly change the conformational preferences of a small molecule 
because of the size and stereoelectronic effects.
88
 Although we were able to predict the position 
of fluorine required for favorable interactions with the protein backbone using FMAP, we did not 
anticipate that CH2F can adopt an orientation where the fluorine points away from the backbone. 
Introduction of the second fluorine into the CHF2 group was necessary to achieve an orientation 
of the C−F bond allowing for favorable C−F···C=O interactions and substantial improvement in 
activity. Analysis of the crystal structure of MI-333 shows that S−C−C−F dihedral adapts 38.5° 
angle. Quantum mechanical energy calculations demonstrate that multiple fluorine atoms might 
be needed to stabilize the appropriate rotameric state.
1
  
Figure 2.3 Effect of fluorine substitutions in 
thiadiazole moiety on activity of menin−MLL 
inhibitors.  
Figure adapted from (Pollock 2015)
1
 A. Compound 
structures and IC50 values were measured by 
fluorescence polarization assay. ΔΔG values are 
calculated relative to MI-326. B. Crystal structures 
of inhibitors bound to menin showing the shortest 
distances between fluorine and menin backbone. 




C.4. Interactions of Trifluoroethyl Group in Thienopyrimidine Core with Menin.  
Comparison of the activities of MI-2-2 and MI-19 indicates that the trifluoroethyl group 
contributes significantly to the high activity of MI-2-2, and replacement of CF3 with CH3 results 
in over 20-fold loss in inhibitory activity (Figure 2.4 A). FMAP analysis for the menin binding 
site suggests that only single fluorine in CF3 group can form C−F···C=O interactions with the 
backbone. To test the contributions of individual fluorine atoms in the CF3 group of MI-2-2, we 
synthesized two compounds with CH2F (MI-836) orCHF2 (MI-859) groups. When compared to 
MI-19, addition of the first fluorine enhanced the activity nearly 5-fold, whereas addition of the 
second fluorine increased the activity further by about 4-fold, making it comparable to MI-2-2 
with CF3 group (Figure 2.4 A). To rationalize the effect of these modifications, we determined 
the crystal structures of MI-836 and MI-859 bound to menin (Figure 2.4 B). We found that the 
single fluorine in MI-836 points toward a hydrophobic site formed by the side chains of Leu177, 
Phe238, Ala182, and Ser155, and therefore, the 5-fold gain in the activity likely results from 
favorable hydrophobic contacts. Introduction of CHF2 in MI-859 allows for the second fluorine 
to be involved in the C−F···C=O interactions with the backbone of His181, accounting for an 
additional 4-fold improvement in activity. Very similar IC50 values of MI-859 (with CHF2) and 
MI-2-2 (with CF3) indicates that the third fluorine is dispensable for binding. Furthermore, the 
cLogP value for MI-859 is approximately 0.6 unit lower than for MI-2-2 (cLogP = 3.89 and 3.32 
for MI-2-2 and MI-859, respectively). Therefore, our approach based on the FMAP calculations 
may be used not only to predict fluorine substitutions in ligand molecules but also to design 
compounds with fewer number of fluorine atoms and reduced lipophilicity without 
compromising ligand binding affinity. Analysis of the MI-2-2-menin structure revealed that the 
methylene group in the CH2CF3 moiety is positioned closely to the backbone carbonyl groups of 
Ser178 and Glu179 and may constitute a further site for fluorine substitutions. However, the 
FMAP analysis revealed that introduction of the CF2 group at this site would not be favorable 
due to poor geometry of the two fluorines with respect to the carbonyl groups of Ser178 and 
Glu179. To test this hypothesis, we synthesized MI-273 with CF2CF3 group and found that such 
a substitution results in a ∼15-fold decrease in the activity when compared to MI-2-2 (Figure 
2.4 A). We determined the crystal structure of MI-273 bound to menin and found that it binds in 
an identical manner as MI-2-2 (Figure 2.4 C). The two additional fluorines in the CF2 group of 
MI-273 are in close distances to the carbonyl oxygens of Ser178 and Glu179 leading to repulsive 
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interactions. This further emphasizes that favorable C−F···C=O interactions require optimal 
geometry, and the FMAP approach can filter-out the sites that are unfavorable for fluorine atoms  
in ligand molecules. 
 
Figure 2.4 Effect of fluorine substitutions in thienopyrimidine moiety on activity of menin−MLL 
inhibitors.  
Figure adapted from (Pollock 2015)
1
 A. Compound structures and IC50 values were measured by 
fluorescence polarization assay.  ΔΔG values are calculated relative to MI-19. B. Crystal structures of 
inhibitors bound to menin showing the shortest distances between fluorine and the menin backbone. 
FMAP prediction is shown as purple surface. Model of MI-19 has been made on the basis of the 
structure of MI-2-2-menin complex. C. Crystal structure of MI-273 bound to menin showing close 
contacts of fluorines in CF2CF3 group with menin. FMAP prediction is shown as purple surface. 
D. Conclusions 
Fluorine scanning strategy has been previously proposed as an effective approach to 
improve the activity of small molecule inhibitors.
69,88,91
 Such a strategy is synthetically 
demanding and requires synthesis of multiple analogues. 
69,91
 In an attempt to facilitate design of 





uses a crystal structure of a protein−ligand complex and calculates sites surrounding a ligand 
which could be favorably occupied by fluorine atoms. We demonstrated that FMAP could be 
used to rationalize improvement in activity upon introduction of fluorine in thienopyrimidine 
class of menin inhibitors as well as for several known inhibitors. FMAP may also represent a 
valuable tool for the design of new fluorine substitutions in protein ligands. FMAP relies solely 
on geometrical and structural criteria, and other effects, such as conformational or electronic 
changes resulting from fluorine substitution are not taken into account, which might represent a 
limitation of this approach. Nevertheless, we expect that FMAP can be very useful in the drug 
discovery projects to rationally design positions for fluorine atoms in ligand molecules. It may 
also support development of ligands with an optimal number of fluorine atoms to improve 
binding affinity while reducing ligand hydrophobicity and molecular weight. 
Introduction of the CF3 group in menin inhibitors as well as in several examples reviewed 
in this study results in a substantial gain in the affinity providing that optimal geometry of the 
C−F bond relative to the backbone carbonyl is achieved. Such C−F···C=O interactions provide 
unique opportunities to introduce favorable interactions between small molecule ligands and the 
polar protein backbone. Due to unique orthogonal geometry relative to the protein backbone, 
these interactions may be introduced into the binding sites where hydrogen bonds are not 
feasible. We found that substitution of CH3 for CF3 may increase ligand binding affinity as much 
as 10-fold. However, multipolar interactions involving the CF3 group may not be solely 
responsible for the increase in binding affinity. The effect of desolvation of more hydrophobic 
CF3 group is expected to lead to larger positive entropy of binding when compared with CH3. 
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The CF3 is roughly twice the size of a methyl group1 and due to a larger size and different shape; 
it may form more optimal van der Waals contacts within the binding site. Furthermore, the two 
additional fluorine atoms may participate in hydrophobic interactions with neighboring atoms. In 
the case of menin inhibitors, we found that not all fluorine atoms in the CF3 group are needed for 
the high affinity interaction. However, introduction of CFH2 or CF2H groups to achieve 
favorable C−F···C=O interactions may impact conformational equilibrium and favor a rotamer 
which cannot favorably interact with protein backbone or might cause high entropic cost of 
freezing out a desired rotamer. Despite that the H to F substitution represents a relatively minor 
modification; it may have a complex impact on ligand binding affinity. Our structural data 
27 
collected for the menin−inhibitor complexes offers a unique set of data which may facilitate 
better understanding of the C−F···C=O interactions.  





With increasing interest and demand in development of PPI inhibitors, efficient approaches are 
needed to optimize protein−ligand interactions at solvent exposed interfaces. As we 
demonstrated for the menin−MLL inhibitors, fluorine interactions with the protein backbone may 
offer such opportunities, particularly at the interfaces involving α-helical or β-sheet structures. In 
this study, we developed the FMAP approach to streamline the design of C−F···C=O 
interactions, which adds a new tool for structure-based design of new inhibitors targeting 
protein−protein interfaces as well as protein ligands in a more general context. The FMAP 
algorithm may facilitate prediction of fluorine substitutions in ligand molecules and support 




Chapter 3: Development of inhibitors targeting the menin-MLL 
interaction  
*The text and figures in this chapter are adapted from the following manuscripts:  
Borkin, D.; He, S.; Miao, H.; Kempinska, K.; Pollock, J.; Chase, J.; Purohit, T.; Malik, B.; Zhao, 
T.; Wang, J.; Wen, B.; Zong, H.; Jones, M.; Danet-Desnoyers, G.; Guzman, M. L.; Talpaz, M.; 
Bixby, D. L.; Sun, D.; Hess, J. L.; Muntean, A. G.; Maillard, I.; Cierpicki, T.; Grembecka, J. 
Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in 
vivo. Cancer Cell 2015, 27, 589-602. 
Borkin, D.; Pollock, J.; Kempinska, K.; Purohit, T.; Li, X.; Wen, B.; Zhao, T.; Miao, H.; Shukla, 
S.; He, M.; Sun, D.; Cierpicki, T.; Grembecka, J. Property Focused Structure-Based 
Optimization of Small Molecule Inhibitors of the Protein-Protein Interaction between Menin and 
Mixed Lineage Leukemia (MLL). J Med Chem 2016, 59, 892-913. 
A. Abstract 
MLL rearrangements generate oncogenic MLL fusion proteins and leads to the 
development of acute leukemia. The leukemic cells critically rely on the MLL fusion protein 
interaction with menin for sustained proliferative capacity.  This provides the rationale for 
targeting the menin-MLL interaction with small molecule inhibitors to abrogate MLL-rearranged 
acute leukemias.  We developed the thienopyrimidine class of small molecules to disrupt the 
menin-MLL interaction.  MI-2-2 served as a promising lead compound with demonstrative 
potency in leukemic cells but required improvements of drug-like properties for investigation of 
in vivo efficacy.  Structure-based design was extensively utilized to design small molecule 
analogs of MI-2-2 leading to MI-136 as a promising pharmacophore.  Systematic investigation 
of indole substituents was performed to improve potency, selectivity, solubility, and 
pharmacokinetic properties in mouse models.  These efforts led to the identification of 
compounds suitable for in vivo analysis and demonstrated a significant survival benefit in murine 
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models of MLL leukemias. Overall, this study provides a promising scaffold for clinical 
optimization and potential therapeutic applications. 
B. Background 
The menin-MLL fusion protein interaction is critical for the progression of MLL-
rearranged acute leukemias.
9,55
  Leukemias harboring chromosomal rearrangements of the MLL 
gene account for up to 10% of acute myeloid and acute lymphoblastic leukemias (AML and 
ALL) 
99
.  MLL rearrangements confers poor prognosis with a 5-year survival rate of about 35%
32
 
as a result of therapeutic intervention with limited efficacy.
24,32,33
   This evidence demonstrates 
the urgent need for effective targeted therapies. 
Menin is an essential oncogenic cofactor for MLL fusion proteins and plays the role as a 
scaffolding protein to bridge MLL and MLL fusion proteins to target genes.
9,55,58
 The menin 
interaction motif of MLL is located at the N-terminus and is maintained in the chromosomal 
rearrangements of MLL.
34,55,59,100
 Leukemic cell proliferation and blockage of hematopoietic cell 
differentiation is dependent on the MLL interaction with menin.
55,58
    
The menin-MLL interaction has been well characterized, including our own work, 
62,64,65
 
and we validated that this protein-protein interaction can be targeted by small molecules.
66,68
 The 
large central binding pocket on menin provides a large hydrophobic cavity for the N-terminal 
region of MLL to bind. Our group has developed the first small molecules targeting the MLL 
binding site on menin and effectively blocking this protein-protein interaction.
66,68
  However, no 
demonstration of in vivo efficacy has been reported for the menin-MLL inhibitors prior to this 
study described herein.  This owes to the difficulty in developing small molecule inhibitors of 
PPIs with favorable drug-like properties 
101
 although examples of PPI inhibitors do exist.
102,103
   
We developed the thienopyrimidine class of small molecule inhibitors with MI-2-2, the 
most potent analog described prior to the data presented in this thesis.  This compound exhibited 
relatively potent activity in MLL rearranged leukemic cells
66
 but required further optimization of 
drug-like properties.  We sought to improve the drug-like properties of the MI-2-2 compound of 
the thienopyrimidine class of menin-MLL inhibitors.  Structural analysis of menin with bound 
inhibitors guided the rationale for modifications while characterization of these inhibitors was 
performed through multi-parameter analysis to improve potency, selectivity, solubility, half-life 
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and exposure for their characterization in mouse models of MLL-leukemias.  My contribution to 
this project focused on structure-based design of small molecule analogs and characterization 
with biophysical and biochemical approaches.  
My contribution to this project was to crystalize the menin-inhibitor complexes, solve the 
crystal structures of these complexes and perform structural characterization of the 
thienopyrimidine class of menin-MLL inhibitors for their binding to menin.  I have also 
contributed to the rational design of new analogs targeting menin-MLL interaction to develop 
more potent and drug-like compounds.  I have also performed biochemical characterization of 
these analogs in an FP assay and biophysical analysis of their direct binding to menin by ITC to 
determine the binding affinities of the thienopyrimidine class of menin-MLL inhibitors. 
 
C. Results and Discussion 
C.1 Modifications of MI-2-2 to explore the menin binding pocket 
 
Figure 3.1 Crystal structure of MI-2-2 bound to menin.   
A. Structure of MI-2-2, IC50 values were measured by fluorescence polarization assay and binding 
affinity to menin determined by ITC.  B. Crystal structure of menin with MI-2-2 bound.  Menin is 
displayed as surface representation and key residues are highlighted. 
MI-2-2 has poor drug-like properties and requires optimization of potency in MLL 
leukemia cells, half-life in microsomal stability assays, and polarity which are currently limiting 
its use for in vivo applications.
70
 The crystal structure of MI-2-2 showed an unoccupied region of 
A. B. 
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menin near the 5,5-dimethyl-thiazolyl fragment, however further substitution of this moiety of 
MI-2-2 is synthetically difficult (Figure 3.1).  Therefore, we decided to leave the 
thienopyrimidine core unchanged and replaced the piperazine with an amino-piperidine linker 
substituted further with a benzyl group to generate compound 1.  The scaffold of compound 1 
exhibited only a 2-fold reduction in potency but provided a more synthetically tractable molecule 
to possibly explore substitutions on the benzyl ring.  Considering the size of the unoccupied 
space of MI-2-2 near the 5,5-dimethyl-thiazolyl fragment, we explored larger substituents at this 
region of the binding site.  Different isomers of the indole to replace the phenyl (compounds 2, 3, 
4) were explored; indole was chosen because of the synthetic feasibility of exploring additional 
substituents (Table 3.1).  As I will describe in Chapter 3, we identified the importance of the 
nitrile in the MIV class of menin-MLL inhibitors with loss of this hydrogen bond with W341 
resulting in a >20-fold decrease in potency. We therefore sought to mimic this interaction in the 
context of the thienopyrimidine scaffold.  Additional substitution of the indole in compound 4 
with a nitrile was performed to generate compound 5 with almost a 2-fold improvement in 
potency, Table 3.1.  Changing the indole orientation to generate compound 6 resulted in an 
additional 5-fold improvement in potency (Table 3.1). 
32 
To understand the molecular 
interactions involved in the MI-136 binding to 
menin we performed structural studies of 
menin-inhibitor complexes.  The 
thienopyrimidine core of MI-136 binds to 
menin in the same manner as compared to MI-
2-2 (Figure 3.2).  The nitrogen of the indole is 
involved in a hydrogen bond with the carboxyl 
group of Glu363 with a distance of 2.8 Å.  
Furthermore, the nitrile group forms a 
hydrogen bond with the sidechain of Trp341 
with a distance of 3.1 Å.  We then explored the 
replacement of the nitrile with other polar 
groups to maintain the hydrogen bond with 
Trp341 while lowering the clogP, Table 3.2.  
Replacement of the nitrile at position 2 of the 
indole with an amide (8) lead to 8-fold 
decrease in potency in the FP assay.  The 
sulfone moiety further decreased the potency 
about 12-fold compared to MI-136.  A more 
bulky 1H-tetrazole moiety does not fit well 
into this pocket reflected by over a 500-fold decrease in potency compared to MI-136.  
Therefore with the limited SAR at position 2 of the indole the nitrile was the most favorable 




Table 3.1 SAR and activities of analogues of the 
thienopyrimidine class of menin-MLL inhibitors. 
IC50 values were measured by fluorescence polarization 
assay, average values from two to three independent 
measurements ± SD are provided.  
Compound R IC50 (nM)
1 100 ± 7.8
2 237 ± 10
3 2350 ± 495
4 284 ± 44
5 153 ± 7.8
6 31 ± 3.5
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MI-136 had an optimal indole isomer and 
nitrile substitution with an IC50 of 31 nM in the FP 
assay (Table 3.1, Table 3.2).   We explored the 
binding affinity of MI-136 to menin by isothermal 
titration calorimetry (ITC) and obtained the Kd = 24 
nM (Figure 3.2).   Cellular potency of MI-136 was 
then assessed in MLL-AF9 transformed murine 
bone marrow cells (mBMCs) using the MTT cell 
viability assay with a growth inhibition at half 
maximal (GI50) of 0.55 µM (Figure 3.2).  The half-
life (T1/2) of MI-136 in murine liver microsomes 
was also measured resulting in T1/2 ~7 min (Figure 
3.2).  Further analysis of MI-136 against a panel of 
GPCRs reveals not substantial off-target 
activation.
71
 This data demonstrates MI-136 is a 
promising starting pharmacophore as a menin-MLL inhibitor.  
MI-136 has limited in vivo applications and requires additional development of potency 
and selectivity in MLL leukemia cells, metabolic stability, PK profile, and polarity of this class 
of menin inhibitors.  We focused medicinal chemistry efforts on the optimization of the 
cyanoindole of the MI-136 scaffold.  The solubility of MI-136 with a clogP = 4.3 needed 
optimization to decrease the lipophilicity which required the addition of more polar substituents.  
Furthermore, the potency of MI-136 in MLL-rearranged leukemia cells needed improvement and 
better selectivity compared to the Hoxa9/Meis1 transformed mBMCs (control cell line) as 
measured by the selectivity index (SI) (Figure 3.2). We also sought to improve the half-life of 
MI-136 in microsomal stability assays. Based on the crystal structure, several positions of the 
cyanoindole (1, 3, 4, 6) in MI-136 can be explored for further substitutions to form favorable 
contacts with menin. Therefore, a multi-parameter optimization was performed generating SAR 
around the MI-136 scaffold to not only increase potency but also improve drug-like properties of 




Table 3.2 SAR and properties of analogues 
with substitutions at position 2 of indole.  
IC50 values were measured by fluorescence 
polarization assay, average values from two to 
three independent measurements ± SD are 
provided. 
Compound R IC50 (nM) clogP
7 (MI-136) -CN 31 ± 3.5 4.3
8 251 ± 78 3.4
9 359 ± 5.0 3.2




Figure 3.2 Crystal structure of MI-136 bound to menin.  
A. Structure of compound 7, MI-136 and IC50 values were measured by fluorescence 
polarization assay, average values from two to three independent measurements ± SD 
are provided. Growth inhibition (GI50) measured in the MTT cell viability assay in 
MLL-AF9 transformed murine bone marrow cells after 7 days of treatment with 
compounds. SI, selectivity index calculated as a ratio of GI50 values measured in 
HM-2 cells and MLL-AF9 transformed cells. (T1/2) Half-life of compounds in mouse 
liver microsomes.  B. Figure adapted from (Borkin 2015).
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 ITC analysis of MI-136 
shows menin binding isotherm.
70
  C. Crystal structure of menin with MI-136 bound.  
Key residues and interactions are highlighted.  
 
C.2 Investigation of indole nitrogen substituents on MI-136 scaffold 
The nitrogen of the indole ring of MI-136 is involved in a hydrogen bond the Glu363 
sidechain and Glu366 sidechain is also in a close proximity (Figure 3.2).  Based on analysis of 
several menin structures these glutamic acid side chains are flexible and this area should be 





polar substitutions may adequately occupy this region of menin with hydrogen bond donor 
groups providing the potential for hydrogen bond formation with these acidic residues. 
To form a hydrogen bond with the acidic residues near this site, we rationalized a 
hydroxyl substituent should form a hydrogen bond with these glutamic acids while lowering the 
clogP.  We explored a hydroxymethyl moiety (11) at the indole nitrogen and found no change in 
potency (Table 3.3).  Further extension of the hydroxyethyl (12) led to no improvement in 
potency compared to MI-136.   Interestingly, compound 11 was about 4-fold more potent in 
growth inhibition of MLL-AF9 cells compared to compound 12 despite similar in vitro activity 
and clogP values (Table 3.3).  
We then explored further extension of the linker to incorporate a 1,2-propanediol group 
to form compound 13.  Compound 13 had similar potency to compound 12 but was a racemic 
mixture.  To identify if a single enantiomer was more potent, we synthesized each enantiomer.  
13-R and 13-S had similar potencies and crystallographic analysis of each enantiomer in 
complex with menin revealed similar binding modes with the only difference being the 
positioning of the secondary hydroxyl (Figure 3.3). The 13-R compound is the only enantiomer 
with the secondary hydroxyl group forming a hydrogen bond with Glu363 (Figure 3.3).  The 
terminal hydroxyl of both enantiomers also forms a hydrogen bond with Glu366 (Figure 3.3). 
Modification of the secondary hydroxyl to a methoxy in the context of each enantiomer 
(14-R, 14-S) led to no significant changes in binding affinity for either enantiomer (Table 3.3). 
We then explored substitution of the terminal hydroxyl to methoxy (15) which led to a 3-fold 
decrease in potency compared to compounds 14-R and 14-S (Table 3.3).  Despite similar in vitro 
potencies for the -R and -S enantiomers of compounds 13 and 14 the cellular activity was about 
2-fold more potent for the -R enantiomer in both cases (Table 3.3).  Further modifications of the 
secondary hydroxyl with a bulkier branched substituent (16) led to almost a 2-fold increase in 
potency in the FP assay. Compound 16 also had 1.5 units higher clogP value compared to 
compound 13.  Importantly, compound 16 had a significantly shorter T1/2 in murine liver 
microsomes with <3 min compared to >60 min for compound 13 (Table 3.3).  Therefore, 
hydrophobic additions to the secondary hydroxyl resulted in improved activity in MLL-AF9 cells 




Figure 3.3 Structure-based design of indole nitrogen substituents.   
A. Structure of compound 13-(RS) and IC50 values were measured by fluorescence 
polarization assay. B. Crystal structure of compound 13-(RS) with both enantiomers 
bound to menin. Hydrogen bonds with Glu363, Glu366 and Trp341are highlighted. 
 
To explore additional hydrogen bond donors and electrostatic interactions with the 
glutamic acids Glu363 and Glu366 an aminoethyl moiety at the indole nitrogen was investigated 
(compound 17).  Compound 17 was 2.5-fold weaker than the hydroxyethyl analog (12) in the FP 
assay and 6-fold weaker in inhibiting proliferation of MLL-AF9 cells (Table 3.3 and 3.4).  This 
positively charged amine may impact cell permeability explaining the decrease in cellular 
activity. To remove the positive charge of the amino group we explored an amide (MI-389, 
compound 18) modification of the indole nitrogen.  Compound 18 had slightly improved potency 
to compound 12 but improved cellular activity (GI50 = 0.78) and exhibited a good half-life in 
mouse liver microsomes (T1/2 = 54 min) (Table 3.4).  The crystal structure of compound 18 in 
complex with menin demonstrated the nitrogen of the amide is involved in hydrogen bonds with 
both Glu363 and Glu366 (Figure 3.4).  18 has also improved the polarity significantly with a 
clogP = 3. Addition of an α-methylated amide (19) had a 10-fold reduction in potency (Table 





Figure 3.4 Structure-based design of indole nitrogen substituents.   
A. Structure of compound 18 and IC50 values were measured by fluorescence 
polarization assay. B. Crystal structure of compound 18 bound to menin. Hydrogen 
bonds with Glu363, Glu366 and Trp341are highlighted.  
 
Next, several 5-member aromatic heterocycles with hydrogen bond donors were 
explored.  A 4-methyl-1H-imidazole group in compound 20 had slight decrease in potency in 
vitro compared to compound 18 but almost a 4-fold improvement in cellular activity (Table 3.4).  
The half-life of 20 was only about 5 min in microsomes.  A 3-methyl-1H-pyrazole in compound 
21 had similar inhibitory activity to compound 20 in vitro and in cells with no improvement in 
half-life (Table 3.4).  A 5-methyl-2H-tetrazole in compound 22 and the 3-methyl-1H-1,2,4-
triazole in compound 23 had about a 5-fold decrease and 3-fold decrease in potency respectively 
compared to compounds 20 and 21.  The 4-methyl-1H-pyrazole in compound 24 had about a 2-
fold improvement in the FP assay compared to compound 20.  The 4-methyl-1H-1,2,3-triazole in 
compound 25 had similar potency compared to compound 24.  Compounds 24 and 25 displayed 
the best microsomal stability half-life in this series of heterocycles with good cellular activity.  
Limitations in the microsomal stability half-life may possibly be overcome by exploring 
modifications at other regions of the cyanoindole. 
Modifications of the indole nitrogen demonstrate a valuable region for substitutions to 
increase potency, solubility and stability of these analogs of MI-136. The substitutions with the 
best potency in MLL-AF9 cells are 4-methylpyrazole (24) and 4-methyltriazole (25). The 






Table 3.3 SAR and properties of analogues with substitutions at position 1 of indole. 
IC50 values were measured by fluorescence polarization assay, average values from two to three independent 
measurements ± SD are provided. Growth inhibition (GI50) measured in the MTT cell viability assay in MLL-AF9 
or Hoxa9/Meis1 (HM-2) transformed murine bone marrow cells after 7 days of treatment with compounds. SI, 
selectivity index calculated as a ratio of GI50 values measured in HM-2 cells and MLL-AF9 transformed cells. (T1/2) 
Half-life of compounds in mouse liver microsomes.  
 
Compound R IC50 (nM) MLL-AF9 HM-2 SI T 1/2 (min) clogP
7 (MI-136) H 31 ± 3.5 0.55 3 5.5 6.8 4.3
11 31 ± 6 0.25 4 16 4.7 3.3
12 35 ± 2.8 1.1 6.2 5.6 18 3.5
13-(RS) 37 ± 2.8 3.4 >12 >3.5 >60 3.1
13-R 46 ± 2.8 1.7 >40 >24 48 3.1
13-S 42 ± 0.7 3.8 ND ND >60 3.1
14-R 40 ± 1.4 0.36 9.7 27 <3 3.9
14-S 37 ± 6.0 0.66 6.9 11 5.2 3.9
15 101 ± 13 2.1 ND ND <3 3.4







Table 3.4 SAR and properties of analogues with substitutions at position 1 of indole. 
IC50 values were measured by fluorescence polarization assay, average values from two to three independent 
measurements ± SD are provided. Growth inhibition (GI50) measured in the MTT cell viability assay in MLL-AF9 
or Hoxa9/Meis1 (HM-2) transformed murine bone marrow cells after 7 days of treatment with compounds. SI, 
selectivity index calculated as a ratio of GI50 values measured in HM-2 cells and MLL-AF9 transformed cells. (T1/2) 
Half-life of compounds in mouse liver microsomes. 
 
  
Compound R IC50 (nM) MLL-AF9 HM-2 SI T 1/2 (min) clogP
17 110 ± 16 6.3 >24 4 >60 3.6
18 (MI-389) 25 ± 4.9 0.78 25 32 54 3
19 244 ± 57 ND ND ND ND 3.3
20 42 ± 9.2 0.2 15 75 4.8 3.7
21 31 ± 4.9 0.3 ND ND 3 3.9
22 153 ± 7.1 ND ND ND ND 3.2
23 94 ± 21 10 ND ND 4 3.4
24 23 ± 4.2 0.26 6.9 27 8.3 3.9
25 27 ± 2.8 0.33 10 30 11 3.5
GI50 (uM)
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C.3. Exploring modifications at positions 3, 4, and 6 of the of indole ring in MI-136 scaffold 
The crystal structure of MI-136 in complex with menin demonstrated that the carbon at 
position 3 of the indole is close to the protein backbone (Figure 3.2).  We explored a few small 
substitutions at this position to possibly improve the potency of MI-136.  Fluorine substitution 
(26) resulted in a 3-fold decrease in potency and poor cellular activity (Table 3.5).  Amino 
substitution (27) and methyl (28) at this position were also not favorable and exhibited poor 
cellular activity (Table 3.5). Based on these data we concluded that position 3 on the indole is 
unable to accommodate further substitutions most likely due to lack of space for modifications. 
 sty
 
Figure 3.5 Structure-based design of substituents at position 4 of the indole.  
A. Structure of MI-463 (compound 30) and IC50 values were measured by fluorescence polarization assay is 
displayed. B. Crystal structure of compound 30 bound to menin. Hydrogen bonds with Glu363 and Trp341are 
highlighted. C. Figure adapted from (Borkin 2015).
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In contrast, the crystal structure of menin-MI-136 revealed that position 4 of the indole 
approaches a hydrophobic patch formed primarily by Tyr323.  Analysis of the MI-136 crystal 
structure suggests that small hydrophobic substitutions could fit in this region of the binding site.  
Chlorine at position 4 (compound 29) had good in vitro activity (IC50 = 22 nM) but cellular 
activity of this compound was relatively weak (GI50 = 1.1 µM in MLL-AF9 transformed cells). 
The microsomal stability half-life of compound 29 was improved 4-fold compared to MI-136.  
Interestingly, substitution with a methyl at position 3 of the indole (MI-463, compound 30) 
increased inhibitory activity by about 2-fold in the FP assay compared to compound 29 and 
showed significant improvement in the potency in MLL-AF9 cells with the GI50 = 0.2 µM 
(Table 3.5).  Compound 30 had about 2-fold decrease in half-life in microsomes compared to 
A. B. C. 
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compound 29. Structural analysis of compound 30 demonstrates a similar binding mode to the 
one observed for MI-136 with the methyl group forming hydrophobic contacts with Tyr323 
(Figure 3.5 B).  Further extension of the methyl to an ethyl (31) led to decrease in both in vitro 
inhibitory activity and cellular potency (Table 3.5).  In attempt to maintain a lower clogP with 
substituents at this position a hydroxyl group was incorporated (32).  Unfortunately, this led to a 
decrease in in vitro inhibitory activity versus MI-463.  Replacement of the hydroxyl with 
methoxy (36) led to a slight improvement in vitro potency but a 2.5-fold improvement activity in 
MLL-AF9 cells compared to the ethyl (31).   
Position 6 of the indole is primarily solvent exposed and therefore small substitutions of 
the indole were explored to stabilize the conformation of the indole.  Fluorine was not tolerated 
at this position as reflected by over 3-fold decrease in activity compared to unsubstituted MI-136 
(Table 3.5).  Hydroxyl at this position (compound 39) lowered the clogP = 3.7 and had excellent 
activity in MLL-AF9 cells with a GI50 = 0.18 µM and improved SI over MI-136.   Further 
substitution to a methoxy (36) or ethoxy (37) resulted in a slight decrease in growth inhibition in 
cells compared to 35 (Table 3.5). 
In order to gain a thorough understanding of the SAR at this position we performed 
structural analysis of compound 36 in complex with menin (Figure 3.6 B).  Compound 36 
demonstrated an intramolecular hydrogen bond (3.0 Å) between the oxygen of the methoxy and 
the nitrogen of the piperidine ring.  This interaction most likely leads to the stabilization of this 
indole conformation that is conducive to the binding conformation to menin (Figure 3.6 B).  
Overall, the hydroxyl and methoxy groups at position 6 were most optimal substituents with 
improvements in cellular activity and slight improvement in clogP.  Improvements in the 
metabolic stability to achieve a longer half-life are required to investigate the efficacy of these 
molecules in the mouse models of MLL leukemia. 
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Figure 3.6 Structure-based design of indole position 6 modifications in MI-136.   
A. Structure of compound 36, compound 36 and IC50 values were measured by fluorescence polarization assay is 









Table 3.5 SAR and properties of analogues with substitutions at position 3, 4, or 6 of indole.   
IC50 values for inhibition of the menin-MLL interaction measured by fluorescence polarization assay, average values 
from two to three independent measurements ± SD are provided. Growth inhibition (GI50) measured in the MTT cell 
viability assay in MLL-AF9 or Hoxa9/Meis1 (HM-2) transformed murine bone marrow cells after 7 days of 
treatment with compounds. SI, selectivity index calculated as a ratio of GI50 values measured in HM-2 cells and 
MLL-AF9 transformed cells. (T1/2) Half-life of compounds in mouse liver microsomes. 
 
  
Compound R1 R2 R3 IC50 (nM) MLL-AF9 HM-2 SI T 1/2 (min) clogP
7 (MI-136) H H H 31 ± 3.5 0.55 3 5.5 6.8 4.3
26 F H H 96 ± 0.7 1.7 ND ND 5.7 4.5
27 NH2 H H 124 ± 30 5.2 ND ND 27 3.3
28 CH3 H H 111 ± 16 2.6 ND ND 4.8 4.9
29 H Cl H 22 ± 3.5 1.1 11 10 28 5
30 (MI-463) H CH3 H 15 ± 1.4 0.2 5.6 28 14 4.7
31 H CH2CH3 H 21 ± 4.2 1 ND ND 10 5.2
32 H OH H 138 ± 15 ND ND ND 4 3.7
33 H OCH3 H 62 ± 17 0.4 5.5 14 10 4.3
34 H H F 109 ± 5.6 3 >12 >4 9 4.5
35 H H OH 20 ± 5 0.18 >10 >56 6.6 3.7
36 H H OCH3 22 ± 0.7 0.34 16 47 3.7 4.3
37 H H Oet 47 ± 4.2 0.45 5.3 12 11 4.8
GI50 (uM)
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C.4 Generating analogs through combinations of optimal substituents on the indole ring in 
MI-136 scaffold 
Combinations of the optimal substituents at positions 1, 4, and 6 of the indole ring were 
explored to identify if the simultaneous integration of these moieties will improve the potency 
and drug-like properties of these inhibitors. We first explored the combinations at positions 4 and 
6 of the indole.  Compound 38 combined the methyl at position 4 and hydroxyl at position 6 
which led to about a 2-fold decrease in potency (Table 3.6) with relatively similar activity in 
MLL-AF9 cells.  Compound 38 had significantly improved microsomal metabolic stability 
compared to 4-methyl (38) or 6-hydroxyl (35) alone.  Methoxy group at position 4 in the context 
of 4-methyl (compound 39) had improved activity in MLL-AF9 cells but slight decreased T1/2 
compared to 38.   
We went on to explore the combinations at position 4 and 6 in the context of 
hydroxyethyl at position 1 of the indole.  Compound 12 with unsubstituted 4 and 6 positions had 
poor cellular activity despite a low clogP = 3.5.  Combinations with methyl at position 4 and the 
absence of a substituent (40), hydroxy (41) or methoxy (42) at position 6 were explored to 
improve potency.  The triple substituted compound (42) with the methoxy at position 6 was the 
most potent in the MTT cellular assay with slight improvement compared to compound 40 or 41.   
The methyl at position 4 (40) was the only analog that improved microsomal stability compared 
to compound 12.  
The amide at position 1 (18) had sub-micromolar potency in MLL-AF9 cells and almost 
an hour half-life in murine microsomes.  Combination with methyl at position 4 (43) or 4-methyl 
and 6-methoxy (44) resulted in improvement in the cellular activity with some improvement in 
half-life.  This group of analogs had improved clogP values as well. There was not much of an 
improvement in cellular potency between compounds (43) and (44), therefore the methoxy at 





Table 3.6 SAR and properties of analogues with substitutions at positions 3, 4, or 6 of indole.  
IC50 values were measured by fluorescence polarization assay, average values from two to three independent 
measurements ± SD are provided. Growth inhibition (GI50) measured in the MTT cell viability assay in MLL-AF9 or 
Hoxa9/Meis1 (HM-2) transformed murine bone marrow cells after 7 days of treatment with compounds. SI, selectivity 
index calculated as a ratio of GI50 values measured in HM-2 cells and MLL-AF9 transformed cells. (T1/2) Half-life of 
compounds in mouse liver microsomes. 
 
  
Compound R1 R2 R3 IC50 (nM) MLL-AF9 HM-2 SI T 1/2 (min) clogP
7 (MI-136) H H H 31 ± 3.5 0.55 3 5.5 6.8 4.3
30 (MI-463) H CH3 H 15 ± 1.4 0.2 5.6 28 14 4.7
38 H CH3 OH 27 ± 1.4 0.22 12 55 56 4.1
39 H CH3 OCH3 40 ± 0.9 0.1 11 110 39 4.7
12 H H 35 ± 2.8 1.1 6.2 5.6 18 3.5
40 CH3 H 44 ± 8.4 0.44 5.6 13 23 3.9
41 CH3 OH 27 ± 0.5 0.4 10 25 11 3.7
42 CH3 OCH3 16 ± 2.0 0.36 15 69 7.8 4.1
18 (MI-389) H H 25 ± 4.9 0.78 25 32 54 3
43 CH3 H 27 ± 5.6 0.47 >25 >53 59 3.4
44 CH3 OCH3 37 ± 3.5 0.42 >25 >60 >60 3.5
GI50 (uM)
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The series of 5-membered aromatic heterocycles resulted in analogs with optimal 
substituents at position 1 of the indole in terms of potency and growth inhibition in MLL-AF9 
cells but required improvement in the microsomal stability half-life of this series. Therefore, 
investigation of combinations of substituents at positions 4 and 6 in the context of 
methylpyrazole (24) and methyltriazole (25) was explored.  The methylpyrazole substituent 
present in 24 was systematically explored with optimal combinations of substituents at position 4 
and 6.  The 4-hydroxy substituent (45) improved cellular activity 4-fold with a GI50 = 83 nM 
value and a SI = >100 (Table 3.7).  Methoxy group at position 4 (46) decreased the potency 
almost 3-fold but improved the microsomal stability half-life over 2-fold. Methyl at position 4 
(compound 47, MI-503) slightly decreased the microsomal stability half-life compared to (46) 
and slightly improved in vitro potency.  Structure determination of compound 47 with menin 
shows the methylpyrazole involved in a hydrogen bond (3.1 Å) with Glu366 (Figure 3.7). The 4-
methyl and 6-hydroxyl combination of substituents (48) did not lead to significant improvements 
in growth inhibition of MLL-AF9 cells.  Compound 49 with the 4-methyl and 6-methoxy 
substituents improved potency in cells and improved the half-life to about 1h (Table 3.7).   
 
Figure 3.7 Exploring combinations of substituent at positions 1 and 4 of indole.  
A. Structure of MI-503, compound 47 and IC50 values were measured by fluorescence polarization assay is displayed. B. 
Crystal structure of compound 47 bound to menin (middle panel). Hydrogen bonds with Glu366 and Trp341are 
highlighted. C. Figure adapted from (Borkin 2015).
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Figure 3.8 Analysis of substituent combinations at positions 1 and 6 of indole.   
A. Structure of compound 45 and inhibitory activity for inhibition of the menin-MLL interaction as determined 
in FP assay is displayed. B. Figure adapted from (Borkin 2016).
71




The 4-methyltriazole (25) was then explored in combination with the 4-methyl (50), the 
4-methyl 6-hydroxyl (51), and the 4-methyl 6-methoxy (52).  Compound 50 exhibited the most 
potent cellular activity and longest microsomal stability half-life, around 1h.  Interestingly, 
comparing compound 50 and 47, the impact of the 4-methyl on compound 50 is almost 3-fold 
higher compared to 47 despite relatively similar half-lives in murine microsomes of the 
unsubstituted 4 position of the indole (Table 3.7).  Structure determination of menin in complex 
with compound 49 shows a similar binding mode to each singly substituted analog of the 




Figure 3.9 Exploring combinations of substituent at positions 1, 4 and 6 of indole.   
A. Structure of compound 49 and IC50 values were measured by fluorescence polarization assay is displayed. B. 
Crystal structure of compound 49 bound to menin. Intramolecular hydrogen bond and hydrogen bonds with 







Table 3.7 SAR and properties of analogues with substitutions at positions 3, 4, or 6 of indole.  
IC50 values were measured by fluorescence polarization assay, average values from two to three independent 
measurements ± SD are provided. Growth inhibition (GI50) measured in the MTT cell viability assay in MLL-AF9 or 
Hoxa9/Meis1 (HM-2) transformed murine bone marrow cells after 7 days of treatment with compounds. SI, selectivity 
index calculated as a ratio of GI50 values measured in HM-2 cells and MLL-AF9 transformed cells. (T1/2) Half-life of 
compounds in mouse liver microsomes. 
 
  
Compound R1 R2 R3 IC50 (nM) MLL-AF9 HM-2 SI T 1/2 (min) clogP
24 H H 23 ± 4.2 0.26 6.9 27 8.3 3.9
45 (MI-538) H OH 21 ± 1.4 0.083 9 108 14 3.7
46 H OCH3 24 ± 3.0 0.29 6.7 23 35 4.1
47 (MI-503) CH3 H 14 ± 2.1 0.22 >5 >23 21 4.4
48 CH3 OH 18 ± 1.4 0.27 13 48 25 4.2
49 (MI-574) CH3 OCH3 12 ± 2.0 0.18 4.2 23 55 4.5
25 H H 27 ± 2.8 0.33 10 30 11 3.5
50 CH3 H 23 ± 2.0 0.25 8 32 59 4
51 CH3 OH 17 ± 1.4 0.42 10 24 25 3.8




Table 3.8 Pharmacokinetic profile of menin-MLL inhibitors in blood plasma of murine models.  
Figure adapted from (Borkin 2015 and Borkin 2016)
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 (Top) Structures and aIC50 values were measured by 
fluorescence polarization assay. Growth inhibition (GI50 values) measured in the MTT cell viability assay in MLL-
AF9 transformed murine bone marrow cells after 7 days of treatment with compounds. (Bottom) Cmax (maximum 
compound concentration) in blood plasma, AUCobs (area under the curve), Clobs (Clearance), T1/2 (half-life), Vss 
(volume of distribution), F (oral bioavailability). MI-574 was an 8 h experiment; the other compounds were 
analyzed with 24h experiments. 
C.5 Pharmacokinetic analysis of menin-MLL inhibitors in a murine model. 
Compounds that exhibited good cellular activity, selectivity, and microsomal stability 
were selected for follow-up studies in mice to determine the PK profile. The PK profile for MI-
136 was determined to be used as a reference.   Intravenous and oral routes of dosing were 
explored for all compounds.   MI-503 and MI-538 demonstrated enhanced exposure (area under 
the curve, AUC), Cmax (maximum compound concentration), and a low rate of clearance (Clobs) 
(Table 3.8) compared to the parent compound, MI-136. There was almost a 2-fold difference in 
T1/2 between compounds MI-503 and MI-538.  Further investigation of this difference revealed 
MI-538 undergoing phase II metabolism with a glucoronidation site at the hydroxyl 
substituent.
71




Figure 3.10 Treatment with MI-503 reduces tumor burden and demonstrates survival benefit.   
Figure adapted from (Borkin 2015).
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 A.  Bioluminescent imaging of MV4:11 cells expressing luciferase 
transplanted into NSGS mice.  The time points after the start of treatment with MI-503 at 60mg/kg, twice daily i.p. 
or vehicle, n = 9 mice per group.
70
 B. Kaplan-Meier survival curves of MI-503 and vehicle treated C57BL/6 mice 
transplanted with 1 x 10
5
syngeneic MLL-AF9 leukemic cells isolated from primary recipient mice (n=9 mice per 
group).  Treatment was performed for 10 days as indicated on the graph.  The p values were calculated using the log 




C.6 MI-503 treatment reduces MLL leukemia burden and improves survival in murine 
model. 
Treatment with MI-503 was explored in a disseminated xenotransplantation murine 
model using MV4;11 cells expressing luciferase.  NSGS mice were injected through the tail vein 
with the intiation of treatment 5 days later.  The progression of leukemia was monitored via 
bioluminescence imaging.  Twice dialy treatment was used as a result of the PK profile of MI-
503 to maintain therapeutically relevant compound concentration in the blood plasma.  
Treatment was performed for ten consecutive days which demonstrated a decreased proliferation 
rate of MV4;11 cells compared to vehicle samples as evident by the reduction in 
bioluminescence intensity (Figure 3.10 A).   
 We then investigated the effect of MI-503 on the survival benefit of a MLL-AF9 
transformed BMCs murine model.  Treatment with MI-503 at 80mg/kg twice daily by oral 
A. B. 
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gavage began 5 days post transplantation and continued for 10 consecutive days.  Treatment with 
MI-503 demonstrated a median survival benefit of ~45% compared to vehicle treated mice.  This 





MLL rearranged leukemias represent an area of urgent need for the development of novel 
therapeutics. 
32
  The menin-MLL interaction has been proposed to be a promising therapeutic 
target as a result of analysis by genetic manipulations.
55,86
  We have demonstrated that inhibition 
of the menin-MLL interactions with pharmacological agents impairs the progression of MLL 
rearranged leukemia.   
Overall we have performed optimization of the lead compound (MI-136) of the 
thienopyrimidine scaffold.  A multi-parameter optimization was performed for this 
thienopyrimidine class of inhibitors to achieve an improved PK profile for in vivo utility.  MI-
136 required improvement in potency, solubility, microsomal stability, and oral bioavailability 
for investigation in vivo.  Unsubstituted position 3 of the indole ring was most optimal with all of 
the substituents explored at this position decreasing in vitro potency.  At position 4 of the indole 
the methyl substituent was optimal and provided potent activity in MLL-AF9 cells.  The 
hydroxyl at position 6 of the indole increased polarity and was potent in MLL-AF9 cells. The 
optimal analog at position 1 was the 4-methylpyrazole which improved solubility and potency in 
cells.  Interestingly, when we combined the optimal substituents at each position we did not find 
a synergistic improvement in the half-life of murine liver microsomes.  Ultimately the 
combinations of the methyl at position 4 and the 4-methylpyrazole at position 1 of the indole 
generating compound MI-503 exhibited the best PK properties.  
We were able to demonstrate that treatment with MI-503 reduces the MLL leukemia 
tumor burden and contributes to a significant survival benefit.  Importantly, despite the role of 
MLL in normal hematopoiesis,
104
 the menin-MLL inhibitors do not effect this process.
70
   This 
analysis supports the further development of the thienopyrimidine class of menin-MLL inhibitors 
for clinical development.  Additional optimization is required to investigate the optimal 
formulation, PK analysis in other species and long-term toxicology.  Additional analogs 
53 
surrounding substituents of the cyanoindole ring could be explored to circumvent any possible 




Chapter 4: Design and characterization of the hydroxy- and 
aminomethylpiperidine class of menin-MLL inhibitors 
* The text and figures in this chapter are adapted from the following manuscripts:  
He, S.; Senter, T. J.; Pollock, J.; Han, C.; Upadhyay, S. K.; Purohit, T.; Gogliotti, R. D.; 
Lindsley, C. W.; Cierpicki, T.; Stauffer, S. R.; Grembecka, J. High-affinity small-molecule 
inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural 
protein-protein interaction. J Med Chem 2014, 57, 1543-56. 
A. Abstract 
The menin-MLL interaction is crucial for the development of MLL rearranged acute 
leukemias.  Therefore, targeting this interaction with small molecule inhibitors represents a 
potential therapeutic method of modulating the disease progression. A high-throughput screening 
campaign led to the identification of a novel class of small molecules targeting the menin-MLL 
complex.  The hydroxy- and aminomethylpiperidine class of menin-MLL inhibitors closely 
mimic the most critical residues of MLL for the binding interaction with menin.  We used 
structure-based design to develop this lead compound into a potent inhibitor of the menin-MLL 
complex and demonstrate efficacy in leukemic cells.   This novel scaffold provides a new class 
of inhibitors for the development of a potential therapeutic approach to targeting menin-MLL 
dependent leukemias.  
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B.  Background 
B.1 Identification of a chemically distinct class of menin-MLL inhibitors 
Developing small molecule inhibitors of protein-protein interactions (PPIs) is a 
challenging task.
105,106
  Small molecule inhibitors of PPIs typically require increased molecular 
weight to achieve sufficient potency.
101
  As a result, they can provide challenges with cell-
permeability, poor oral bioavailability, and optimized drug like properties.
101
  Successful 
development of PPI inhibitors have been reported 
106-110
 providing evidence that some PPIs are 
susceptible to small molecule inhibition.  Some examples have reached clinical trials,
111,112
 
supporting the effort for development of PPI inhibitors.   
We and others have demonstrated that the menin-MLL interaction is an important target 
for MLL-rearranged leukemias.
77,68
  However, there are several difficulties targeting this PPI. 
The large interface of the menin-MLL interaction poses a difficult system to inhibit with small 
molecule inhibitors.  The most important hotspot residues have been characterized but 
simultaneous inhibition of the P10, P13 and F9 pockets may be difficult.  Additionally, the 
bivalent interaction motifs provide another level of complexity and difficulty in the development 
of inhibitors of the interaction.
66,67
  
We have described the development of the thienopyrimidine class of menin-MLL 
inhibitors in previous chapters but we sought to identify a novel pharmacophore to target this 
interaction. The thienopyrimidine classes of inhibitors do not bind to all of the hotspot regions 
important for the MLL high affinity interaction with menin.
66
 The P10 pocket is unoccupied by 
the thienopyrimidine class of menin-MLL inhibitors with the F9 and P13 pockets occupied by 
these compounds. This limitation could provide a barrier to achieve potent menin-MLL 
inhibitors. Therefore, a chemically distinct scaffold from the thienopyrimidine class of inhibitors 
will provide an alternative method for developing inhibitors of this interaction.  It is important in 
inhibitor discovery campaigns to have more than one lead compound because it is difficult to 
predict the potential for downstream toxicity or off-target effects that are associated with an 
entire class of compounds.  In addition, recent other efforts to identify inhibitors of this 
interaction have been reported including peptidomimetics but the absence of cellular and in vivo 
data suggests possible issues around drug-like property optimization.
67
 This demonstrates the 
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need for alternative pharmacophores to increase the potential of identifying a clinical candidate 
therapeutic. 
My contribution to this project was to crystalize the menin-inhibitor complexes, solve the 
crystal structures of these complexes and perform structural characterization of the 
thienopyrimidine class of menin-MLL inhibitors for their binding to menin.  I also contributed to 
the rational design of these inhibitors to develop more potent analogs with improved drug-like 
properties.  I also performed biochemical characterization of these analogs in an FP assay to 
determine inhibitory activity of these compounds and biophysical analysis by ITC to assess the 
binding affinity of the methylpiperidine analogs for their binding to menin. 
C.  Results and Discussion 
C.1 HTS campaign and identification of the minimal pharmacophore.  
A HTS campaign was performed to identify novel small molecule inhibitors of the 
menin-MLL complex using a library of about 288,000 compounds at the NIH Molecular 
Libraries Probe Production Centers Network (MLPCN).
113
  The primary screen utilized a 
fluorescence polarization (FP) assay with a fluorescein-labeled MBM1.
73
 A follow-up secondary 
screen was performed with a homogenous time-resolved fluorescence (HTRF) assay.
73
 Finally, 
NMR saturation transfer difference (STD) was used to validate the direct binding of these small 




The best inhibitor identified from this screen was 1, 
MIV-1, (4-(2-hydroxy-3-(4-
(hydroxydiphenylmethyl)piperidin-1-yl)-propoxy)benzonitrile 
(Figure 4.1). This compound belongs to the 
hydroxymethylpiperidine class and exhibited an IC50 value of 
12.8 μM for inhibition of the menin-MLL interaction.  
To identify the minimal pharmacophore for this class 
of compounds we investigated removal of the hydroxyl group 
in the linker of MIV-1 to generate MIV-2 (2) (Table 4.1).  
The potency for MIV-2 was unaffected with an IC50 = 10.8 
μM.  Further loss of the hydroxyl substituent from the 
quaternary carbon led to more than 20-fold decrease in 
potency (3).  Additionally, removal of the nitrile group 
resulted in an IC50 = >250 μM in compound 4.  This analysis helped to identify the minimum 
scaffold that is needed for the potency of the initial HTS hit.     
 
Table 4.1 SAR and activity of MIV analogues.  
IC50 values were measured by fluorescence polarization assay, average 
values from two to three independent measurements ± SD are provided. 
 
Compound X R1 R2 R3 R4 IC50 (µM)
1                     
(MIV-1)
-OH -CN -OH 12.8 ± 1.6
2                     
(MIV-2)
-OH -CN -H 10.8 ± 0.2
3 -H -CN -H 205 ± 63
4 -OH -H -H >250
5                     
(MIV-nc)
-OH -H -CN -H 234 ± 22
 
Figure 4.1 Identification of the 
most potent HTS hit.  
Figure adapted from (He 2014).
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Figure 4.2 Determining binding affinity of each MIV-3 enantiomer.  
Figure adapted from (He 2014).
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 A. Structure and IC50 values were measured by fluorescence polarization assay for 




B.  A. 
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C.2 Structure based-design of MIV analogs  
MIV-2 was then used as an initial lead inhibitor for further medicinal chemistry 
development to increase inhibitory activity of these compounds for blocking the menin-MLL 
interaction.  We first explored substitutions of a phenyl ring with various hydrophobic 
substituents listed in (Table 4.2).  Replacement of the phenyl ring with hydrogen or a methyl led 
to a ~20-fold loss in potency; suggesting that larger bulky hydrophobic substituents at this site 
are most likely needed to maintain the inhibitory potency of these inhibitors. Therefore, we 
explored a few larger alkyl groups such as n-butyl (7) and iso-propyl (9) which resulted in IC50 = 
15.3 µM and IC50 = 4.1 µM respectively.  We performed systematical analysis of cycloalkyl 
substituents ranging from cyclopropyl to cyclohexyl.  Cyclopentyl was the most potent saturated 
carbocycle we explored with an IC50 = 390 nM for the racemic mixture (Figure 4.2).  Further 
increase in the ring size resulted in decreased activity as demonstrated with the cyclohexyl 
analogue 12, which resulted in about 4-fold decrease in in vitro potency. We concluded that 
cyclohexyl was the optimal substitution at this position based on the SAR performed at this site.  
We further assessed the individual enantiomers of MIV-3, and MIV-3R has an IC50 = 
270 nM, while MIV-3S has an IC50 = 529 nM (Figure 4.2).  We then explored MIV-3R and 
MIV-3S by ITC with Kd = 285 nM and Kd = 952 nM respectively (Figure 4.2).    MIV-3R 
demonstrates over 40-fold improvement compared to the initial HTS hit MIV-1. 
60 
 
Figure 4.3 MIV-3 enantiomers bind to menin in the MLL binding site.  
Figure adapted from (He 2014).
73
 Crystal structures of menin in complex with each 
enantiomer of MIV-3. 2Fo − Fc electron density maps for ligands contoured at the 1σ 
level. Menin is shown as a surface representation. 
C.3 Hydroxymethylpiperidine Inhibitors Mimic the Most Critical Interactions of MLL 
with Menin. 
To gain a complete understanding of the differences in the binding affinity of the MIV-3 
enantiomers we performed structural studies of each enantiomer bound to menin.   Both 
enantiomers bind in a similar extended fashion (Figure 4.3).  The majority of the contacts of the 
MIV-3 with menin are hydrophobic in nature with only one direct hydrogen bond with the nitrile 
and the indole nitrogen of Trp341 of menin (Figure 4.4).  There is a water-mediated hydrogen 
bond between the hydroxyl group of MIV-3 and the Asp190 side chain on menin.  Loss of either 
hydrogen bond resulted in about 20-fold decrease in inhibitory activity as shown by analogues 3 
and 4 demonstrating the importance of this hydrogen bond network (Table 4.1).   
The phenyl ring of  MIV-3R fits into the hydrophobic cavity occupied by F9 of MBM1 
formed by side chains of residues Leu177, Phe238, Ser155 and Met278 (Figure 4.4 B).  The 
61 
cyclopentyl ring occupies the P10 region of MBM1 and is in close contacts with side chains of 
Ser155, Phe238, Ala242, Cys241, and Tyr276 (Figure 4.4).  The piperidine ring and benzonitrile 
in both enantiomers have a similar binding mode with menin.  The alkoxy region overlaps with 
the region occupied by P13 of MBM1 that is composed of Tyr319 and Tyr323 on menin and 
forms hydrophobic interactions.  The benzonitrile reaches beyond the P13 region and forms a 
hydrogen bond with the side chain of Trp341 (Figure 4.4).  Interestingly, this area of the binding 
site on menin is not engaged by MBM1 of MLL but forms important interactions with the 




Figure 4.4 MIV-3R binding mode to menin.  
Figure adapted from (He 2014).
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 A. Superposition of the most important residues of MLL 
for binding to menin (cyan carbon atoms) and MIV-3R (green carbon atoms).  Menin is 
displayed as a surface representation with electrostatics displayed as negative (red) and 
positive (blue). B. Molecular contacts involved in the MIV-3R binding interaction with 
menin are highlighted. 
We have previously identified the three most critical residues for the MBM1 peptide to 
bind with high affinity to menin Phe9, Pro10, and Pro13.
59
  Superposition of the MBM1 peptide 
with the MIV-3R inhibitor reveals a close overlay of these residues with the small molecule 
inhibitors of the hydroxymethylpiperidine class.  The phenyl ring of MIV-3R overlaps with Phe9 




(Figure 4.4 A).  The alkoxy region in MIV-3R mimics the contacts of Pro13 with menin, while 
the benzonitrile extends outside of the P13 pocket and makes additional hydrogen bond 
interactions with W341 menin.  The relatively strong potency of these inhibitors is derived from 
the close mimicking of the important interactions of MLL with menin specifically mimicking 
residues Phe9, Pro10, Pro13 and making additional contacts by extending outside of the P13 
pocket. 
C.4 Design of orthogonal multipolar interaction of MIV analog with the menin backbone 
The MIV-3 crystal structure allowed us to use structure based-design to help rationalize 
exploratory modification and generate a well-informed SAR.  The class of thienopyrimidine 
analogs and the MI-2-2 crystal structure demonstrated the importance of the trifluoro 
modification.
66
  One of the fluorine atoms in MI-2-2 approaches the protein backbone of His181 
and is in close proximity to the amide peptide bond.
1,66
  Characterization of this region of MI-2-2 
class of compounds exposed the importance of this interaction as replacement of all of the 
fluorine atoms to hydrogen atoms results in over a 25-fold decrease in in vitro potency.
1,68
 To 
investigate if a fluorine-backbone interaction would be favorable with this scaffold we generated 
MIV-4 by replacing the phenyl ring with 3-fluorobenzene modification (Table 4.2).  This 
modification improved potency by 2-fold (Table 4.2) compared to MIV-3.  The MIV-4 menin 
structural analysis was performed to validate the binding mode (Figure 4.5).  The structure 
confirmed the presence of the fluorine-backbone interaction with the carbonyl carbon of His181 
within a distance of 3.2 Å.  In addition we explored a (15) 3-chlorobenzene and (14) 3,5-
fluorobenzene both of which resulted in decreased activity (Figure 4.5).  Therefore, the 3-
fluorobenzene substituent represents the optimal substituent identified through our SAR efforts 
at this position. 
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Figure 4.5 Crystal structure of MIV-4 bound to menin.  
Figure adapted from (He 2014).
73
 Highlighting the fluorine of MIV-4 
orthogonal multipolar interaction with the menin backbone.  Short 
distances to the protein backbone are shown as dashed lines. 
C.5 Increasing the polarity of the MIV class of menin-MLL inhibitors 
The R2 substituent that occupies the P10 pocket was also investigated to identify an 
optimal substituent.  The cyclopentyl ring is very lipophilic with a clogP = 5.6 for MIV-3. We 
wanted to explore modifications at this position and MIV-3S only has 2-fold decrease in potency 
compared to MIV-3R. Therefore, to facilitate medicinal chemistry exploration MIV-3S was 
used as a starting molecule to design an analog.  Both the MIV-3S co-crystal structure with 
menin and the menin apo structure showed a water molecule near the P10 pocket within 
hydrogen bond distance of Tyr276.  Based on the MIV-3S crystal structure we rationalized that 
correct positioning of the nitrogen of a pyridine should allow interactions with this water 
molecule resulting in water mediated hydrogen bond with Tyr276.  The introduction of this 
nitrogen atom should also help increase the hydrophilicity of the inhibitor (clogP = 3.7).  We 
explored a pyridine (MIV-5, 16) and thiazole (17) substituent at this R2 position, both of which 
resulted in an increase in potency and improved polarity with a clogP of 3.7 and 3.5, respectively 
(Table 4.2).   The MIV-5 menin co-crystal structure confirmed the presence of this bridged 
hydrogen bond between pyridine the water molecule and Tyr276.  The racemic mixture of MIV-
5 was used for crystallization and only the S enantiomer was seen as bound to menin (Figure 
4.6).  Additional separation of the enantiomers demonstrated that MIV-5S had about a 4-fold 
improved inhibitory activity (IC50 = 195 nM) compared to the R enantiomer. 
65 
The optimal substituents identified for the R1 and R2 positions were then combined to 
generate a hybrid structure (18).  This compound demonstrated about a 3-fold improvement in 
IC50 value compared to MIV-3R (IC50 = 90 nM of R enantiomer of 18, Table 4.2).  This 
compound is the most potent hydroxymethylpiperidine menin-MLL inhibitor.   
 
Figure 4.6 Crystal structure of MIV-5 bound to menin.  
Figure adapted from (He 2014).
73
 Highlighting the pyridine involved in the 
water mediated hydrogen bond with Tyr276.  The nitrile is extending 
beyond the P13 pocket and involved in hydrogen bond interactions with 
Trp341. 
C.6 Identification of optimal substituents at the tail region 
To further increase the polarity of these compounds we explored modifications of the tail 
region.  The nitrile of the MIV class of compounds is involved in a hydrogen bond with Trp341 
(Figure 4.6).  In order to maintain this hydrogen bond while increasing the polarity of this tail 
group, replacement of the nitrile with sulfonamide (MIV-7, 20) was explored.  MIV-7 increased 
the potency (IC50 = 114nM) about 3-fold compared to MIV-5 (Table 4.2). The MIV-7 crystal 
structure confirms that the hydrogen bond is maintained with Trp341.  Additionally, the 
sulfonamide introduces another hydrogen bond with the side chain of Glu363 (Figure 4.6) most 
likely leading to the improvement in potency.  This SAR demonstrates the sulfonamide as a 
feasible substitution for the nitrile resulting in an increase in the hydrophilicity of these 
compounds (clogP = 3.7 for MIV-5 and clogP = 2.5 for MIV-7). 
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Figure 4.7 Crystal structure of MIV-5 and MIV-7 bound to menin.  
Figure adapted from (He 2014).
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 A. Highlighting the nitrile of MIV-5 involved in 
hydrogen bond interactions with Trp341. B. MIV-7 sulfonamide interaction with 
Trp341 and an additional water-mediated hydrogen bond with E363. 
C.7 Exploring the hydrogen bond network in the head region 
The hydroxyl group in the crystal structure of MIV-3 is solvent exposed and involved in 
water mediated hydrogen bond with Asp180 (Figure 4.8).  Introduction of a positively charged 
amino group at this position should maintain this hydrogen bond while introducing longer range 
electrostatic interactions.  The amino moiety was introduced to develop compound MIV-6 and 
demonstrated 6-fold improvement in in vitro potency (IC50 = 67 nM) compared to MIV-3. The 
enantiomers were isolated with the IC50 = 56 nM of the R enantiomer being the more potent in 
this class of menin-MLL inhibitors. The co-crystal structure of MIV-6R-menin demonstrated the 
binding mode of this class of compounds is not affected by this modification (Figure 4.8).   
MIV-6R is the most potent analog reported with a Kd = 85 nM (Table 4.2).  The importance of 
the long range electrostatic interactions is evident in this analog and may more broadly provide 




      
Figure 4.8 MIV-3R and MIV-6R binding modes to menin are investigated.   
Figure adapted from (He 2014).
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  The crystal structure of menin in complex with A. 
MIV-3R or B. MIV-6R. The polar interactions with the head group are shown. E359 is 
present in two conformations. Both compounds are involved in a water mediated 
hydrogen bond. 
D. Conclusions 
Menin is an essential interaction partner for MLL fusion proteins providing an important 
target for small molecule inhibitor development.
12,55,58
  This PPI is difficult to inhibit with small 
molecule inhibitors as a result of the large menin-MLL binding interface and the limitation that a 
small molecule inhibitors can only occupy a small region of this site.
59
  Characterization of this 
interaction identified that the residues F9, P10, and P13 are the most critical for MBM1binding 
to menin.
59
  Therefore, small molecule inhibitors do not need to disrupt this entire menin-MLL 
interaction but specific targeting of these hot spot residues can provide disruption of the entire 
complex.  
Extensive structure-based design was employed to optimize the MIV-1 compound 
identified in the HTS screen into efficacious inhibitors of the menin-MLL complex. We 
identified the minimal pharmacophore from the MIV-1 hit and then optimized the hydrophobic 
interactions of the phenyl groups by exploring several carbocycles.   Cyclopentyl replacements 
of the phenyl ring generated MIV-3 and lead to a significant 30-fold improvement in the 
inhibitory activity of the menin-MLL interaction.  Structural analysis of the MIV-3 enantiomers 
in complex with menin helped rationalize modifications for improvements in potency.  These 
small molecule inhibitors mimic the three most important interactions of MBM1 with menin (F9, 
P10, P13).  This class of compounds are capable of extending beyond the P13 pocket with the 
B. A. 
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nitrile forming an additional hydrogen bond with the side chain of W341 and is very important 
for the binding affinity, reflected by an IC50 >250 μM in the absence of this nitrile.   
Development of the thienopyrimidine SAR, as described in Chapter 2 and Chapter 3, 
helped to identify the importance of orthogonal multipolar interactions of the inhibitor-menin 
fluorine-backbone interactions.
1,68
  We were able to apply this knowledge to the improvement of 
the methylpiperidine class of inhibitors by introducing a fluorine atom into the phenyl ring 
(MIV-4) and form orthogonal multipolar interactions with the backbone of His181.  We 
improved solubility of these inhibitors with pyridine replacement of the phenyl (MIV-5) and 
sulfonamide replacement of the nitrile (MIV-7).  The most substantial modification was seen 
with the replacement of the hydroxyl group for the amino which resulted in long-ranged 
electrostatic interactions with Asp180.  MIV-6R demonstrates about a 230-fold improvement in 
inhibitory activity compared to MIV-1.   
These compounds represent a promising scaffold for further optimization.  All of the 
MLL hotspot residues are occupied by this class of inhibitors including the P10 pocket, which 
remains unoccupied in the thienopyrimidine scaffold of menin-MLL inhibitors.
68
  However, the 
methylpiperidine class of inhibitors requires further optimization of potency in MLL leukemia 
cells and PK properties to explore applications in murine models of leukemia.  This study 
provides a good basis for the further development of these inhibitors into valuable chemical tools 
or potential therapeutics. 
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Table 4.2 SAR and activity of MIV analogues 
 
Compound X R1 R2 R3 IC50
6 -OH -CN 295 ± 50 µM
7 -OH -CN 15.3 ± 3.8 µM
8 -H -CN 11.2 ± 3.9 µM
9 -OH -CN 4.1 ± 0.6 µM
10 -OH -CN 4.0 ± 1.4 µM
11                     
(MIV-3)
-OH -CN 390 ± 45 nM
11a                    
(MIV-3R)
-OH -CN 270 ± 49 nM
11b                     
(MIV-3S)
-OH -CN 529 ± 129 nM
12 -OH -CN 1.7 ± 0.6 µM
13                     
(MIV-4)
-OH -CN 1.7 ± 0.6 µM
14 -OH -CN 436 ± 9 nM
15 -OH -CN 226 ± 35 nM
16                     
(MIV-5)
-OH -CN 302 ± 49 nM
17 -OH -CN 242 ± 27 nM
18 (RS) -OH -CN 225 ± 28 nM
18R -OH -CN 90 ± 6 nM
18S -OH -CN 1.4 ± 0.2 µM
19                     
(MIV-6)
-NH2 -CN 67 ± 10 nM
19a                     
(MIV-6S)
-NH3 -CN 81 ± 5 nM
19b                     
(MIV-6R)
-NH4 -CN 56 ± 3 nM
20                     
(MIV-7)
-OH -SO2NH2 114 ± 2 nM




IC50 values were measured by fluorescence polarization assay, average  
values from two to three independent measurements ± SD are provided.  
Compound X R1 R2 R3 IC50
6 -OH -CN 295 ± 50 µM
7 -OH -CN 15.3 ± 3.8 µM
8 -H -CN 11.2 ± 3.9 µM
9 -OH -CN 4.1 ± 0.6 µM
10 -OH -CN 4.0 ± 1.4 µM
11                     
(MIV-3)
-OH -CN 390 ± 45 nM
11a                    
(MIV-3R)
-OH -CN 270 ± 49 nM
11b                     
(MIV-3S)
-OH -CN 529 ± 129 nM
12 -OH -CN 1.7 ± 0.6 µM
13                     
(MIV-4)
-OH -CN 1.7 ± 0.6 µM
14 -OH -CN 436 ± 9 nM
15 -OH -CN 226 ± 35 nM
16                     
(MIV-5)
-OH -CN 302 ± 49 nM
17 -OH -CN 242 ± 27 nM
18 (RS) -OH -CN 225 ± 28 nM
18R -OH -CN 90 ± 6 nM
18S -OH -CN 1.4 ± 0.2 µM
19                     
(MIV-6)
-NH2 -CN 67 ± 10 nM
19a                     
(MIV-6S)
-NH3 -CN 81 ± 5 nM
19b                     
(MIV-6R)
-NH4 -CN 56 ± 3 nM
20                     
(MIV-7)
-OH -SO2NH2 114 ± 2 nM
21 -OH -SO2NH2 148 ± 19 nM
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Chapter 5: Development of covalent inhibitors of the menin-MLL 
interaction 
A. Abstract 
Rational design of covalent inhibitors has gained attention as recent examples of targeted 
covalent therapeutics have demonstrated clinical efficacy in oncology. Covalent inhibitors 
exhibit unique properties including increased residence time, require different PK profile 
compared to reversible inhibitors, and allow for the assessment of target engagement.  There are 
no published examples of covalent inhibitors targeting protein-protein interactions.  We have 
rationally designed covalent inhibitors targeting the menin-MLL interaction using the 
thienopyrimidine class of menin-MLL inhibitors as a starting pharmacophore.  We employed 
structure-based design to develop covalent inhibitors of the menin-MLL interaction focusing on 
the indole nitrogen substituents to engage the sidechain of Cys329.  Several reactive chemotypes 
were investigated and characterized to assess the rate of menin engagement and nonspecific 
reactivity rate with a biologically relevant thiol containing biomolecule, glutathione.  In cellular 
studies, covalent inhibitors exhibited increased potency and improved selectivity index compared 
to the noncovalent analogs.  Through the irreversible binding mechanism of covalent inhibitors, 
we were able to assess menin engagement in vivo. Overall, we have developed rationally 
designed covalent inhibitors of the protein-protein interaction between menin-MLL. This work 
provides a detailed approach for the characterization and assessment of covalent inhibitors 
targeting protein-protein interactions. 
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B.  Background 
B.1 Advantages and disadvantages of covalent inhibitors 
Traditionally, small molecule inhibitor campaigns were not intentionally explored for 
covalent modifiers.
114-116
 This is due to major concerns with covalent inhibitors surrounding the 
potential for off-target toxicity as a result of nonspecific reactivity with biomolecules or non-
target proteins.
117
  Additionally, activation of the immune system can occur through 
haptenization of proteins as a result of nonspecific macromolecular reactions.
118
  These safety 
concerns have led to a disinclination towards the development of covalent small molecule 
therapeutics.
119
 However recently covalent inhibitors targeting kinases have been successful in 
clinical trials
120
 and FDA approved targeted therapies have shown efficacy with limited toxicity 
shedding new light to this approach.
121
  
If there are so many concerns with the safety and toxicity of covalent inhibitors why 
would anyone rationally design a covalent drug?  Covalent inhibitors have unique features 







  While safety concerns with covalent inhibitors needs to be 
investigated,
126
 these inhibitors offer a unique approach to inhibition of the target protein and 
may provide a therapeutic benefit. 
B.2 Design of covalent inhibitors of PPIs 
Cysteine residues are frequently targeted for covalent modification because they are the 
most intrinsically nucleophilic residue.
127
 It is difficult to target residues other than cysteine 
because less nucleophilic residues require stronger reactive groups for covalent modification and 
may increase the potential for off-target reactivity.  Activated cysteine residues in proteases are 
more reactive therefore the small molecule reactive groups can be more weakly electrophilic.  
Cysteine residues that are not activated, such as the cysteines on menin, require a different 
strategy to develop selective covalent molecules. 
Cysteine reactive moieties that may be viable candidates for applications in humans are 
being assessed.
128,129
 Michael acceptors are typically used as cysteine reactive moieties where the 
β-carbon is an electrophile.  The electrophilicity or reactivity of these groups can be tuned 




Cysteine reactive moieties such as acrylamides, vinylsulfonamides, propynamides and 
halomethylketones can have low rates of non-specific reactivity with free thiols, or intrinsic 
reactivity.  Clinically approved rationally designed covalent molecules that target non-active site 
cysteine residues in kinases contain acrylamide reactive groups (Afatinib, Ibrutinib). 
130,131
  
Whether other reactive moieties that target cysteine may be viable candidates for drug discovery 
applications and have good safety profile is currently being explored.
128
   
B.3 Biochemical characterization of covalent inhibitors  
Covalent inhibitors bind irreversibly to the protein target; therefore, are able to achieve a 
long residence time.
122
  Once the target is inhibited by the covalent inhibitor the efficacy is 
maintained until physiologically relevant levels of the target protein is produced through de novo 
synthesis.  Therefore, the efficacy of covalent inhibitors is dependent on the rate of re-synthesis 
of the target protein as long as the drug dosage allows for engagement of the target protein. The 
rate of protein re-synthesis is an important parameter to quantify because the duration of the 
biological effect is only a result of the protein-inhibitor complex.
122,132
 This unique mechanism 
of action is particularly attractive for proteins that have a long half-life or need to be inhibited to 
near entirety to demonstrate efficacy. This irreversible binding mechanism of these inhibitors can 
also be a major concern if other proteins or biomolecules are covalently modified. 
Covalent inhibitors require a different pharmacokinetic profile as compared to reversible 
inhibitors.
119
  Irreversible covalent inhibitors do not reach a dynamic equilibrium; once they react 
there is no dissociation. Therefore, a long half-life of covalent inhibitors in vivo may not be 
required.
119
  Covalent inhibitors with a long half-life could contribute to increased toxicity as a 
result of increasing the amount to reactivity to other biomolecules. Covalent inhibitors should be 
designed to rapidly covalently modify the target protein and then become quickly metabolized 




    
Reactive moieties that are used for the covalent modification of the inhibitor to the target 
protein should be chosen carefully.  These covalent chemotypes should have low intrinsic rates 
of reactivity to reduce the potential for off-target reactivity. 
128
  The intrinsic rate of reactivity of 
covalent inhibitors is assessed by the non-specific reactivity with biologically relevant 
nucleophiles such as glutathione.
128,129,134
  Glutathione (GSH) is present ubiquitously at high 
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concentrations in the cell.  Studies have demonstrated that a high rate of covalent reactivity with 
GSH correlates with off-target binding burden in hepatocytes and hepatotoxicity.
126,135,136
  
Additionally, off-target reactivity will diminish the concentration of functional covalent 
inhibitors to covalently engage the target protein.  Modifying the electrophilicity of the Michaels 
acceptor, or electrophilic tuning, can help decrease the intrinsic rate of reactivity of these 
inhibitors minimizing non-specific reactivity.  
Low rates of reactivity can help reduce off-target covalent modifications but the 
molecules must still react with the target protein. Covalent small molecule inhibitors with low 
intrinsic rates of reactivity rely on the reversible interactions to drive the specificity of these 
inhibitors with the target protein. This allows for selective covalent modification only when the 
reactive moiety is positioned in close proximity to the targeted residue. One of the key properties 
of covalent inhibitors is the rate of reactivity with the protein target (target engagement).  
Importantly, the rate of target engagement for covalent inhibitors is an important metric to 
perform direct comparison between covalent analogs.  







  Determining target engagement enables the correlation of inhibited 
target protein to other inhibitor induced phenotypic effects e.g. growth inhibition. Importantly 
identifying off-target proteins that are covalently modified can yield insight into the potential 
toxicity.  These off-target interactions may potentially be ameliorated through modifications in 
the noncovalent binding interactions but also tuning the electrophilicity of the Michaels acceptor.   
Structure-based design of small molecules can greatly facilitate design rationale for 
chemical modifications to form favorable interactions that improve potency.
137,138
 This structural 
analysis can be used to identify a cysteine that is accessible to target with a small molecule 
covalent modifier.
134,137,139
 Starting with a non-covalent inhibitor and targeting a cysteine residue 
near the small molecule binding pocket is an effective strategy to develop covalent inhibitors.
137
  
This strategy allows for a more heavy reliance on the non-covalent interactions to drive the 
specificity of the covalent linkage.
119
  Therefore the electrophile must be in correct orientation 
and close proximity to the target nucleophile for the formation of the covalent linkage.  Structure 
based-design can greatly facilitate the rational design of noncovalent inhibitors into covalent 
inhibitors through targeting a residue adjacent to the inhibitor binding pocket.   
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My contribution to this project was the rational design of covalent menin-MLL inhibitors 
performed by converting the reversible thienopyrimidine class of menin-MLL inhibitors into 
irreversible compounds by exploring several different reactive moieties.  I also performed 
crystallization of the small molecules in complex with menin, solved the crystal structures of the 
complexes and performed structural analysis of the complexes.  I characterized the covalent 
inhibitors in a biochemical FP assay and using biophysical methods to compare the potency of 
covalent thienopyrimidine analogs, rate of menin engagement, and general reactivity with 
glutathione.  Finally, I determined the rate of menin engagement with covalent thienopyrimidine 
menin-MLL inhibitors in MLL leukemia cell lines and in mouse bone marrow samples isolated 
from mice treated with these compounds.   
C.  Results 
C.1 Investigation of accessible cysteine residues near the small molecule binding pocket of 
menin 
We applied structure-based drug design to develop potent inhibitors of the menin-MLL 
interaction.  Through the design process of the reversible inhibitors, we identified regions of the 
menin binding pocket that could be explored to attain more potent inhibitors.  Targeting Cys329 
was selected for covalent modification using the thienopyrimidine class of reversible inhibitors 
as a starting pharmacophore.  The thienopyrimidine class was chosen based on the potential for 




Figure 5.1 Crystal structure of MI-503 bound to menin.   
Highlighting the Cys329 local landscape. Modifications of the indole nitrogen can be 





C.2 Structure based-design of covalent thienopyrimidine class of menin-MLL inhibitors 
MI-503 of the thienopyrimidine class was used as a starting compound to explore longer 
substitutions of the indole nitrogen to reach Cys329.  Cys329 is surrounded on one side by a 
hydrophobic patch formed by Val371 and Leu375 and on the adjacent side two arginine residues 
Arg330 and Arg332.  Arg330 is involved in a salt bridge with Glu288. An overview analysis of 
menin co-crystal structures revealed the Arg330 side chain exhibits a stable orientation as 
displayed in Figure 5.1.  This suggested that might be able to exploit the surrounding landscape 
of Cys329 to make favorable noncovalent interactions that result in the correct geometric 
positioning of a covalent moiety to react with the side chain of Cys329. 
 
 
Table 5.1 SAR and activities of covalent analogues 
of the thienopyrimidine class of menin-MLL 
inhibitors.  
IC50 values were measured by fluorescence 
polarization assay, average values from two to three 
independent measurements ± SD are provided. 
We removed the methylpyrazole of MI-503 and replaced it with a N-ethylpiperazine (BD613) 
with less than a 2-fold decrease in potency as determined by the MLL12 FP assay (Table 5.1).  
This N-ethylpiperazine linker was utilized to explore the different covalent moieties. We first 
explored acrylamide reactive moieties which were chosen as a result of recent FDA approval of 
irreversible therapeutics harboring acrylamide moieties that have demonstrated safety and 
clinical utility.
130,131
 The first acrylamide menin-MLL inhibitor we explored was BD615 which 
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used the N-ethylpiperazine linker with an acrylamide reactive group.  To verify a covalent 
adduct was formed between the inhibitor and menin, we used whole protein molecular weight 
(MW) determination by mass spectrometry (MS) (see Methods section: LC-MS determination 
of covalent adducts to menin).  We found that menin alone has a MW of 71.3 kDa and if 
BD615 was covalently bound we would expect an addition mass of 650 Da but the MW 
corresponding to the covalent adduct with menin was not identified (Figure 5.2 A). We 
performed structural analysis of BD615 in complex with menin and found it did not bind 
covalently to menin with the acrylamide pointing towards the solvent (Figure 5.2 B).   
 
Figure 5.2 Design of BD615 with an acrylamide reactive moiety.  
A. MS analysis of menin with in the presence and absence of BD615.  B. Structure and activity of BD615 in FP 





We then explored a propynamide reactive moiety (BD712) using the same linker as in 
BD615. By MS, BD712 was shown to form a covalent adduct to menin with an overnight 
incubation of a 2-fold excess BD712 and all of the menin was fully reacted (Figure 5.3 B).  The 
additional MW corresponds to one molecule of BD712 attached to menin validating this reaction 
is selective to only cysteine. We determined the crystal structure of BD712 in complex with 
menin to analyze the molecular interactions (Figure 5.3 A).  We identified BD712 forms a 
covalent bond with Cys329 with the propynamide oriented with the oxygen in close distance (3.0 
Å) to Arg330 side chain.  The Cys329 side chain in the BD712 crystal structure is in a different 
orientation when compared to menin alone and menin in complex with inhibitors that do not 
interact with this Cys329 (Figure 5.3).  Therefore, the cysteine side chain must adopt a different 
conformation to allow for the covalent reaction with BD712.   
 
Figure 5.3 Design of irreversible inhibitor BD712 with a propynamide reactive moiety.  
A. MS analysis of menin with in the presence and absence of BD712.  B. Structure and activity of BD712 in FP 





We then explored the vinylsulfonamide reactive moiety (BD688).  BD688 covalently 
modified menin with an overnight incubation at 2-fold molar excess of compound and identified 
all of the menin was covalently bound to BD688 (Figure 5.4 A).  We then determined the crystal 
structure of BD688 bound to menin to validate the covalent linkage of Cys329 with BD688 
(Figure 5.4 B).  There is a continuous electron density from BD688 extending through Cys329 
sidechain as shown in Figure 5.4 B indicating a covalent bond has been formed.  The 
sulfonamide moiety is positioned with an oxygen atom of the sulfonamide involved in a direct 
hydrogen bond with Arg330 at 2.9 Å.  The linker was long enough to allow for the 
vinylsulfonamide reactive moiety to covalently modify Cys329. 
We have demonstrated the linker used in BD615 is sufficient for the vinylsulfonamide 
(BD688) and propynamide (BD712) to form covalent bonds with Cys329.  The linker was likely 
too short or there was not enough flexibility to allow for the acrylamide to correctly orient itself 
to form the covalent bond with Cys329 of menin. The acrylamide reactive moieties require 
further optimization to develop into covalent modifiers.   
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Figure 5.4 Design of irreversible inhibitor BD688 with a vinylsulfonamide reactive moiety.  
A. MS analysis of menin in the presence and absence of BD688.  B. Structure and activity of BD688 in FP assay. C. 







C.3 Characterizing the potency and rate of menin engagement of the covalent inhibitors. 
We explored biochemical analysis of the activity of the covalent menin-MLL inhibitors 
with the MLL12 FP assay. However, the IC50 values in the MLL12 FP assay do not reflect the 
covalent nature of these analogs as a result of only an hour incubation of these inhibitors with 
menin. Therefore, we developed the MLL43 FP assay to more accurately characterize the 
potency of these inhibitors (Table 5.2).  In the MLL43 assay both MLL binding motifs (MBM1 
and MBM2) are present, which leads to a stronger binding interaction of MLL43 peptide with 
menin compared to the MLL12 (MBM1) peptide. This leads to higher IC50 values, and with 
longer incubation times more accurately reflects the relative potency of these analogs. We found 
that BD615 is 3-fold and 12-fold weaker than the covalent inhibitors BD712 and BD688, 
respectively (Table 5.2). However, we are unable to determine whether the modifications are 
increasing the noncovalent interactions or increasing the rate of covalent adducts formation.   
An important parameter to compare these analogs is the reactivity rates with the target 
protein or rate of menin engagement.  We have used MS previously to determine whether the 
developed inhibitors bind covalently.  To determine pseudo-first order reaction rates we changed 
the conditions to allow for saturating concentrations of compound (10-fold molar excess) over 
menin concentration. This will allow us to determine pseudo-first order reaction kinetics and 
characterize the rate of covalent adduct formation to menin (Equation 5.1 and 5.2).  We used 
MS to explore the rate of reactivity and characterize the SAR for the covalent inhibitors with 
saturating concentrations of inhibitor relative to menin (Figure 5.5). We found BD688 to engage 
menin 4-fold faster when compared to BD712 (Table 5.2).  We can utilize this method to 






Table 5.2 SAR and properties of analogues.  
IC50 values were measured by fluorescence polarization assay, average values from two to three 
independent measurements ± SD are provided. Pseudo-first order reaction kinetics (kobs) was 
used to calculate the rate of menin engagement and half-life (t1/2). 
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Equation 5.1 Equilibrium equation.
119
  
Inhibition of menin occurs through a two-step mechanism of action. First the non-covalent interactions followed by 
the electrophile positioned in close proximity to a cysteine 329 residue for the covalent reaction to occur. The rate of 
covalent bond formation (k2) can be determined using pseudo-first order reaction kinetics.  
 
Equation 5.2 Pseudo-first order rate equation and half-life derivatization. 
Using a 10-fold molar excess of compound over menin protein we can determine the rate of covalent linkage (k2) by 
mass spectrometry to quantify the rate of covalent adduct formation (% reacted). 
 
 
Figure 5.5 Characterizing irreversible inhibitor rates of menin engagement.  
Ratio of menin to menin with a covalent adduct is quantified by whole protein molecular weight determination by 
mass spectrometry.  Top is a centered spectra of the bottom spectra plotting relative intensity vs molecular weight. 
The centered spectrum is used to compare the intensity levels as a percent relative to the total intensity from menin 
and menin adduct intensities.   
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C.4. Structure-based design and characterization of acrylamide covalent inhibitors 
The vinylsulfonamide (BD688) and the propynamide (BD712) were found to bind menin 
covalently and had the same linker, however this was not an optimal linker for the acrylamide 
(BD615) to form a covalent adduct with menin.  To investigate if the linker length was too short 
we extended the linker through an exocyclic acrylamide (BD964) to increase the flexibility near 
the reactive moiety.  BD964 was validated to bind covalently to menin by MS and structural 
characterization was performed to explore the molecular contacts (Figure 5.6). The oxygen of 
the amide does not point towards Arg330 as in BD712; instead the nitrogen of the amide is 
involved in a water-mediated hydrogen bond with Arg330.  The cysteine sidechain is in a similar 
orientation compared to menin without inhibitors therefore the sidechain of Cys329 does not 
need to adapt a different rotameric state as in BD712 to form a covalent linkage.    
We next investigated the impact of a phenyl replacement (BD1044) of the piperidine in 
BD964. BD1044 binds covalently to menin by MS with a rate of reactivity 5-fold faster than 
BD964 (Table 5.3). To explore the orientation of the amide and the linker we performed 
structural studies which demonstrated the amide oxygen of BD1044 points away from Arg330 
similar to BD964 (Figure 5.7).   
We then pursued a pyridine replacement of the phenyl to form BD1119.  BD1119 
exhibited an increased rate of menin engagement with over a 20-fold increase compared to 
phenyl ring (BD1044) and a half-life of less than a minute (Table 5.3). We performed structural 
analysis to explore the molecular contacts of this modification.  The nitrogen of the pyridine was 
oriented towards Arg330 and involved in a water mediated hydrogen bond with Arg330 (Figure 
5.8).  This same water molecule is also in hydrogen bond distance to the nitrogen of the amide 
allowing for both these nitrogen atoms to coordinate the water mediated hydrogen bond with 
Arg330 of menin (Figure 5.8).   
Acrylamide reactive moieties were explored in the context of the thienopyrimidine 
scaffold to develop covalent inhibitors of the menin-MLL interaction.  These acrylamides 
moieties have very different rates of menin engagement with half-lives ranging from less than a 
minute to several hours.  We have generated covalent inhibitors with improved rates of menin 




Table 5.3 SAR and properties of analogues.  
IC50 values were measured by fluorescence polarization assay, average values from two to three independent 
measurements ± SD are provided. Pseudo-first order reaction kinetics (kobs) was used to calculate the rate of menin 
engagement and half-life (t1/2). 
 
 
Figure 5.6  Structure-based design of acrylamide covalent inhibitors. 
A. Structure of BD964 with IC50 values measured by fluorescence polarization assay, pseudo-first order reaction 
kinetics (kobs) was used to calculate the rate of menin engagement and half-life (t1/2). B. Extension of the reactive 
moiety through an exocyclic acrylamide forming BD964. The orientation of the chair is opposite of BD688 with the 




Figure 5.7 Structure-based design of aromatic substituted acrylamides with menin. 
A. Structure of BD1044 with IC50 values measured by fluorescence polarization assay, pseudo-first order 
reaction kinetics (kobs) was used to calculate the rate of menin engagement and half-life (t1/2). B. Crystal structure 
of BD1044 bound to menin. The phenyl replacement of piperidine in BD964 orients the amide oxygen away 
from Arg330.  
 
 
Figure 5.8 Structure-based optimization of polar interactions of aromatic substituted acrylamides with 
menin. 
A. Structure of BD1119 with IC50 values measured by fluorescence polarization assay, pseudo-first order 
reaction kinetics (kobs) was used to calculate the rate of menin engagement and half-life (t1/2). B. Crystal 
structure of BD1119 bound to menin. Substitution of the phenyl with a pyridine allows both the nitrogen of 
the pyridine and the nitrogen of the amide forms a bridged hydrogen bond with a water molecule to the side 




C.5 Investigating the reactivity of the covalent menin-MLL inhibitors with glutathione. 
The formation of covalent adducts between the menin inhibitors and small molecule 
nucleophiles can be used to quantify the intrinsic rate of reactivity to gain insight into the 
potential toxicity of these inhibitors.  Covalent inhibitors should not exhibit significant rates of 
reactivity towards thiol containing molecules such as glutathione (GSH). High GSH reactivity 
has been correlated with hepatocellular toxicity,
126,135,136
  and if the inhibitor is reacting quickly 
with GSH this will reduce the amount of functional inhibitor to engage the target protein. GSH is 
the primary intracellular nucleophile with important antioxidant functions and is found at high 
concentrations in the cell (up to 5mM).  Therefore, we analyzed the reactivity of the menin-MLL 
inhibitors with GSH to assess intrinsic reactivity. 
       
Table 5.4 Reactivity of inhibitors with glutathione.  
Rates of compound reactivity with GSH quantified by area under the curve for the LC trace at A280nm.  Pseudo-
first order reaction kinetic rates (kobs) were used to calculate the rate of loss of the parent compound with half-life 
(t1/2) values.   
Reactive menin inhibitors were incubated at 25µM with 5mM GSH at various time points 
and the rate of parent compound loss as a result of adduct formation with GSH was analyzed by 
LC-MS to determine the pseudo-first order reaction rates.  We used an FDA approved covalent 
inhibitor Afatinib as a benchmark to compare the intrinsic reactivity of the menin-MLL 
inhibitors. Afatanib is an acrylamide-based covalent inhibitor targeting human epidermal growth 
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factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases. We sought to 
characterize the covalent inhibitor analogs of menin and compare to Afatinib (Table 5.4).   
BD615 was not able to covalently engage menin, but we identified that this compound is 
very reactive with GSH (t1/2 = 19 min).  BD964 and BD1044 had the slowest rates of GSH 
reactivity.  BD964 exhibited about a 3-fold faster rate of reactivity with GSH despite almost a 
19-fold decreased rate in menin engagement compared to BD1044.  While BD688, BD615 and 
BD1119 all displayed similar rates of GSH reactivity this was about 2-fold slower compared to 
Afatinib.  This evidence demonstrates that the menin-MLL inhibitors we have developed are less 
reactive towards GSH when compared to an FDA approved and clinically efficacious therapeutic 
and therefore should be suitable to explore in vivo. 
C.6 Activity of covalent inhibitors of the menin-MLL interaction in leukemic cells. 
We then explored the potency of the covalent menin-MLL inhibitors in MLL-AF9 
leukemia cells.  Hoxa9/Meis1 (HM-2) transformed cells were used as a negative control.  An 
MTT viability assay was used to determine the growth inhibition at 50% maximum (GI50) of 
MLL-AF9 cells and HM-2 cells with the selectivity index (SI) calculated as a ratio of GI50 values 
obtained in HM-2 cells to MLL-AF9 cells.  We found that even though BD615 does not 
covalently engage menin, it is only 3-fold weaker in GI50 compared to the covalent acrylamide 
BD964 (Table 5.5).  BD964 had a 2-fold reduced GI50 compared to the vinylsulfonamide BD688 
and aromatic acrylamide BD1044.  BD1044 had the best selectivity index with a 43-fold more 
potent activity in MLL-AF9 cells compared to the HM-2 control cell line.  The most potent 
analog was BD1119 with a GI50 = 20nM in MLL-AF9 transformed murine BMCs (Table 5.5). 
BD964 has a slow rate of menin engagement with a half-life of about 4h but the GI50 is similar to 
BD688 and BD1044 which have 100-fold and 20-fold faster rates of menin engagement 
respectively (Table 5.5).  BD1119 demonstrated a 16-fold faster rate of menin engagement and 
30-fold faster rate of GSH reactivity compared to BD1044 but only a 2-fold improvement in 
potency in MLL-AF9 cells (Table 5.5).  Overall, the covalent inhibitors demonstrated more 
potent GI50 values in MLL-AF9 cells as compared to BD615 an analog that does not engage 
menin.  BD1119 had fast rates of menin engagement with a half-life <1 minute and was the most 





Table 5.5 SAR and properties of analogues.  
IC50 values were measured by fluorescence polarization assay, average values from two to three independent 
measurements ± SD are provided.  Pseudo-first order reaction kinetics (kobs) was used to calculate the rate of menin 
engagement and half-life (t1/2). Growth inhibition (GI50) measured in the MTT cell viability assay in MLL-AF9 or 
Hoxa9/Meis1 (HM-2) transformed murine bone marrow cells after 7 days of treatment with compounds. Activity in 
HM-2 cells was measured for compounds with best activity in MLL-AF9 cells. SI, selectivity index calculated as a 
ratio of GI50 values measured in HM-2 cells (control cell line) and MLL-AF9 transformed cells. 
C.7 Detection of menin engagement in MLL leukemic cells and bone marrow in vivo. 
To explore the level of menin engagement following treatment with covalent inhibitors 
we developed a pulldown assay using biotinylated-MLL43 peptide immobilized to magnetic 
beads through a biotin-streptavidin complex (Schematic 5.1).  The immobilized MLL43 on the 
beads will bind to uninhibited menin which we can then analyze by western blot. With this 
pulldown assay, we can quantify the menin that is not inhibited upon treatment with the 
inhibitors.  We used KOPN8 cells to explore the covalent inhibitors menin engagement.  
CETSA
140
 analysis was also performed to investigate the levels of menin engagement, which 
utilizes the heating of cells to unfold menin that is not stabilized through inhibitor binding.  Cell 
samples were heated for 3min at 51̊C. At the temperature 51̊C, we found selective unfolding of 
menin that is not bound to an inhibitor while menin bound to an inhibitor is stabilized and 
MLL43
Compound R1 R2 IC50 (nM) kobs (s
-1
) t1/2 (min) kobs (s
-1
) t1/2 (min) MLL-AF9 BMC HM-2 BMC SI
BD615 H 440 ± 103 x x 6.17E-04 18.7 250nM ND ND
BD712 Me 167 ± 50.3 1.36E-03 8.5 ND ND 150nM ND ND
BD688 Me 35.7 ± 10.7 5.26E-03 2.2 6.08E-04 19.0 50nM 1.5µM 30
BD964 Me 30.8 ± 13.2 5.44E-05 212 4.83E-05 239.0 90nM 2.5µM 28
BD1044 Me 7.0 ± 2.3 1.02E-03 11.3 1.50E-05 770.2 40nM 1.7µM 43
BD1119 Me 34.4 ± 14.3 1.59E-02 0.7 4.92E-04 23.5 20nM 0.5µM 25
GI50Menin Engagement GSH Reactivity
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remains in solution.  This approach allows us to quantify the level of menin that is bound to the 
inhibitor. 
 
Schematic 5.1 Design of the menin pulldown assay with MLL43 coated 
beads.   
Menin is pulldown from cell lysate with biotinylated-MLL43 and coupled to 





Figure 5.9 Menin engagement in cells.   
A. KOPN8 cells were used to explore a 4h and 24h treatment of selected covalent inhibitors. Menin was pulled down 
with MLL43 coated beads and western blot analysis was performed to assess the level of uninhibited menin.  B.  
CETSA analysis of menin engagement was performed in KOPN8 cells with a 4h treatment. Samples were heated at 
51C̊ for 3min. 
To determine the levels of menin engagement we explored the covalent inhibitors in 
KOPN8 cells analyzed by pulldown and CETSA (Figure 5.9).  Similar results from both the 
pulldown and CETSA analysis of menin engagement.  BD1119 has the highest level of menin 
engagement with an IC50 of about 10nM.  BD1044 and BD688 show similar levels of 
engagement with an IC50 = 150nM.  BD964 has an IC50 = 600nM with a 4h incubation and this 
improves about 4-fold when compared to the 24h incubation.  When the incubation time is 
increased from 4h to 24h for BD964, the levels of menin engagement has a similar IC50 to 
BD1044 while there is a little improvement between the IC50 of BD1044 at 4h and 24h time 
points. This is because BD1044 is able to react covalently to menin within the 4h incubation 
based on the half-life of menin engagement (t1/2 = 11 min) whereas BD964 (t1/2 = 4h) requires a 
longer incubation of 24h.  Overall the IC50 values for menin engagement in MLL leukemia cells 
from the CETSA and pulldown analysis correlate well with the GI50 values in MLL-AF9 




We then explored menin turnover in KOPN8 and MV4;11 cells with 1 μM BD688 for 4 h 
and assessed the rate of newly synthesized menin using the pull down assay (Figure 5.10).  In 
KOPN8 and MV4;11 cells the rate of menin turnover is between 6h and 12h.  This analysis will 
help to determine the dosing regimen for in vivo treatment in mice to demonstrate a therapeutic 
response. In vivo the covalent inhibitors bind irreversibly to menin and remain bound until the 
protein is degraded; therefore their activity is dependent on the rate of de novo menin synthesis.   
 
Figure 5.10 Determination of the rate of menin turnover with washout experiments.  
KOPN8 and MV4:11 human leukemia cell lines with MLL rearrangements were treated with 1μM BD688 for 4h to 
allow for full menin engagement.  The remaining unreacted BD688 was washed out and the rate of menin turnover 




Figure 5.11 CETSA analysis to assess menin engagement in the bone marrow in vivo. 
C57BL/6 mice were treated with a single dose of BD1119 (50 mg/kg) or vehicle via i.p.  Bone marrow samples 
were harvested and levels of menin engagement was assessed by pulldown with the MLL43 coated beads and 
western blot analysis. n = 2 mice per treatment group and time point. 
 
We went on to investigate the menin engagement in the bone marrow in vivo by CETSA 
analysis. We explored the target engagement of menin in vivo with BD1119 based on the fast 
rate of menin engagement of this compound (t1/2 = 0.7 min). C57BL/6 mice were dosed with 
50mg/kg BD1119 via i.p. injection and levels of menin engagement were explored at 2h and 6h 
time points compared to vehicle (Figure 5.11).  In the vehicle treated samples no menin is 
present at 51̊C while at 2h time point there is a strong band for menin demonstrating BD1119 is 
bound to menin.  At 6h time points the levels of menin that remain bound to the inhibitor starts to 
decrease as a result of menin turnover.  At early time points we can measure significant levels of 
menin engagement but at later time points menin becomes resynthesized and the levels of menin 
bound to the inhibitor are decreasing. This data demonstrates that menin is covalently engaged in 
the bone marrow in vivo following treatment with BD1119.   
D.  Conclusion 
The work presented in this chapter describes the development of rationally designed 
covalent small molecule inhibitors of the menin-MLL interaction.  We used structure-based 
design to convert the non-covalent thienopyrimidine class of inhibitors into covalent inhibitors 
targeting Cys329 of menin.  We explored different reactive moieties and found the same linker 
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used for the vinylsulfonamide and propynamide reactive groups was not suitable for the correct 
positioning of the acrylamide to react with Cys329. The sidechain of Arg330 is an important 
hydrogen bonding partner with either direct or water mediated hydrogen bonds formed in all of 
the reactive groups explored.  This hydrogen bonding interaction may help provide appropriate 
geometry for the reactive group to form the covalent bond with the sidechain of Cys329. 
The reactive moieties we explored in the context of the thienopyrimidine scaffold were 
developed into potent inhibitors of the menin-MLL interaction and exhibit varying rates of 
menin engagement in vitro. The acrylamide of BD1119 was found to covalently engage menin 
with the fastest rate, which correlated well with the potency in MLL-AF9 cells.  All of the 
covalent menin inhibitors explored exhibited slower rated of GSH reactivity compared to 
Afatinib, an FDA approved covalent therapeutic. BD1119 was the most reactive menin inhibitor 
with GSH but the rate was 2-fold lower than Afatinib, suggesting BD1119 may be tolerated with 
respect to hepatocellular toxicity.
126,135,136
   Inhibition of menin-MLL interaction is correlated 
with the degree of growth inhibition demonstrating the importance of the menin-MLL interaction 
in sustaining leukemic cell proliferation.  The half-life of menin is relatively short with complete 
turnover of menin is occurring within 6-12 hours. Importantly, in mouse models we have 
demonstrated that treatment with BD1119 allows for rapid menin engagement in the bone 
marrow in vivo.  The thienopyrimidine compounds that contain reactive moieties represent the 
first covalent inhibitors of the menin-MLL interaction and lay the groundwork for further 





Chapter 6: Conclusions and Future Directions 
A. Conclusions 
Translocations of MLL resulting in the onset of acute leukemias are associated with poor 
prognosis demonstrating an urgent need for novel therapies.
32
  The MLL interaction with menin-
LEDGF has been demonstrated to be a vital component in MLL fusion leukemia.
9,55
 Genetic 
manipulation of the menin-MLL interaction which leads to the abrogation of the menin-MLL-
LEDGF complex demonstrated the importance of the ternary complex formation for sustained 
leukemic cell proliferation.
55,86
 Therefore, the reliance of MLL fusion proteins on the interaction 
with menin-LEDGF can be exploited to develop a novel therapeutic approach.
9,55
 We have 
performed structural investigation of the molecular interactions involved in forming this ternary 
complex and has provided insight into the specific molecular interactions that need to be targeted 
by small molecule inhibitors.
62
  Our own studies have demonstrated that pharmacologic agents 
can target the menin-MLL interaction and inhibit leukemic cell proliferation.
59,66
  Studies in our 
laboratory have identified small molecule inhibitors of the menin-MLL interaction through  HTS 
campaign, which after optimization have demonstrated in vitro inhibition of the menin-MLL 
interaction and modest cellular activity.
59,66,73
  These inhibitors required further development to 
improve potency and PK properties for analysis in vivo in mice models of MLL leukemia. 
The results I have presented within this thesis highlight the thorough characterization of 
the menin-MLL-LEDGF interaction to give insight into the development of small molecule 
inhibitors.  We developed the first small molecule inhibitors of the menin-MLL interaction, 
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providing a proof-of-concept that menin is able to bind small molecules that could disrupt the 
menin-MLL interaction.
68,73
 Additionally, we have further optimized the small molecule 
inhibitors of the menin-MLL interaction to serve as lead compounds for clinical 
development.
1,66,68,70,71,73,141
   
A.1 Fluorine-backbone interactions contribute to high affinity interaction with menin 
The H to F substitution is a relatively minor modification, but as we demonstrated it can 
have a significant impact on binding affinity.  We characterized the importance of the trifluoro 
moiety of the thienopyrimidine class of menin-MLL inhibitors which contributes significantly to 
the binding affinity of this class of molecules.  We performed systematic exploration of the 
number of fluorine atoms at two distinct sites followed by structural and biochemical analysis.  
We found that not all fluorine atoms present in the CF3 group are required for the high affinity 
interaction.  Our analysis of the fluorine-backbone interaction of the menin inhibitors and 
investigation of PDB structures that contain these orthogonal multipolar interactions allowed us 
to develop the FMAP algorithm.  We designed the FMAP algorithm to predict sites of a protein 
backbone that should interact favorably with fluorine atoms of a ligand through an orthogonal 
multipolar interaction.  We have validated FMAP can predict favorable fluorine interaction sites 
of menin inhibitors with the protein backbone and of several other published protein-inhibitor 
complexes.  Not all of the fluorine atoms of the trifluoro moiety are necessary for the high 
affinity interaction with menin. Therefore, FMAP can facilitate the rationale design of ligands 
with the optimal number of fluorine atoms to improve potency.  The development of FMAP 
algorithm should aid in the rational design of fluorine-backbone interactions for protein ligands 
to improve small molecule binding affinity.
1
 
The development of small molecule inhibitors targeting PPIs is difficult due to relatively 
large and flat interfaces frequently observed at PPI interfaces.
110,142
  Importantly, PPI interfaces 
often  engage the secondary structure elements such as α-helices and β-sheets.
143,144
  Our analysis 
using the  FMAP algorithm highlights the potential to form orthogonal multipolar interactions 
between small molecule ligands and protein backbone in α-helices and β-sheets and 
demonstrates that β-sheets have a much larger accessible area to form these interactions.  This 
validates the importance of exploring the possibility of introducing the orthogonal multipolar 
interactions in the development of PPI inhibitors. C−F···C=O interactions with optimal geometry 
98 
can provide a substantial gain in the binding affinity of small molecules to proteins.  For example 
a simple CH3 to CF3 substitution in the context of the menin inhibitors demonstrated over 10-
fold increase in potency. Considering small molecule inhibitors that target PPIs typically have a 
high molecule weight to competitively bind the target protein, this approach can be applied to 
increase the binding affinity of the small molecule to the target protein without substantial 
increase in the molecular weight of such compounds. Additionally, orthogonal multipolar 
interactions require that the C-F bond has perpendicular geometry relative to the protein 
backbone; therefore, this may provide an opportunity to form favorable ligand interactions with 
the polar protein backbone when the introduction of hydrogen bonds would not be possible due 
to geometric limitations.  With the increasing need to develop inhibitors of PPIs, application of 
the FMAP algorithm should help to efficiently design fluorine orthogonal multipolar interactions 
of small molecule inhibitors with the protein backbone.  
A.2 Optimization of small molecule inhibitors of the menin-MLL interaction to 
demonstrate in vivo efficacy 
We performed optimization of several classes of menin-MLL inhibitors into potent 
inhibitors using structure-based drug design. Two distinct chemotypes were identified through 
the HTS, the hydroxymethylpiperidine class and thienopyrimidine class. The 
hydroxymethylpiperidine class of inhibitors (MIV series) was significantly improved potency 
upon, with the aminomethylpiperidine inhibitor (MIV-6) representing the most potent inhibitor 
of this class (Figure 6.1).
73
  A multi-parameter optimization of the thienopyrimidine class of 
menin-MLL inhibitors was performed to improve potency, cellular activity, and PK properties. 
70,71
 These efforts led to the development of a series of compounds demonstrating in vivo 
efficacy in murine models of leukemia with MI-503 demonstrating a survival benefit up to 45% 
(Figure 6.1).
70,71
  Importantly, normal hematopoiesis in murine models tolerates the menin 
inhibitors demonstrating a therapeutic opportunity to treat MLL leukemias.
70
 
We then used the thienopyrimidine class of inhibitors as an initial scaffold to develop 
covalent inhibitors of the menin-MLL interaction and to target Cys329 of menin. These covalent 
compounds were characterized to determine the potency, rates of reactivity to menin, intrinsic 
reactivity towards GSH, and menin engagement in vivo.  We have demonstrated that inhibition 
of the menin-MLL interaction with covalent inhibitors can be achieved and contributes to 
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improved growth inhibition in MLL leukemia cells.  The covalent inhibitors developed have 
different rates of menin engagement with the fastest compound BD1119 t1/2 = <1min.  All of the 
covalent menin inhibitors exhibited relatively low rates of intrinsic reactivity against GSH 
compared to Afatinib (BD1119 has a 2-fold slower reactivity rate towards GSH compared to 
Afatinib).  In mice, we have demonstrated that treatment with BD1119 engages menin in the 
bone marrow cells in vivo.  The half-life of menin in KOPN8 and MV4;11 leukemia cells was 
determined to be between a 6-12 h half-life which represents a relatively quick turnover.  
Therefore, covalent menin inhibitors as a potential therapeutic approach would be limited by the 
rate of menin turnover and would require dosing regimens 2-4 times per day to maintain 
inhibition of the menin-MLL interaction. 
 There are no published examples of rationally designed covalent inhibitors targeting 
PPIs. Therefore, the rational design of the covalent menin-MLL inhibitors and t methodology  
we used to characterize these compounds can serve as a set of guidelines to aid in the 
development and characterization of covalent small molecule inhibitors targeting other PPIs.  We 
found the rate of menin turnover in cells to be an important factor in applying covalent menin 
inhibitors in biological studies.  Therefore, before starting a covalent small molecule inhibitor 
campaign, it is important to determine the rate of the target protein de novo synthesis.  Covalent 
inhibitors are only effective when the protein is covalently bound to the small molecule, 
therefore the rate of protein synthesis to physiologically relevant levels may be the limiting 
factor in the application of covalent inhibitors.  Ideally this rate of de novo synthesis of the target 
protein should be slow (t1/2  > 12h) to consider covalent inhibitors as a potential therapeutic 
strategy to block a specific target protein.  To reduce the potential off target effects, the selection 
of covalent moieties should begin with weak electrophiles to generate covalent small molecule 
analogs. Weak electrophiles can be more easily explored when starting with a potent reversible 
inhibitor because the noncovalent interactions of the small molecule drive the potency and 
selectivity to position the electrophile in close proximity to the cysteine residue to allow for the 
covalent bond to form. This may reduce the potential for general reactivity of these covalent 
moieties towards other proteins and other thiol containing biomolecules. Next, it is important to 
characterize the potency, reactivity, selectivity and cellular activity of covalent small molecule 
inhibitors,  and various biochemical, biophysical and cell biology methods can be applied for this 
purpose. Here, we utilized a biochemical FP assay to quantify inhibition of the targeted 
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interaction and the rate of covalent bond formation to the target protein by LC-MS to determine 
the rate of irreversible binding. The rate of target engagement should be relatively fast (t1/2 < 
10min) to allow for rapid and complete inhibition of the target protein.  To characterize the 
inhibitors general reactivity towards proteins that contain surface cysteines and biomolecules 
containing free thiols the reactivity with GSH can be used as a surrogate.  This reactivity ideally 
should be slow and we used Afatinib as a benchmark for comparison (t1/2 > 11min for Afatinib).  
Finally, we determined the rate of target engagement in both cellular studies and in vivo to 
validate whether inhibitors can covalently engage menin in situ. We developed the pulldown 
assay to quantify the uninhibited target protein and used CETSA to quantify the inhibited target 
protein.  We found the IC50 values for both the pulldown and CETSA agreed well with each 
other.  Overall, the methodology we developed and applied to characterize the covalent menin 
inhibitors will help set the foundation for the rational design and thorough characterization of 
irreversible inhibitors targeting PPIs. Our work also demonstrates that targeting PPI interfaces 
with covalent inhibitors is feasible and can represent a new direction to overcome some of the 
challenges associated with developing PPIs inhibitors.  
 
Figure 6.1 Development of menin-MLL inhibitors.  
A. The hydroxymethylpiperidine class of menin inhibitors with MIV-6 the most potent analog developed in this series. 
B. MI-1 the HTS hit developed to MI-136 to serve as a lead scaffold.  MI-503 exhibited improved PK properties for 




B. Future Directions 
B.1 Future development of the menin-MLL inhibitors 
The menin-MLL inhibitors are a successful example of targeting protein-protein 
interactions with the reversible and irreversible inhibitors of the thienopyrimidine class and 
reversible methylpiperidine class.  We have demonstrated the oncogenic effects of MLL-
rearrangements can be reversed through disruption of the menin-MLL interaction.   Overall, we 
have developed a series of menin-MLL inhibitors that exhibit a good PK profile to demonstrate 
in vivo efficacy supporting the effort for further exploration in clinical applications.
71
  Additional 
analysis needs to be performed with the formulation of these inhibitors, long-term toxicology, 
and investigation in additional species such as rats and dogs. Menin-MLL inhibitors represent a 
promising therapeutic approach for the MLL-rearranged leukemias. 
B.2 Investigation of menin-MLL inhibitors in other malignancies  
The menin-MLL interaction has a well characterized role in the progression of MLL-
rearranged leukemias but other cancers that do not have MLL translocations may be dependent 
on the wildtype-MLL interaction with menin.
11,42
  WT MLL is amplified in types of AML and 
myelodysplasia, and therefore menin-MLL inhibitors may provide a therapeutic benefit for these 
malignancies, particularly that have high Hoxa9 expression.
145
  In addition, menin interacts with 









  Considering the role of MLL1 in the regulation of MDR1, inhibitors of menin-MLL 
interaction may be important to chemo-sensitize cancer cells.
82
  This evidence provides rationale 
for the exploration of the menin-MLL inhibitors in the context of various genetic backgrounds 
other than MLL translocations. Overall, the menin-MLL inhibitors may provide broader 
therapeutic advantages for the treatment of other malignancies.   
B.3 Structural investigation of the IBD interaction with MLL identifies new interaction 
motif and potential therapeutic target 
The results I have shown in Appendix A demonstrate thorough characterization of the 
menin-MLL-LEDGF interaction with the identification of a novel interaction motif of MLL with 
IBD.
141
 We identified a novel interaction motif of MLL binding to IBD, IBM2. Interestingly, the 
binding region of IBM2 on IBD overlaps with the HIV-IN binding site on IBD.  In AlphaLISA 
102 
based competition experiments we determined that the MLL and IN interaction with IBD 
compete with each other and are mutually exclusive.  Targeting the IBM2 site with inhibitors 




Our structural characterization of the MLL-IBD interaction led to the identification of the 
IBM2 binding site on MLL that binds to IBD domain of LEDGF.  The importance of the IBM1 
and IBM2 binding motifs on MLL demonstrates that inhibition of either of these sites results in 
the disruption of the MLL interaction with IBD.  Additionally, the IBM2 motif of MLL has an 
overlapping binding interface on IBD with HIV-IN suggesting this IBM2 binding site could be a 
promising therapeutic target for both MLL and HIV pathogenesis. This led us to explore small 
molecules that bind to the IBD of LEDGF through performing a fragment screen, of which 
details can be found in Appendix B.  Targeting the interactions of IBD may provide an 
alternative therapeutic approach to disrupt the menin-MLL ternary complex rather or in addition 





Materials and Methods 
Plasmid construction. A cDNA encoding the full-length human menin was cloned into the 
pET32a vector (Promega) containing an N-terminal thioredoxin-His6 tag.
59
  cDNA encoding 
HIV-IN and MLL110-160 constructs were synthesized by GeneArt Strings (Invitrogen).
141
  




Protein expression and purification.  Full-length human menin was expressed in a pET32a 
vector (Promega) containing N-terminal thioredoxin His6-tag in Rosetta (DE3) cells. Menin was 
purified using nickel-agarose (GE Healthcare) followed by ion exchange with Q-Sepharose (GE 
Healthcare). Protein was subsequently cleaved with thrombin followed by nickel agarose 
purification to separate the thioredoxin tag from menin. Purified protein was dialyzed to 50 mM 




MLL constructs were expressed in RosettaTM (DE3) cells (EMD) as an insoluble 
protein. The inclusion bodies were solubilized in 6M guanidine HCl and refolded on-column 
bound to Ni-NTA resin (Qiagen). The thioredoxin-His6x tag was cleaved by TEV protease, and 
proteins were purified by ion exchange chromatography with SP Sepharose resin (GE 
Healthcare). MLL was concentrated and dialyzed into 50 mM Tris, pH 7.5, 50 mM NaCl, and 1 
mM TCEP.  The generation of deletion constructs was performed by mutagenesis according to 
the QuikChange Site-Directed Mutagenesis kit protocol to introduce different internal deletions 




IBD was expressed in Escherichia coli as an insoluble protein. The inclusion bodies were 
solubilized in 6M guanidine HCl and refolded on-column bound to Ni-NTA resin (Qiagen). The 
thioredoxin-His6x tag was cleaved by TEV protease, and proteins were purified by ion exchange 
chromatography with SP Sepharose resin (GE Healthcare). IBD was concentrated and dialyzed 
into 50 mM Tris, pH 7.5, 50 mM NaCl, and 1 mM TCEP. IBD labeled with stable isotope (
15
N) 
was expressed in M9 minimal media in E. coli. The same purification procedure above was used. 
HIV-IN was purified with HisTrap HP (GE Healthcare) and then by ion exchange 
chromatography on a Q Sepharose column (GE Healthcare). Details of IBD and HIV-IN 





  Inhibition of the menin-MLL-IBD interaction was determined with an 
AlphaLISA assay with  62.5 nM His-Trx-MLL160, 62.5 nM menin, and 62.5 nM Flag-IBD.  1h 
incubation at room temperature in 50 mM MOPS (pH 7.25), 50 mM NaCl, 1 mM TCEP, 0.02% 
(w/v) BSA, and 0.025% (v/v) Tween-20.  Ni-chelate-coated donor beads and anti-Flag acceptor 
beads (10 mg/mL final concentration) were added and incubated for 1 hour. The luminescence 
signal was recorded using excitation at 680 nm and emissions at 615 nm using the PHERAstar 
microplate reader (BMG). Competition experiments with either integrase domain binding motif 
(IBM) 2 peptide or HIV-IN were performed with twofold serial dilutions. Data were analyzed 
using the Origin 7.0.
167
 To assess the inhibition of HIV-IN interaction with IBD, we employed a 
very similar protocol as discussed previously using 62 nM His-HIV-IN and 1 mM Flag-IBD. Ni-
chelate-coated donor beads and anti-Flag acceptor beads were used at 2.5 mg/mL concentration. 
Competition experiments were performed with IBM2 using threefold serial dilutions. Details 
have been described previously.
141
 
Biochemical Characterization of Menin−MLL Inhibitors. Inhibition of the menin−MLL 
interaction by small molecules was assessed by fluorescence polarization (FP) assay. 
Fluorescein-labeled MLL (MBM1) peptide (MLL12) at 10 nM, menin at 100 nM, and varying 
concentrations of compounds were used for IC50 determination in the FP buffer (50 mM Tris, pH 
7.5, 50mM NaCl, 1 mM DTT). Compounds (5% final DMSO concentration) were added to the 
menin−MLL peptide complex and incubated for 1 h.  Fluorescein-labeled MLL (MBM1 and 
MBM2) peptide (MLL43) at 4 nM, menin at 4 nM, and varying concentrations of compounds 
were used for IC50 determination in the FP buffer (50 mM Tris, pH 7.5, 50mM NaCl, 1 mM 
105 
DTT). Compounds (5% final DMSO concentration) were added to the menin−MLL peptide 
complex and incubated for 3h. Changes in fluorescence polarization were measured using the 
PHERAstar microplate reader (BMG). A detailed protocol has been described previously.
59,68
 
Isothermal Titration Calorimetry (ITC).  Menin was extensively dialyzed at 4 °C against ITC 
buffer (50 mM phosphate, pH 7.5, 50 mM NaCl, 1 mM β-mercaptoethanol) and degassed prior 
to measurement. Compounds were dissolved in DMSO and diluted with the ITC buffer to final 
concentrations (50−100 μM, 5% DMSO). Protein solution was adjusted to contain 5% DMSO 
final concentration. The titrations were performed using a VP-ITC titration calorimetric system 
(MicroCal) at 25 °C. The calorimetric cell, containing menin (concentrations in the range 5−10 
μM), was titrated with the compounds (50−100 μM) injected in 10 μL aliquots. Data was 
analyzed using Origin 7.0 (OriginLab) to obtain Kd and stoichiometry.
70,71,73
   
Menin-MLL1-160 complex was purified by size exclusion chromatography and titrated 
with IBD using a VP–Isothermal Titration Calorimeter. Menin-MLL1-160 complex was used at 
20μM concentration, 1000-fold above Kd for menin-MLL1-160 interaction.
141
  A detailed 
protocol has been described previously. 
59,141
 
Crystallization of the Menin Complexes with Small Molecule Inhibitors. Co-crystallization 
of menin with small molecule inhibitors was performed with 2.5 mg/mL menin15 incubated with 
3-fold molar excess small-molecule inhibitors. Crystals were obtained using a sitting-drop 
technique at 10 °C in 0.2 M ammonium acetate, 0.1 M HEPES, pH 7.5, and 25% w/v PEG 3350. 
Prior to data collection, crystals were transferred to cryosolution containing 20% PEG550 MME 
and flash-frozen in liquid nitrogen as described previously.
1,66,70,71,73
 
Crystallographic Data Collection and Structure Determination. X-ray diffraction data for co-
crystals of menin with small molecule inhibitors were collected at 21-ID-D, 21-ID-F, and 21-ID-
G beamlines at the Life Sciences Collaborative Access Team at the Advanced Photon Source. 
Data was processed with HKL-2000.
168
 Structures of the complexes were determined by 
molecular replacement using MOLREP with the apo structure of human menin (PDB code: 




 and the CCP4 
package.
171
 In the final stages, refinement was performed with addition of the TLS groups 
defined by the TLSMD server.
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 coordinates and structure factors 
have been deposited in the Protein Data Bank.   
NMR Spectroscopy. NMR experiments were done on the Bruker Advance III 600-MHz 




N heteronuclear single quantum 






NMR Fragment Screen. Samples were made with 80 µM concentration 
15
N IBD in 50 mM 
Tris, pH 7.5, 50 mM NaCl, 1 mM TCEP, 5% DMSO with the final NMR sample containing 7% 
D2O.  Compound mixtures contained 20 compounds with a final concentration of 250uM.  
Samples that contained hits were deconvoluted to identify the single compound that binds to 
IBD. 
Chemical shift perturbations. The magnitude of the fast-exchanging chemical shifts 




N chemical shifts in Hz.
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∆𝛿𝑁𝐻 =  √((𝛿𝑁15𝑓𝑟𝑒𝑒 −  𝛿𝑁15𝑏𝑜𝑢𝑛𝑑)2 + (𝛿𝐻1𝑓𝑟𝑒𝑒 −  𝛿𝐻1𝑏𝑜𝑢𝑛𝑑)2) 
Equation B.1 Calculation of chemical shift perturbations 
Determination of KD by analysis of chemical shift perturbations of small molecule 
titrations. Chemical shift perturbations for small molecule titrations were fit in Origin
167
 
employing a binding isotherm described by the Equation B.1.  [IBD] = 80 µM was used in  all 
titrations; [Ligand] represents varied ligand concentration. Bmax was determined by the fitting of 
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Equation B.2 Calculation of KD for ligand titration. 
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NMR 3PA Method of quantifying SAR. The 3PA method for comparing the relative binding 
affinity of small molecules was calculated using the average value for the chemical shift 
107 




H HSQC peaks (T398, A390, Q391) with 500 μM or 1 mM 
compound in 5% DMSO and compared to DMSO control. Chemical shift perturbations caused 
by compound binding were calculated as in Equation B.1. 
LC-MS determination of covalent adducts to menin. 
Sample Preparation: Samples contained 5µM compound, 500nM menin in PBS at pH7.4 with 
5% DMSO. Reactions were incubated at room temperature for variable time and quenched with 
2.5µL of 4% Formic acid (0.2% FA final).   
Method: A Thermo Finnigan Surveyor Autosampler, PDA Plus UV detector and MS Pump 
along with an LTQ linear ion trap mass spectrometer were used to collect sample data under 
XCalibur software control.  A 5µL sample in “no waste” mode was injected onto a Phenomenex 
Jupiter 5u 300A C5 (guard column) 2 x 4.00 mm at 45 
○
C. Mobile phase composition: Buffer A 
(95:5 water:acetonitrile, 0.1% FA) and Buffer B (acetonitrile, 0.1% FA). Gradient elution was 
used with an initial mobile phase of 85:15 (Buffer A:B) and a flow rate of 250µL/min. Upon 
injection, 85:15 A:B was held for 1.3min, Buffer B was increased to 90% over 3.2min, held for 
1min, and then returned to initial conditions in 0.1min and held for 2.4min.  The total run time 
was 8min.  A post-column divert valve employed to direct void volume salts to waste was used 
for the first 2min of the sample method. Blank injection of Buffer A was used in between each of 
the sample injections.  A needle wash of 1:1 acetonitrile:water with 0.1% FA was used. 
The electrospray ionization (ESI) source used a 300 
○
C capillary temperature, 40 units 
sheath gas flow, 20 units aux gas flow, 3 units sweep gas flow, 3.5 kV spray voltage, 120 V tube 
lens. 
Data Collection: Data collection was performed in the positive ion full scan mode 550-1500 Da, 
10 microscans, 200 ms max ion time.   
Data Processing: Protein mass spectra were acquired as XCalibur data files. The best scans were 
added together using XCalibur Qual Browser. The spectra were displayed using “View/Spectrum 
List with a Display option to display all peaks. The Edit/Copy cell menu was used to copy the 
mass spectrum into the PC clipboard. The spectrum in the PC clipboard was pasted into Excel. 
The first two columns (m/z and Intensity were kept and the third column (Relative) was deleted. 
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The remaining two columns were then saved as a tab delimited file (m/z and intensity) as 
filename.txt from Excel. The Masslynx Databridge program was then used to convert the 
filename.txt tab delimited file to Masslynx format. In some cases an external calibration using a 
(similarly converted) myoglobin spectrum was applied in Masslynx to correct the m/z values of 
the menin protein m/z data. MaxEnt1 software from the MassLynx software suite was used for 
deconvolution of the mass spectrum to yield the average MW of the protein(s).  The percentage 
of covalent adduct formation was determined from the deconvoluted result and used to calculate 
the rate of the covalent reaction.  
LC-MS determination of covalent adducts to GSH. 
Sample Preparation: Samples were prepared with 500uL of 5mM Glutathione, 25uM 
compound in PBS at pH7.4 with 5% DMSO and incubated at 37 
○
C.  
Method: A Thermo Finnigan Surveyor Autosampler, PDA Plus UV detector and MS Pump 
along with an LTQ linear ion trap mass spectrometer were used to collect sample data under 
XCalibur software control.  A 20µL sample in “full inject” mode was injected onto a 
Phenomenex Jupiter 5u 300A C18 2 x 4.00 mm at 45 
○
C. Mobile phase composition: Buffer A 
(95:5 water:acetonitrile, 0.1% FA) and Buffer B (acetonitrile, 0.1% FA). For menin-MLL 
inhibitors, the gradient elution was used with an initial mobile phase of 95:5 (Buffer A:B) and a 
flow rate of 250µL/min. Upon injection, Buffer B was increased to 90% over 12min, held for 
0.5min, and then returned to initial conditions in 0.1min and held for 2.4min.  The total run time 
is 18.5min.  For analysis of Afatinib the gradient elution method was adjusted to a an initial 
mobile phase of 92:8 (Buffer A:B) and a flow rate of 250µL/min. Upon injection, Buffer B was 
increased to 18% over 14min, and then returned to initial conditions in 0.1min and held for 
4.5min. The total run time was 28min. A post-column divert valve employed to direct void 
volume salts to waste was used for the first 2min of the sample method. A needle wash of 1:1 
acetonitrile:water with 0.1% FA was used. 
The electrospray ionization (ESI) source used a 300 
○
C capillary temperature, 40 units 
sheath gas flow, 20 units aux gas flow, 3 units sweep gas flow, 3.5 kV spray voltage, 120 V tube 
lens. 
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Data Collection: Data collection was performed in the positive ion full scan mode 550-1500 Da, 
10 microscans, 200 ms max ion time.   
Sample preparation of murine bone marrow cells. C57BL/6 mice were treated with 50 mg/kg 
of BD1119 via intraperitoneal (ip) administration. Compounds were dissolved in the vehicle 
containing 25% (v/v) DMSO, 25% (v/v) PEG-400, and 50% (v/v) PBS. Vehicle mice were 
sacrificed at 2h after treatment and BD1119 treated mice were sacrificed at 2h and 6h time points 
after administration of the compound. Bone marrow cells (BMCs) were isolated from the tibia 
and femur. BMCs were washed with PBS and resuspended in PBS for CETSA analysis.  
Sample preparation of human leukemia cell lines. Human leukemia cell lines: MV4;11 and 
KOPN8 were cultured in RPMI-1640 medium with 10% FBS and 1% penicillin/streptomycin. 4 
x 10
6
 cells were seeded in T-25 cell culture flasks (BD Biosciences, San Jose, CA, USA) in 
appropriate volume of culture medium, cells were treated with compounds (0.25% final DMSO 
concentration) or DMSO for 4 hours or 24 hours at 37°C, 5% CO2. Following the incubation the 
cells were harvested and washed with PBS in order to remove excess drug. Cells were pelleted 
followed by the addition of lysis buffer (50mM Hepes pH 7.5, 250 mM NaCl, 1mM EDTA, 
2.5mM EGTA, 1mM NEM, 1mM NaF, 100uM Na3Vo4, 10mM Beta Glycerophosphate, 10% 
glycerol, 1% NP-40) at 30uL volume and lysed using 3 cycles of freeze-thawing with liquid 
nitrogen. The lysates were centrifuged at 20000 x g for 10 minutes at 4°C and supernatants were 
transferred to new tubes. 
Cellular Thermal Shift Assay. Cellular thermal shift assay (CETSA) was performed as 
described previously.
140
 Briefly equal amounts of cell suspensions were aliquoted into a 0.2 mL 
PCR tubes. These 0.2mL PCR tubes were heated individually at different temperatures for 3 
minutes (Eppendorf, Hamburg) followed by cooling for 3 minutes at room temperature.  Cells 
were pelleted followed by the addition of lysis buffer (30uL) and lysed using 3 cycles of freeze-
thawing with liquid nitrogen. The lysates were centrifuged at 20,000 x g for 10 minutes at 4°C 
and supernatants were transferred to new tubes and analyzed by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) followed by western blot analysis. 
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MLL43 Bead preparation. Biotinylated MLL43 peptide was ordered from GenScript with the 
sequence: GSGMAHSARWRFPARPGTTGGGGGGGRRGLGGAPRQRVPALLLPPG with C-
Terminal Amidation and N-Terminal Biotin.  
Biotinylated MLL43 beads were prepared with 100uL of 10mg/mL Streptavidin Magnetic beads 
(Pierce) were washed according to manufacturer’s protocol. Beads were resuspended in 200uL 
of 0.5mM biotinylated-MLL43 in PBS and incubated for 18 hours at 4°C while rotating.  Beads 
were washed extensively with PBS and stored in PBS containing 0.05% sodium azide. 
MLL43 pulldown of menin assay. Whole cell lysates were incubated with MLL43 coated beads 
at 4°C for 18h while rotating.  Beads were isolated and washed extensively in lysis buffer 
containing an additional 0.5M NaCl. The beads were then applied to SDS-PAGE electrophoresis 
and Western blotting. Antibodies used include rabbit anti-menin (A300-115A, Bethyl 
Laboratories, Inc.), mouse anti-GAPDH (AM4300, Ambion), horse anti-mouse HRP (7076, Cell 





Appendix A: The same site on IBD of LEDGF binds to both MLL 
and HIV-IN. 
* The text and figures in this chapter are adapted from the following manuscript: Murai, M. J.; 
Pollock, J.; He, S.; Miao, H.; Purohit, T.; Yokom, A.; Hess, J. L.; Muntean, A. G.; Grembecka, 
J.; Cierpicki, T. The same site on the integrase-binding domain of lens epithelium-derived 
growth factor is a therapeutic target for MLL leukemia and HIV. Blood 2014, 124, 3730-7. 
A. Abstract 
Lens epithelium-derived growth factor (LEDGF) plays a vital role in the pathogenesis of 
both MLL leukemias and HIV type-1 viral replication.  In MLL rearranged leukemias, the 
integrase-binding domain (IBD) of LEDGF is involved in the interaction with MLL.  To fully 
characterize this interaction we performed structural analysis of the IBD domain, which revealed 
a novel interaction motif of MLL, termed IBD binding motif 2 (IBM2). Validation of this 
interaction was performed through biochemical and biophysical analysis.  The IBM2 site of 
MLL was identified to overlap with the HIV-IN binding interface on IBD. We have 
demonstrated the interaction with IBD to MLL or HIV-IN is mutually exclusive. Importantly, a 
peptide corresponding to the IBM2 sequence is capable of disrupting the IBD interaction with 
MLL or HIV-IN. This evidence suggests targeting the IBM2 binding site on LEDGF represents a 
novel approach for the development of therapeutics for MLL-dependent and HIV pathogenesis.   
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B.  Background 
Lens epithelium-derived growth factor (LEDGF) is a chromatin associated protein
9
 and 
acts as a transcriptional co-activator regulating stress related genes.
146,147





 and HIV infection.
150
  LEDGF translocations have 
been reported with nucleoporin NUP98 gene in leukemia patients, 
151,152
 and are upregulated in 
subset of acute myeloid leukemias (AML) resistant to chemotherapy.
153
   
Evidence for the role of LEDGF in leukemogenic transformation by MLL fusion proteins 
has been demonstrated.
9
  LEDGF co-precipitates with MLL wild type and MLL fusion proteins 
along with menin 
9
 and co-localizes with MLL-menin complex at Hoxa9 and Meis1 gene loci. 
9
 
Hoxa9 and Meis1 genes are important downstream targets of the menin-MLL-LEDGF complex 
and are required for normal hematopoiesis and have been linked to MLL fusion pathologies. 
2,19
 
The oncogenic function of MLL fusion proteins is critically dependent on the association with 
menin and LEDGF.
9
  The Integrase Binding Domain (IBD) of LEDGF is the domain of LEDGF 
involved in the interaction with MLL variants and menin.
9
   Disruption of the menin-MLL fusion 
protein interaction with LEDGF abrogates the progression of acute leukemia in vivo.
9
  This 
evidence demonstrates the potential of targeting the LEDGF interaction with MLL as a 
therapeutic approach for MLL-rearranged leukemias.   
Additionally, the IBD of LEDGF interaction with HIV-1 integrase (IN) and the 
importance of LEDGF in HIV type 1 (HIV-1) pathogenesis has been well characterized.
154,155
 




  Small 
molecules and peptidomimetics have been developed to bind the HIV-IN and disrupt the 
interaction with IBD of LEDGF inhibiting HIV-IN activity and viral replication. 
158,159
  This 
evidence suggests the IBD of LEDGF plays an important role in both MLL-rearranged 
leukemias and HIV pathogenesis. 
The molecular interactions of IBD of LEDGF with MLL are not thoroughly 
characterized.  Structural analysis (PDB: 3U88) of the menin-MLL-IBD ternary complex clearly 
highlights the interactions of MLL residues 113-134 with IBD.
62
 The Phe129 and Phe133 are 
clearly forming hydrophobic interactions with a groove of IBD. This data correlates well with 
previous studies describing the importance of Phe129 for binding to IBD.
9
  ITC analysis of the 
113 
menin-MLL complex, with the MLL construct containing residues 6-153, binds to IBD with a Kd 
= 470 nM.  Although the MLL construct used for crystallization consisted of MLL residues 6-
153, in the crystal structure electron density for residues 135-153 were not clearly defined and 
left unmodeled.  It has also been demonstrated that deletion of residues 123-153 of MLL 
abolished the interaction of MLL with IBD suggesting the presence of additional interactions 
which were absent in the crystal structure.
9
   
To investigate this interaction we determined the solution structure of MLL in complex 
with IBD; revealing a novel interaction motif of MLL
141
  Importantly, this new motif of MLL 
overlaps with the binding site of HIV-IN on IBD of LEDGF.
141
 This suggests that targeting this 
site of IBD may have therapeutic applications in both MLL rearranged leukemias and HIV 
pathogenesis.   
My contribution to this project was to characterize the binding affinity of MLL mutants 
in complex with menin to the IBD-LEDGF by ITC. I have also developed the biochemical 
AlphaLISA assays to probe the interactions of the IBM2 site of MLL with IBD or HIV-IN. 
C. Results and Discussion 
 
Figure A.1 Structure determination and biophysical characterization of the MLL-IBD interaction.  
A. The solution of IBD in complex with MLL (PDB: 2MTN)
141
.  B.  Figure adapted from (Murai 2014)
141
  
Construct of MLL residues 1-160 highlighting IBM1 and IBM2.  C.  Figure adapted from (Murai 2014)
141




C.1 Structural and biochemical analysis of the menin-MLL interaction with IBD. 
The construct used for the solution structure was designed to include residues 110-160 of 
MLL fused to residues 337-442 of LEDGF which corresponds to IBD. The solution structure of 
MLL-IBD was then solved by Marcelo Murai and Tomasz Cierpicki (Figure 7.1 A).
141
  This 
structure highlighted two separate fragments of MLL forming interactions with IBD, IBD 
binding motif 1 (IBM1) (residues 123-134) and IBM2 (residues 147-152) (Figure 7.1 A and B)  
The IBM1 site was determined in the crystal structure of the ternary complex but the IBM2 site 
was absent.
62
  IBM1 and IBM2 are separated by a 12 amino acid linker.  IBM2 residues F148 
and F151 form interactions with a hydrophobic region of IBD. 
I validated these interaction motifs of MLL for binding to IBD sing isothermal titration 
calorimetry (ITC). First, I characterized the interaction of IBD with menin-MLL1-160 which had 
a binding affinity of 1.4 µM, approximately 10-fold higher compared to the interaction between 
IBD and MLL in the absence of menin (14.7 µM) (Figure A.1 C).
141
  Mutagenesis was then 
performed to validate the IBM1 and IBM2 interaction motifs (Figure A.1 C). The IBM1 
interaction with menin-MLL was abolished with the F129A mutation and F148A and L149A 
double mutant eliminated the IBM2 interaction with IBD.   Each of these mutants in IBM1 and 
IBM2 independently was sufficient to completely disrupt the IBD interaction with menin-MLL.  
This analysis demonstrates both the IBM1 and IBM2 sites are necessary for the high-affinity 
interaction of menin-MLL with IBD.
141
 
C.2 HIV-IN binding to IBD overlaps with the MLL binding interface. 
In HIV pathogenesis, HIV-IN binds to the IBD of LEDGF and is necessary for the 
integration of the HIV genome.
9,154
  In MLL transformations, the IBD of LEDGF is involved in 
ternary complex formation with menin-MLL and is critical for the progression of MLL 
rearranged leukemia.
9,154
 Both MLL and HIV-IN are involved with protein-protein interactions 
with IBD of LEDGF. The crystal structure of IN-IBD complex
160
 (PDB: 2B4J) was 
superimposed with the MLL-IBD solution structure
141
 (PDB: 2MTN) demonstrating the IBM2 
site of MLL overlaps with the IN binding site on IBD (Figure A.2 A).  W131 of IN binds to the 
same hydrophobic region on IBD as F148 of MLL. To investigate whether IN will inhibit the 
isotherms of IBD titrated to menin in complex with different constructs of MLL. 
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MLL interaction with IBD I developed an AlphaLISA assay to probe the IBD-MLL interaction 
with IN.  The AlphaLISA assay utilized a Ni-chelate donor and anti-Flag acceptor beads with the 
proteins 62.5 nM His-MLL160, 62.5 nM menin, and 62.5 nM Flag-IBD.  The competition 
experiment with IN was done with 2-fold serial dilutions. It has been reported that IN binds to 
IBD with an affinity of about 10nM
161
 and we found in our AlphaLISA assay IN competes with 
menin-MLL binding to IBD with an IC50 = 301 nM. Therefore, IN can compete with MLL for 
the binding to IBD.   
To further characterize the overlap of the binding interface of MLL and IN to IBD, I 
explored an IBM2 peptide to disrupt these interactions with IBD.  Again an AlphaLISA assay 
was used to explore the potential for the IBM2 peptide to compete with the IBD interactions 
using the assay described above for the ternary complex and developed another AlphaLISA 
assay to probe the IBD-IN interaction. To assess the inhibition of HIV-IN interaction with IBD, 
the AlphaLISA assay was optimized with 62 nM His-HIV-IN and 1 mM Flag-IBD.  I identified 
that the IBM2 peptide was able to compete with IBD binding to menin-MLL (IC50 = 318 µM) 
and IBD binding to HIV-IN (IC50 = 223 µM). The binding affinity of IBM2 peptide was 
estimated to be about 10-fold weaker than the binding of MLL1-160 to IBD.
141
 Although the 
interaction of the isolated IBM2 peptide is not very potent, this evidence demonstrates the 
potential to develop an inhibitor to disrupt both the IN and MLL interaction with IBD.  
Therefore, this provides proof of concept that the IBM2 binding site on IBD can be targeted with 
potentially a small molecule or a peptidomimetic to disrupt the IBD interaction with both MLL 
and IN.  
116 
 
Figure A.2 The IBD interface with MLL and IN overlaps.   
A. Figure adapted from (Murai 2014)
141
 Structures of IBD-MLL overlain with IBD-IN.  W131 of IN overlaps with 
F148 of IBM2 of MLL. HIV-IN (blue), IBD (green), MLL (orange). B. Figure from (Murai 2014)
141
 AlphaLISA 
assay of the menin-MLL-IBD ternary complex demonstrated disruption of the complex when IN is titrated in.  C. 
Figure adapted from (Murai 2014)
141
 menin-MLL-IBD AlphaLISA assay with IBM2 competition. D. Figure adapted 
from (Murai 2014)
141






D.  Conclusions 
The solution structure of the MLL-IBD complex allowed us to identify a novel 
interaction site of MLL with IBD, termed IBM2. The IBM2 site is required for the menin-MLL 
complex to bind to IBD.
141
  Additionally, the IBM2 motif overlaps with the binding site of IN to 
IBD demonstrating the MLL and IN interaction with IBD is mutually exclusive.
141
   Importantly, 
the IBM2 peptide is able to inhibit the IBD interactions with both MLL and IN demonstrating the 
potential for an inhibitor targeting this site of IBD.   This evidence validates the IBM2 binding 
site of IBD as a potential therapeutic target in both MLL leukemias and HIV pathogenesis.   
Antiviral drugs have been developed to target the IBD-IN interaction but all bind to HIV-
IN.
162
  Viral proteins can more quickly develop mutations and become resistant to current 
therapies therefore inhibitors that bind to IBD of LEDGF may serve as a promising 
therapeutic.
163
 Targeting the menin-MLL-LEDGF complex has been demonstrated to be an 
attractive therapeutic target for MLL rearranged leukemias.
9,164
  Inhibitors targeting the menin-
MLL interaction have been developed
66,68
 however concerns surrounding menin’s role as a 
tumor suppressor protein in endocrine tissues
57
 may have undesired consequences if inhibited.  
Overall, this analysis demonstrates an opportunity of an alternative approach to target the menin-
MLL-LEDGF ternary complex for potential therapeutic applications.
141





Appendix B: Fragment screening of IBD-LEDGF by NMR 
A. Abstract 
The menin-MLL-LEDGF complex assembly is critical for the progression of MLL 
rearranged acute leukemias.  Targeting the menin-MLL interaction to disrupt this complex has 
been achieved but the binding of small molecules to menin raise concerns surrounding the role of 
menin as a tumor suppressor protein in the endocrine system.  Therefore, targeting the IBD-MLL 
interaction with small molecule inhibitor may serve as a promising alternative approach to 
disrupt this ternary complex.  To identify if small molecules can bind to IBD we employed a 
fragment-based screening campaign.  We identified two chemically distinct small molecules and 
validated binding to IBD.  The binding site on IBD for both small molecules overlaps well with 
the IBM1 motif of MLL.  With modest affinity of these small molecules, further optimization is 
required to demonstrate inhibition of the menin-MLL interaction with IBD. This study provides 
proof of concept that small molecule binding to IBD at a relevant site for MLL binding can be 
achieved.   
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B.  Background 
LEDGF has been demonstrated to play a critical role in MLL-rearranged pathogenesis 
through the association with menin-MLL.
9
  The integrase binding domain (IBD) of LEDGF has 
been determined to interact with menin-MLL.
9,62
  Importantly disruption of the menin-MLL 
fusion protein interaction with LEDGF abolishes the progression of acute leukemia.
9
  This 
evidence highlights the potential for inhibitors targeting the IBD interaction with menin-MLL to 
have therapeutic applications in MLL leukemias.  
Our lab has demonstrated that disruption of menin with small molecule inhibitors inhibits 
MLL leukemia cell proliferation.
66,68
 However, we have demonstrated the importance of the 
IBD-MLL interaction, of which; inhibitors have yet to be identified. The LEDGF interaction 
with the menin-MLL complex involves multiple points of contact.
62,141
 We have performed 
extensive characterization of the IBD interaction with menin-MLL and have identified two IBD 
binding motifs 1 (IBM1) and IBM2 of MLL.
62,141
   These interactions were validated by 
mutagenesis demonstrating the importance of both of these interactions.
141
 Furthermore, this 
provides rationale for targeting either of these sites with small molecule inhibitors.
62,141
   
In this study we performed a fragment-based screening approach to identify inhibitors of 
the IBD interaction with menin-MLL.  Two small molecules were found to bind to IBD and 
overlap with the IBM1 binding site of MLL.  This work is highly innovative because to date 
there is no report of small drug like molecules that bind to LEDGF.  Disruption of IBD 
interactions with menin-MLL fusion proteins with small molecules is a novel strategy to develop 
targeted therapeutics for MLL-related leukemias.   





N HSQC experiments.  I then selected commercially available analogs of the 









N HSQC chemical shift perturbations and mapped these perturbations onto the IBD solution 
structure to identify the binding region of 3CC7 to IBD. 
120 
C. Results and Discussion 
C.1 Identification and characterization of small molecule fragments that bind to IBD. 
To explore the potential for small molecules to bind to IBD of LEDGF we performed a 
fragment-based screen.  A library of ~500 chemically diverse fragment-like compounds was 









correlations for uniformly labeled 
15
N IBD.  The screening was performed in a multiplex format 
with 20 compounds per NMR sample.  Hits were defined when chemical shift perturbations with 
greater than 0.03ppm shifts in the 
1
H dimension or greater than 0.03ppm shifts in the 
15
N 
dimension compared to DMSO control.  The two compounds we identified from this screen were 
3CC7 and 6CC3 which are shown in Figure B.1.    
We performed titration experiments with 3CC7 from 250uM-2mM and 6CC3 up to 3mM 
to determine the Kd by NMR utilizing the chemical shift perturbations and Equation B.2 (See 
Methods section).  Over 20 chemical shifts were used to calculate the average binding affinity. 
The most potent small molecule identified was 3CC7 with a binding affinity of about 2mM, and 
6CC3 was 2-fold weaker.  Small molecule fragments typically exhibit very weak binding and 
require optimization but first we sought to identify if these small molecules bind to a site that 
might overlap with the MLL binding interface. 
121 
 
Figure B.1 Identification and characterization of fragment screening hits.   





HSQC experiments with a selection of the spectra shown on the right.  Blue = DMSO, green = 125uM, 




The IBD domain consists of a small 4-helix bundle therefore small molecules could 
potentially bind at the interface of any of these helices.  Based on the similar residues resulting in 
chemical shift perturbations for both 3CC7 and 6CC3 we concluded both hits bound to the same 
region on IBD.  To identify the region of IBD these small molecules were binding to, we mapped 
the difference in chemical shift perturbations of 3CC7 at 2mM compared to DMSO.  We found 
the largest chemical shifts perturbations localized at the IBM1 binding site (Figure B.2).  
Interestingly, the small molecules identified in this screen bind to an important site on IBD for 
the MLL interaction.   
122 
 
Figure B.2 Solution structure of IBD with chemical shift 
perturbations mapped at 2mM 3CC7.   
The solution structure highlights the residues with chemical shift 
perturbations upon the addition of 3CC7 relative to DMSO 
control.  IBM regions 1 and 2 of MLL are highlighted in cyan. 
C.2 Development of the structure activity relationship (SAR) for 3CC7  
When comparing the structural similarities between compounds 6CC3 with 3CC7, both 
of these molecules are composed of two aromatic rings with an amine substituted heterocycle 
and a phenyl ring substituted with a small hydrophobic moiety. We sought to further explore 
analogs of the more potent hit compound 3CC7.  Commercially available analogs of 3CC7 was 
limited to only a few molecules and no analogs of 6CC3 where explored.  To compare analogs 
we used an NMR-based method 3 Peak Affinity (3PA).
166
 This 3PA approach uses the average 
value in Hz of 3 HSQC peaks (T398, A390, Q391) in the presence of compound (500 µM or 
1mM).   The peaks for these residues (T398, A390, Q391) had some of the largest chemical shift 
123 
perturbations upon the addition of compounds with IBD.  3CC7 has a 3PA (500 µM) = 34.7Hz 
and 3PA (1mM) = 56.7Hz. 
We first explored similar compounds that were present in our fragment screen to 
understand the critical features of 3CC7 binding to IBD.  3BB6, 6HH5, 2CC9, and 3EE11 had 
similar structures with limited to no binding to IBD.  3EE11 was the most potent analog that was 
in our screen with a 3PA (1mM) = 8.46Hz.  3EE11 had a different arrangement of the 
thiadiazole substituted with an amine and a methyl in place of the trifluoromethyl. Despite these 
differences 3EE11 still exhibited some binding to IBD but was almost 7-fold weaker binding 
than 3CC7. 
We then pursued some small molecule analogs of 3CC7 that were commercially 
available.  3CC7_1 with the absence of the trifluoromethyl had no binding to IBD demonstrating 
the importance of this hydrophobic region of 3CC7.   Loss of the amine substitution of the 
thiadiazole (3CC7_2) also exhibited 6-fold decrease in binding.  Interestingly, replacement of 
the trifluoromethyl with methyl (3CC7_3) demonstrated no significant change in binding.   
Therefore, we sought to explore the trifluoromethyl with methoxy (3CC7_4) and found it was 
about 2-fold weaker than 3CC7.  This limited SAR analysis demonstrates the importance of the 
amine in the thiadiazole moiety and the requirement of the hydrophobic interactions at the para- 
position of the phenyl ring.  Based on the comparison with 6CC3 there is potentially more room 




Table B.1 SAR and 3PA values for 3CC7.   
Binding of these inhibitors to IBD is quantified by the 3PA method by 



















D.  Conclusion 
We performed fragment-based screening of IBD with a library of chemically diverse 
small molecules.  This effort resulted in the identification of two chemically distinct small 





chemical shifts, quantifying the magnitude of chemical shift perturbations using Equation B.1, 
and mapping the magnitude of the chemical shift perturbations onto the solution structure of 
IBD.  The binding site was localized to the IBM1 binding site of MLL onto IBD.  These small 
molecules were too weak to test in the AlphaLISA assay and require further optimization of 
potency before inhibition of the menin-MLL interaction with IBD in biochemical assays can be 
determined.  Limited 3CC7 analog SAR was explored via commercially available analogs.  
Therefore further investigation will require medicinal chemistry efforts to explore analogs.   
This study demonstrates that small molecules can bind to the IBM1 binding site of MLL 
onto IBD.  Based on mutagenesis analysis of the IBM1 site with F148A resulting in the 
abrogation of the menin-MLL association with IBD we expect inhibition of this IBM1 
interaction should mimic these results.  Additionally in previous studies
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 it was determined the 
peptide of IBM2 was sufficient to disrupt the menin-MLL interaction with IBD.  This suggests 
that small compounds or peptides can bind to both of these sites on IBD that interface with the 
MLL binding motifs.  Additionally, this provides an alternative approach to disrupt the menin-













Compound BD615 BD688 BD712 BD964 BD1044 BD1119
Space group P212121 P212121 P212121 P212121 P212121 P212121
Cell Dimensions
a, b, c (A) 48.1, 79.7, 125.0 49.3, 80.1, 124.6 49.2, 79.9, 124.2 48.4, 79.8, 124.9 47.8, 80.4, 124.3 48.0, 80.4, 123.9
Solvent (%) 44.0 45.5 45.1 44.4 44.0 44.0
Resolution (A) 1.95 (1.98-1.95) 1.50 (1.53-1.50) 1.62 (1.65-1.62) 2.04 (2.10-2.04) 2.21 (2.25-2.21) 2.15 (2.19-2.15)
Unique reflections 34975 (1690) 78547 (3670) 63035 (3097) 46273 (2570) 26109 (1267) 26733 (1295)
Total Reflections 236421 534936 457523 256955 184564 194211
Rsym 0.142 (0.686) 0.081 (0.582) 0.114 (0.909) 0.133 (0.779) 0.147 (0.930) 0.093 (0.811)
I/Sigma*I 20.59 (2.23) 24.24 (2.32) 20.31 (2.15) 15.9 (1.67) 20.33 (1.82) 22.77 (2.06)
Completeness (%) 97.3 (96.2) 98.4 (93.5) 99.9 (99.5) 88.1 (99.0) 99.9 (100) 98.8 (96.2)
Redundancy 6.8 (6.8) 6.8 (6.0) 7.3 (7.1) 5.6 (6.7) 7.1 (6.4) 7.3 (6.6)
Refinement
Rwork/Rfree 17.9/21.3 15.4/17.9 17.7/20.3 21.5/27.9 19.9/24.3 21.42/26.93
No. atoms 
Protein 3640 3694 3736 3612 3586 3505
Water 250 601 579 114 76 104
Mean B-factor (A2) 31.86 15.69 15.46 47.32 46.56 41.07
R.m.s. Dev.
Bond lengths (A) 0.016 0.016 0.016 0.016 0.018 0.018
Bond angles(o) 1.68 1.77 1.67 1.59 1.96 1.80
Ramachandran plot
Most favored regions (%) 98.06 98.06 97.65 98.06 96.52 95.19
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